TEL.054-264-5234iŒ¤‹†Žº)
054-264-5237 (‹³ŽöŽº)
[Œ´’˜˜_•¶]
1. ŽO‰YŠî–õA‰Í–{¬•S‡A”‘qNŽ¡A‘åàV—²ŽuA“à–ì’qMA’Ò‘åŽ÷A»ì—zˆêA—閨аA—é–Ø’‘ãAt“úL”üA‹´–{”ŽAŒ–ØŒ˜ˆê˜YAX–{’B–çAˆÉ“¡–M•FA‰êì‹`”VA“à“cM–çF–òŠw‹³ˆç‚É‚¨‚¯‚éˆã—ÃRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“‹y‚шã—ÃXƒLƒ‹‹³ˆç‚Ì‚½‚ß‚Ì ‰¼‘zŒ»ŽÀiVRjƒRƒ“ƒeƒ“ƒc‚ÌŠJ”
¶ŠUŒ’N‰ÈŠwƒWƒƒ[ƒiƒ‹, 2, 11-23i2024j
2. Yoshinori Nakano, Motoyasu Miura, Noriyuki Namiki, Shinya Uchida: Effects of Flavors on Taste Sensation of Pioglitazone Orally Disintegrating Tablets.
Chem Pharm Bull., 72, 936-943i2024j
3. ”‘qNŽ¡A“n•Ó“úØŽqA‘åé^—“ÞAŽO‰YŠî–õA•À–Ø“¿”VA“à“cM–çFŒû“à‰Š—\–h‚¨‚æ‚ÑŽ¡—Âð–Ú“I‚Æ‚µ‚½‰@“à»ÜƒAƒƒvƒŠƒm[ƒ‹‚¨‚æ‚у|ƒ‰ƒvƒŒƒWƒ“ƒNƒtƒH[ƒ€»Ü‚ÌŠJ”
“ú–{•a‰@–òÜŽt‰ïŽGŽ, 60, 1095-1100i2024j
4. ŽO‰YŠî–õA—閨аA‹e’r‘å–²A‹{‘‘å‰îAˆä–{~ŽqA‰Í–{¬•S‡A”‘qNŽ¡AóˆäŸŽqAŽR–{–ƒ—¢ŽqAˆÉ“¡Ž¡AŽR“àŽÆA“à“cM–çFF·’l‚ð—p‚¢‚½‹qŠÏ“IùÜ’…F•]‰¿–@‚ÌŠJ”
ˆã—ÖòŠw, 50, 387-396i2024j
5. Motoyasu Miura, Seiki Kojima, Shimako Tanaka, Yasuharu Kashiwagura, Noriyuki Namiki, Shinya Uchida: Palatability evaluation of orally disintegrating tablets using a visual analog scale in clinical trials.
Int J Clin Pharmacol Ther., 62, 353-362i2024j
6. ²X–؈ê‘ãA“c’†—T”VA”Ñ“‡G–¾A¼ˆä’—TABi JingAœA“c¹–ëA“à“cM–çF”ñ‚—î2 Œ^“œ”A•aгŽÒ‚É‚¨‚¯‚éŒûo“à•ö‰óù‚ɑ΂·‚é–ž‘«“x\Œ’N•ÛŒ¯ƒf-ƒ^‚ð˜AŒg‚³‚¹‚½Web ƒAƒ“ƒP[ƒg’²¸\
–ò—‚ÆŽ¡—Ã, 52, 1161-1183i2024j
[‘à]
1. ŽO‰YŠî–õA“à“cM–çF‚‚·‚è‚Ì“Y‰ÁÜ‘å‘S@ŒÅŒ`ÜE”¼ŒÅŒ`Ü•Ò@‹¸–¡Ü
’²Ü‚Æî•ñ, 30, 63-65i2024j
2. ‰Í–{¬•S‡A“à“cM–çF‚‚·‚è‚Ì“Y‰ÁÜ‘å‘S@ŒÅŒ`ÜE”¼ŒÅŒ`Ü•Ò@–FÜ^—¿^’…Ü
’²Ü‚Æî•ñ, 30, 66-68i2024
[’˜‘]
1. {ŽR—R‰ÀŽqA“à“cM–çF‘æ4Í Case 1 ”D•w@
ŠO—ˆE–ò‹ÇŠ´õÇŠw@R‹Û–ò‚Ì“K³Žg—p‚âÁ“Å–ò‚ð—p‚¢‚½Š´õ‘Îô‚É‹‚‚È‚é•poƒP[ƒXƒXƒ^ƒfƒBApp.178-183i2024j
[ƒvƒƒV[ƒfƒBƒ“ƒO]
1. ‰Í–{¬•S‡A•À–Ø“¿”VA“à“cM–çF‰@“à»ÜƒAƒŠƒsƒvƒ‰ƒ][ƒ‹ŠÜ—LƒOƒ~»Ü‚ÌŠJ”F‰@“à»Ü‚Æ‚µ‚Ă̒²»‚Æ•ž—pŠ´
PLCMik–òjŒ¤‹†‰ï ‘æ 17 ‰ñƒVƒ“ƒ|ƒWƒEƒ€u‰‰—vŽ|WApp.9-12A2024”N2ŒŽ22“ú
[Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€]
1. ‰Í–{¬•S‡A•À–Ø“¿”VA“à“cM–çF‰@“à»ÜƒAƒŠƒsƒvƒ‰ƒ][ƒ‹ŠÜ—LƒOƒ~»Ü‚ÌŠJ”F‰@“à»Ü‚Æ‚µ‚Ă̒²»‚Æ•ž—pŠ´
PLCMik–òjŒ¤‹†‰ï‘æ17‰ñƒVƒ“ƒ|ƒWƒEƒ€i–¼ŒÃ‰®jA2024”N2ŒŽ22“ú
2. ‰ª‘º—I^A‰Í–{¬•S‡AŽRú±—MAŽO‰YŠî–õA”‘qNŽ¡A—閨аAŽR“àŽÆA“à“cM–çF|Ž_ƒJƒ‹ƒVƒEƒ€ŠÜ—LƒOƒ~»Ü‚Ì’²»‹y‚Ñ•ž—p«‚Ì•]‰¿
“ú–{–òŠw‰ï‘æ144”N‰ïi‰¡•ljA2024”N3ŒŽ29“ú
3. ‘å‘ëWˆêAŽO‰YŠî–õA‹e’r‘å–²A‰Í–{¬•S‡A”‘qNŽ¡A—閨аAŽR“àŽÆA“à“cM–çFùÜ‚ÌF·’l‚ð—p‚¢‚½‹qŠÏ“I’…F•]‰¿–@‚ÌŒŸ“¢
“ú–{–òŠw‰ï‘æ144”N‰ïi‰¡•ljA2024”N3ŒŽ29“ú
4. ’†‘º‹M‰ÀAŽO‰YŠî–õArˆä—B‰ÔA{ŽR—R‰ÀŽqA‰Í–{¬•S‡A”‘qNŽ¡A“à“cM–çFVancomycin‚̉‰ñTDM‚ÉŠî‚ÂŒŒŸ÷’†”Z“x—\‘ª‚̑Ó–«
“ú–{–òŠw‰ï‘æ144”N‰ïi‰¡•ljA2024”N3ŒŽ29“ú
5. ¼ŽR—R^AŽO‰YŠî–õA•Ÿ“cÊ…A‰Í–{¬•S‡A”‘qNŽ¡A“à“cM–çF‰t‘Ì‚‘¬ƒNƒƒ}ƒgƒOƒ‰ƒt/Ž¿—Ê•ªÍŒv‚ð—p‚¢‚½5Ží‚Ìã”笒·ˆöŽqŽó—e‘̃`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQ–ò‚ÌŒŒŸ÷’†”Z“x“¯Žž’è—Ê–@
“ú–{–òŠw‰ï‘æ144”N‰ïi‰¡•ljA2024”N3ŒŽ31“ú
6. ŽÂŒ´—C“ÞA”‘qNŽ¡AŽRª‘‹IŽqAXš —D‰ÔA‰Í–{¬•S‡AŽO‰YŠî–õA“à“cM–çFƒQƒ‹Œ`¬“Á«‚ð—L‚·‚éåñጎ¡—×pƒtƒH[ƒ€»Ü
“ú–{–òÜŠw‰ï‘æ39”N‰ïi_ŒËjA2024”N5ŒŽ23“ú
7. •y“c—C‘¾˜YA”‘qNŽ¡AâV“¡ŠJA—é–Ø“Þ—YlA‰Í–{¬•S‡AŽO‰YŠî–õA¼ˆä—ÇŠ²A“à“cM–çF’ˆÓŒ‡”@E‘½“®ÇŽ¡—Âð–Ú“I‚Æ‚µ‚½ƒAƒgƒ‚ƒLƒZƒ`ƒ“ŠÜ—Lƒe[ƒv»Ü‚ÌŠJ”
“ú–{–òÜŠw‰ï‘æ39”N‰ïi_ŒËjA2024”N5ŒŽ23“ú
8. ‰Í–{¬•S‡A‰ª‘º—I^AŽRú±—MAŽO‰YŠî–õA”‘qNŽ¡A—閨аAŽR“àŽÆA•À–Ø“¿”VA“à“cM–çF‘¬‚â‚©‚È•ö‰ó«‚Æ—D‚ꂽ•ž—pŠ´‚ð—L‚·‚é|Ž_ƒJƒ‹ƒVƒEƒ€Œûo“à•ö‰óù‚Ì’²»
“ú–{–òÜŠw‰ï‘æ39”N‰ïi_ŒËjA2024”N5ŒŽ25“ú
9. ŽO‰YŠî–õA‘å‘ëWˆêAˆä–{~ŽqA‰Í–{¬•S‡A”‘qNŽ¡A—閨аAŽR“àŽÆA“à“cM–çFŽÀ—Õ°‚ւ̉ž—p‚ð–ÚŽw‚µ‚½F·’l‚ð—p‚¢‚½‹qŠÏ“IùÜ’…F•]‰¿–@
“ú–{–òÜŠw‰ï‘æ39”N‰ïi_ŒËjA2024”N5ŒŽ25“ú
10. Motoyasu Miura, Shimako Tanaka, Yasumi Nakashima, Yasuharu Kashiwagura, Mariko Tatsuguchi, Keiichi Odagiri, Noriyuki Namiki, Naoki Inui, Hiroshi Watanabe, Shinya Uchida: Population pharmacokinetic analysis of drugs for pulmonary hypertension and estimation of plasma concentrations in pediatric and adult patients
16th congress of the European Association for Clinical Pharmacology and TherapeuticsiRotterdam, NetherlandjA2024”N6ŒŽ10“ú
11. Tatsuya Yagi, Yasuaki Mino, Hiromi Kato, Matsuyuki Doi, Soichiro Mimuro, Yoshiki Nakajima, Takafumi Naito, Motoyasu Miura, Junichi Kawakami: Association between dexmedetomidine concentration in plasma and sleep quality in postoperative patients; a prospective observational study
16th congress of the European Association for Clinical Pharmacology and TherapeuticsiRotterdam, NetherlandjA2024”N6ŒŽ10“ú
12. Shinya Uchida, Motoyasu Miura, Seiki Kojima, Yasuharu Kashiwagura, Noriyuki Namiki: Palatability evaluation of orally disintegrating tablets using a visual analog scale in clinical trials
16th congress of the European Association for Clinical Pharmacology and TherapeuticsiRotterdam, NetherlandjA2024”N6ŒŽ10“ú
13. “à“cM–çFODùŠJ”‚Ì‚½‚߂̗հ»ÜŠwŒ¤‹†
‘æ“ñ‰ñ ’†“úˆã–ò•i»Ü‚ÆŒûo“à•ö‰óùƒZƒ~ƒi[i’†‘E‘å˜AjA2024”N6ŒŽ24“ú
14. Mariko Tatsuguchi, Ryota Satoh, Keitaro Akita, Yuma Nishiyama, Motoyasu Miura, Shinya Uchida, Naoki Inui, Yuichiro Maekawa, Hiroshi Watanabe: Effects of balloon pulmonary angioplasty on the pharmacokine cs of riociguat in pa ents with chronic thromboembolic pulmonary hypertension
7th World Symposium on Pulmonary HypertensioniBarcelona, SpainjA2024”N6ŒŽ29“ú
15. ŽO‰YŠî–õA‘å‘ëWˆêAˆä–{~ŽqA‰Í–{¬•S‡A”‘qNŽ¡A—閨аAŽR“àŽÆA“à“cM–çFŽÀ—Õ°‚É‚¨‚¯‚é”x‚ŒŒˆ³Ž¡—Öò‚Ì¬Ž™‹y‚ѬlгŽÒ¬‡•êW’c–ò•¨“®‘Ôƒ‚ƒfƒ‹‚Ì\’z
‘æ70‰ñ“ú–{–òŠw‰ï“ŒŠCŽx•”‘å‰ïi–¼ŒÃ‰®jA2024”N7ŒŽ6“ú
16. ŽO‰YŠî–õA“c’†Ž‡äAŒÑ“cW‰›A’†›¸”ª‹÷A—´Œû–œ—¢ŽqA¬“cØŒ\ˆêA•À–Ø“¿”VAŠ£’¼‹PA“nç³—TŽiA“à“cM–çF¬Ž™‹y‚ѬlгŽÒ‚É‚¨‚¯‚é”x‚ŒŒˆ³Ž¡—Öò‚Ì•êW’c–ò•¨“®‘Ô‰ðÍ
‘æ9‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïi‹v—¯•ÄjA2024”N8ŒŽ10“ú
17. ‰Í–{¬•S‡A‰ª‘º—I^AŽO‰YŠî–õA”‘qNŽ¡A—閨аAŽR“àŽÆA“à“cM–çF—D‚ꂽ•ž—pŠ´‚ð—L‚·‚é|Ž_ƒJƒ‹ƒVƒEƒ€ŠÜ—LŒoŒû»Ü‚Ì’²»
‘æ29‰ñ ‘n܃tƒH[ƒ‰ƒ€ ŽáŽèŒ¤‹†‰ïiɪjA2024”N9ŒŽ12“ú
18. ‰Í–{¬•S‡F¬Ž™Š³ŽÒ‚Ö‚Ì—Õ°‰ž—p‚ð–ÚŽw‚µ‚½‰@“à»ÜƒXƒ‹ƒtƒ@ƒƒgƒLƒTƒ][ƒ‹/ƒgƒŠƒƒgƒvƒŠƒ€ŠÜ—LƒOƒ~»Ü‚ÌŠJ”
USƒtƒH[ƒ‰ƒ€2024iɪjA2024”N9ŒŽ27“ú
19. “à“cM–çA²X–؈ê‘ãA“c’†—T”VA”Ñ“‡G–¾A¼ˆä’—TABi JingAœA“c¹–ëF”ñ‚—î2Œ^“œ”A•aгŽÒ‚É‚¨‚¯‚éODù‚Ö‚Ì–ž‘«“x`ƒŒƒZƒvƒgî•ñ‚Æ•R‚¯‚½WebƒAƒ“ƒP[ƒg’²¸
‘æ12‰ñ“ú–{‚‚·‚è‚Æ“œ”A•aŠw‰ïŠwpW‰ïiå‘äjA2024”N10ŒŽ6“ú
20. ¥‰i^•áAⓌᩉîA‘å—ѳ˜aAŸÇ“cŠ]A¼“‡‹ÅAŽR–{–ƒ—¢ŽqAŽO‰YŠî–õA“à“cM–çF‹}«ƒJƒtƒFƒCƒ“’†“łɑ΂µ‚ÄŒŒ‰t“§Í‚ðŽÀŽ{‚µ‚½1—á
‘æ52‰ñ“ú–{‹~‹}ˆãŠw‰ï‘‰ïEŠwpW‰ïiå‘äjA2024”N10ŒŽ15“ú
21. ŽO‰YŠî–õA‘å‘ëWˆêAˆä–{~ŽqA‰Í–{¬•S‡A”‘qNŽ¡A—閨аAŽR“àŽÆA“à“cM–çFùÜ‚ÌF·’l‚ð—p‚¢‚½’…F•]‰¿‹y‚у‰ƒ}ƒ“Œ°”÷‹¾‚ð—p‚¢‚½•\–Ê•ªÍ
“ú–{•a‰@–òÜŽt‰ï“ŒŠCƒuƒƒbƒNE“ú–{–òŠw‰ï“ŒŠCŽx•”‡“¯Šwp‘å‰ï2024iŠò•ŒjA2024”N10ŒŽ27“ú
22. {ŽR—R‰ÀŽqA¬“c’m‘åA_ŒËGŒ›AŽO‰YŠî–õA“à“cM–çAŸNˆä˜aŽqFL”͈͔MгŽÒ‚ÅA”ç³’…‘OŒã‚Ńoƒ“ƒRƒ}ƒCƒVƒ“ƒNƒŠƒAƒ‰ƒ“ƒX‚ª‘å‚«‚•Ï“®‚µ‚½ˆêÇ—á
‘æ34‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiç—tjA2024”N11ŒŽ4“ú
23. ‰Í–{¬•S‡A‰ª‘º—I^AŽRè—MAŽO‰YŠî–õA”‘qNŽ¡A—閨аAŽR“àŽÆA•À–Ø“¿”VA“à“cM–çF•ž–òƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚ð–ÚŽw‚µ‚½|Ž_ƒJƒ‹ƒVƒEƒ€ŠÜ—LŒûo“à•ö‰óùAƒ~ƒjƒ^ƒuƒŒƒbƒg‹y‚уOƒ~»Ü‚Ì’²»‚Æ•ž—p«•]‰¿
‘æ34‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiç—tjA2024”N11ŒŽ4“ú
24. “à“cM–çFyƒVƒ“ƒ|ƒWƒEƒ€ 1z–òÜŽt‚Ì’nˆæ•Î݉ðÁ‚ÉŒü‚¯‚Äu–òŠw•”㋉¶‚Ɖº‹‰¶‚ª‡“¯‚µ‚½Ã‰ªŒ§‰Á–Î’n‹æ‚ł̒nˆæˆã—ÃŽÀK‚ÌŽŽ‚Ý v
‘æ96‰ñˆã—ÖòŠwŒöŠJƒVƒ“ƒ|ƒWƒEƒ€iɪjA2024”N11ŒŽ10“ú
25. ŽO‰YŠî–õA“c’†Ž‡äŽqAŒÑ“cW‰›A’†›¸”ª‹÷A—´Œû–œ—¢ŽqA¬“cØŒ\ˆêA‰Í–{¬•S‡A”‘qNŽ¡A•À–Ø“¿”VAŠ£’¼‹PA“nç³—TŽiA“à“cM–çFƒxƒCƒY–@‚ð—p‚¢‚½¬Ž™‹y‚Ѭl”x“®–¬«”x‚ŒŒˆ³Š³ŽÒ‚ÌŒŒŸ÷’†–ò•¨”Z“x„’è
‘æ45‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïié‹ÊjA2024”N12ŒŽ14“ú
26. ΓcŒõ‹HAŽO‰YŠî–õArˆä—B‰ÔAŽR–{–ƒ—¢ŽqA¼“‡‹ÅA‰Í–{¬•S‡A”‘qNŽ¡AˆÉ“¡Ž¡A“à“cM–çFBromovalerylurea’·Šú‰ß—Ê•ž—pгŽÒ‚Ì’èíó‘Ô‚É‚¨‚¯‚錌´’†–ò•¨”Z“x„’è‚ðs‚Á‚½1Ç—á
‘æ45‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïié‹ÊjA2024”N12ŒŽ14“ú
27. —´Œû–œ—¢ŽqA²“¡—º‘¾AH“cŒh‘¾˜YAŽO‰YŠî–õA“à“cM–çAŠ£’¼‹PA‘Oì—Tˆê˜YA“nç³—TŽiFBPA‘OŒã‚ÅƒŠƒIƒVƒOƒAƒg‚ƃGƒhƒLƒTƒoƒ“‚Ì–ò•¨“®‘Ô‚ðŒŸ“¢‚µ‚½CTEPH‚Ì3Ç—á
‘æ45‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïié‹ÊjA2024”N12ŒŽ14“ú
28. ‰Í‡•ÛŽ}AˆÉ“¡—R•FA’†ˆäŒ‹“ÞAŽO‰YŠî–õA“à“cM–çA’†‘ºl”ŽAŒÃ“‡‘厑A“cŒF‹K•ûAˆßŠ}mA‘댴FéAŽR“c_F‘å‹K–ÍŽ©Žå—Õ°ŽŽŒ±‚̃f[ƒ^ƒ}ƒlƒWƒƒ“ƒg‚É‚¨‚¯‚éPython‚ðŽg—p‚µ‚½ì‹ÆŒø—¦‰»‚ÌŽŽ‚Ý
‘æ45‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïié‹ÊjA2024”N12ŒŽ14“ú
[ŽóÜ]
1. ‰ª‘º—I^FŠw¶—DG”•\Üu|Ž_ƒJƒ‹ƒVƒEƒ€ŠÜ—LƒOƒ~»Ü‚Ì’²»‹y‚Ñ•ž—p«‚Ì•]‰¿v
“ú–{–òŠw‰ï‘æ144”N‰ïA2024”N3ŒŽ28“ú`31“ú
2. ŽO‰YŠî–õF—DG‰‰‘èÜuƒxƒCƒY–@‚ð—p‚¢‚½¬Ž™‹y‚Ѭl”x“®–¬«”x‚ŒŒˆ³Š³ŽÒ‚ÌŒŒŸ÷’†–ò•¨”Z“x„’èv
‘æ45‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïA2024”N12ŒŽ13“ú`14“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
1.Yasuharu Kashiwagura, Shota Takusagawa, Yasuyuki Ikematsu, Shimako Tanaka, Noriyuki Namiki, Shinya Uchida: Tablet characteristics and pharmacokinetics of orally disintegrating tablets containing coenzyme Q10 granules prepared by different methods.
Acta Pharm., 73, 107-119i2023j
2. Sayuri Kawamoto, Shimako Tanaka, Motoyasu Miura, Yasuharu Kashiwagura, Chiaki Kamiya, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki, Shinya Uchida: Palatability of Aripiprazole Gummies Prepared from Commercially Available Products: Pharmaceutical Formulation for Improving Patient Adherence
Chem Pharm Bull., 71, 441-446i2023j
3.Shimako Tanaka, Sayuri Kawamoto, Yasuharu Kashiwagura, Akio Hakamata, Keiichi Odagiri, Takashi Okura, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki, Shinya Uchida: Improved Palatability of Gummy Drugs of Epinastine Hydrochloride Using Organoleptic Taste-Masking Methods
BPB reports, 6, 184-188i2023j
[‘à]
1. {ŽR—R‰ÀŽqA“à“cM–çFƒP[ƒX‚ł킩‚鈕ûⳂ̃`ƒFƒbƒNƒ|ƒCƒ“ƒgŠO—ˆE–ò‹ÇŠ´õÇŠw ‘æ10‰ñ ”D•w^Žö“û•w
ŒŽŠ§–òŽ–, 65, 333- 337i2023j
[Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€]
1. rˆä—B‰ÔAŽO‰YŠî–õAŽá¼‚µ‚Ì‚ÔA“c’†Ž‡äŽqA—´Œû^—ŽqA_’Jç–¾AˆÀˆäGŽ÷A²“¡—º‘¾AH“cŒh‘¾˜YAŠ£’¼‹PA“nç³—TŽiA‘Oì—Tˆê˜YA“à“cM–çFRiociguat‚ƃoƒ‹[ƒ“”x“®–¬Œ`¬p‚Ì•¹—p—Ö@‚ðŽÀŽ{‚µ‚½–«ŒŒðÇð«”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚錌Ÿ÷’†–ò•¨”Z“x
“ú–{–òŠw‰ï‘æ143”N‰ïiŽD–yjA2023”N3ŒŽ27“ú
2. —é–Ø“Þ—YlA”‘qNŽ¡AâV“¡ŠJAŽO‰YŠî–õA¼ˆä—ÇŠ²A“à“cM–çFƒe[ƒv»Ü‚É‚¨‚¯‚éƒAƒgƒ‚ƒLƒZƒ`ƒ“‚Ìin vitro”畆“§‰ß«‚É‹y‚Ú‚·Œo”ç‹zŽû‘£i܂̉e‹¿
“ú–{–òŠw‰ï‘æ143”N‰ïiŽD–yjA2023”N3ŒŽ28“ú
3. ŽRª‘‹IŽqA”‘qNŽ¡A“n•Ó“úØŽqAŽÂŒ´—C“ÞA‰Í–{¬•S‡AŽO‰YŠî–õA“à“cM–çFåñጂ̑n•”‚ŃQƒ‹‰»‚·‚郈ƒE‘fŠÜ—LƒtƒH[ƒ€»Ü‚Ì’²»
“ú–{–òÜŠw‰ï‘æ38”N‰ïi–¼ŒÃ‰®jA2023”N5ŒŽ17“ú
4. ŽRú±—MA‰Í–{¬•S‡AŽ›“c•üŽjA“c’†Ž‡äŽqA”‘qNŽ¡A‘D“nŽOŒ‹A¬ŠÖ“¹•vA‰““n¹—A—Ñ@@‘å’nA•À–Ø“¿”VA‘å¼G“TA—é–Øº•vA—ÑGŽ÷A“à“cM–çF¬Ž™Š³ŽÒ‚ð‘ÎÛ‚Æ‚µ‚½‰@“à»ÜƒXƒ‹ƒtƒ@ƒƒgƒLƒTƒ][ƒ‹EƒgƒŠƒƒgƒvƒŠƒ€”z‡ÜŠÜ—LƒOƒ~»Ü‚ÌŠJ”
“ú–{–òÜŠw‰ï‘æ38”N‰ïi–¼ŒÃ‰®jA2023”N5ŒŽ17“ú
5. •Ÿ“cÊ…AŽO‰YŠî–õAŽR–{xA“c’†Ž‡äŽqAŒÑ“cW‰›AŒÑ“cW‰›A’†›¸”ª‹÷A”‘qNŽ¡A—´Œû–œ—¢ŽqA¬“cØŒ\ˆêA•À–Ø“¿”VAŠ£’¼‹PA“nç³—TŽiA“à“cM–çF¬Ž™‹y‚Ѭl”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚étadalafil‹y‚Ñambrisentan‚Ì•êW’c–ò•¨“®‘Ô‰ðÍ
“ú–{–òÜŠw‰ï‘æ38”N‰ïi–¼ŒÃ‰®jA2023”N5ŒŽ17“ú
6. ‰Í–{¬•S‡A“c’†Ž‡äŽqAŽO‰YŠî–õA”‘qNŽ¡A_’Jç–¾AŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VA“à“cM–çFƒAƒŠƒsƒvƒ‰ƒ][ƒ‹ŠÜ—LƒOƒ~»Ü‚ÌŒ’N¬l‚ð‘ÎÛ‚Æ‚µ‚½–¡ŠoН”\ŽŽŒ±
‘æ7‰ñ“ú–{—Õ°–ò—Šw‰ï@“ŒŠCE–k—¤’n•û‰ïiƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2023”N6ŒŽ4“ú
7. “à“cM–çFƒCƒ“ƒgƒƒ_ƒNƒVƒ‡ƒ“
ƒVƒ“ƒ|ƒWƒEƒ€u’²Üã‚ÌH•v‚©‚ç¶‚Ü‚ê‚éV‚½‚Ȼ܂̉”\«—Õ°‰ž—p‚Ö‚Ì—Õ°–ò—“IƒAƒvƒ[ƒ`v
‘æ7‰ñ“ú–{—Õ°–ò—Šw‰ï@“ŒŠCE–k—¤’n•û‰ïiƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2023”N6ŒŽ4“ú
8. ŽO‰YŠî–õA“c’†Ž‡äŽqA²“¡—º‘¾A”‘qNŽ¡A—´Œû–œ—¢ŽqA•À–Ø“¿”VAŠ£’¼‹PA‘Oì—Tˆê˜YA“nç³—TŽiA“à“cM–çF’¼ÚŒoŒûR‹ÃŒÅ–ò‚Ì–ò•¨Ž¡—ƒjƒ^ƒŠƒ“ƒO‚ւ̉ž—p‚ð–Ú“I‚Æ‚µ‚½ŒŒŸ÷’†”Z“x‚ÌLC/MS“¯Žž’è—Ê–@‚ÌŠm—§
‘æ39‰ñ“ú–{TDMŠw‰ïEŠwp‘å‰ïi‹ž“sjA2023”N6ŒŽ24“ú
9. Shinya Uchida, Motoyasu Miura, Shimako Tanaka, Chiaki Kamiya, Keiichi Odagiri, Noriyuki Namiki, Naoki Inui, Hiroshi Watanabe: Verification of an approach for quantitative drug-drug interaction assessment and prediction of the area under the curve using limited-point blood sampling in a cocktail study.
19th World Congress of Basic & Clinical PharmacologyiGlasgow, ScotlandjA2023”N7ŒŽ4“ú
10. ‰Í–{¬•S‡A“c’†Ž‡äŽqAŽO‰YŠî–õA”‘qNŽ¡AŠ£’¼‹PA“nç³—TŽiA•½‰ªû€ŒáA•À–Ø“¿”VA“à“cM–çFƒAƒŠƒsƒvƒ‰ƒ][ƒ‹Œûo“à•ö‰óù‚ð—p‚¢‚½ƒOƒ~»Ü‚ÌŠJ”‚Æ•ž—p«•]‰¿
‘æ31‰ñDDSƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXiɪ{ƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2023”N9ŒŽ8“ú
11. ‹e’r‘å–²AŽO‰YŠî–õA‘å‘ëWˆêA‹{‘‘å‰îA‰Í–{¬•S‡A”‘qNŽ¡A—閨аAŽR“àŽÆA“à“cM–çF F·’l‚É‚æ‚éùÜ’…F•]‰¿‚ÌŠJ”
‘æ17‰ñŽŸ¢‘ã‚ð’S‚¤ŽáŽè‚Ì‚½‚߂̈ã—Öò‰ÈŠwƒVƒ“ƒ|ƒWƒEƒ€i¼–{jA2023”N9ŒŽ16“ú
12. ŒË’ËŒö‘åA‰Í–{¬•S‡AŽO‰YŠî–õA”‘qNŽ¡AˆÀˆäGŽ÷AŠ£’¼‹PA“à“cM–çF‰t‘̃Nƒƒ}ƒgƒOƒ‰ƒtŽ¿—Ê•ªÍŒv‚ð—p‚¢‚½ŒŒŸ÷’†ƒjƒ“ƒeƒ_ƒjƒu”Z“x•ªÍ–@‚ÌŠJ”‚ƃoƒŠƒf[ƒVƒ‡ƒ“
‘æ17‰ñŽŸ¢‘ã‚ð’S‚¤ŽáŽè‚Ì‚½‚߂̈ã—Öò‰ÈŠwƒVƒ“ƒ|ƒWƒEƒ€i¼–{jA2023”N9ŒŽ17“ú
13. ŽO‰YŠî–õF–òÜŽt”ŽŽm‚ÌŠˆ–ô -–òÜŽt‹y‚Ñ‘åŠw‹³ˆõ‚Ì—§ê‚©‚ç-
—ߘa5”N“x‘æˆê‰ñ‘Œö—§‘åŠwlވ笃[ƒNƒVƒ‡ƒbƒvi‘åãjA2023”N9ŒŽ30“ú
14. Motoyasu Miura, Shimako Tanaka, Chiaki Kamiya, Naoki Katayama, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Junichi Kawakami, Hiroshi Watanabe, Noriyuki Namiki, Shinya Uchida: Verification of a cocktail approach for quantitative drug-drug interaction assessment by a comparative analysis between the results of a single drug and cocktail drug
‘æ33‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiå‘äjA2023”N11ŒŽ3“ú
15. ‘åàV—²ŽuAˆÉ“¡–M•FAX–{’B–çA•숺ŽqA“à“cM–çA–î•”Ÿ–ÎA‰Í¼‚«‚æ‚ÝA—é–Ø‹M–çAˆäŒ´ÛŽqA ŸNˆäŒ’ŽjAˆäã’BGAŽR“c×YA‰êì‹`”VFɪŒ§—§‘åŠwE•a‰@E’nˆæ–ò‹Ç˜AŒg‚É‚æ‚é–ò•¨—Ö@Œ¤C‰ï‚ÌŒ»‹µ
‘æ33‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiå‘äjA2023”N11ŒŽ4“ú
16. ‰Í–{¬•S‡A“c’†Ž‡äŽqAŽO‰YŠî–õA”‘qNŽ¡A_’Jç–¾AŒÑ“cW‰›A¬“cØŒ\AŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VA“à“cM–çF‰@“à»ÜƒAƒŠƒsƒvƒ‰ƒ][ƒ‹ŠÜ—LƒOƒ~»Ü‚Ì’²»‚Æ‚»‚Ì•ž—p«•]‰¿
‘æ33‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiå‘äjA2023”N11ŒŽ4“ú
17. ”‘qNŽ¡AŽRª‘‹IŽqAŽÂŒ´—C“ÞA‰Í–{¬•S‡AŽO‰YŠî–õA“à“cM–çFåñጎ¡—Âð–Ú“I‚Æ‚µ‚½‰@“à»ÜƒˆƒE‘fŠÜ—LƒtƒH[ƒ€»Ü‚Ì’²»
‘æ33‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiå‘äjA2023”N11ŒŽ4“ú
18. ”‘qNŽ¡F•ªŒõƒCƒ[ƒWƒ“ƒO‹Zp‚ð—p‚¢‚½ƒe[ƒv»Ü‚̻܊w“I•]‰¿
USƒtƒH[ƒ‰ƒ€2023iɪjA2023”N11ŒŽ17“ú
19. ŽO‰YŠî–õFÅVƒoƒ“ƒRƒ}ƒCƒVƒ“•êW’c–ò•¨“®‘Ôƒpƒ‰ƒ[ƒ^ŽZo‹y‚ÑÅ“KŒŒ’†ƒoƒ“ƒRƒ}ƒCƒVƒ“”Z“xƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“ƒVƒXƒeƒ€Šm—§
USƒtƒH[ƒ‰ƒ€2023iɪjA2023”N11ŒŽ17“ú
20. ”ª–Ø’B–çAŒ©–ì–õWAŽO‰YŠî–õA‰Á“¡O”üA“à“¡—²•¶A“yˆä¼KAŒäŽº‘ˆêA’†“‡–FŽ÷AìトêFpŒãгŽÒ‚É‚¨‚¯‚éƒfƒNƒXƒƒfƒgƒ~ƒWƒ“‚̇–°‚ÌŽ¿‰ü‘PŒø‰Ê‚̌‘̊ԕϓ®—vˆö‚ÌŒŸØ
‘æ44‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi_ŒËjA2023”N12ŒŽ14“ú
21. ŽO‰YŠî–õA¬“‡´Ž÷A”‘qNŽ¡A•À–Ø“¿”VA“à“cM–çFŒûo“à•ö‰óù•ž—p«•]‰¿‚É‚¨‚¯‚éVisual analogue scales‚ÌŒQŠÔ‹y‚ÑŒJ•Ô‚µÄŒ»«‚ÌŒŸ“¢
‘æ44‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi_ŒËjA2023”N12ŒŽ15“ú
22. —´Œû–œ—¢ŽqA²“¡—º‘¾AH“cŒh‘¾˜YAŽO‰YŠî–õA“à“cM–çAŠ£’¼‹PA‘Oì—Tˆê˜YA“nç³—TŽiFBPA‘OŒã‚ÅƒŠƒIƒVƒOƒAƒg‚Ì–ò•¨“®‘Ô‚ðŒŸ“¢‚µ‚½CTEPH‚Ì9Ç—á
‘æ44‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi_ŒËjA2023”N12ŒŽ16“ú
[‚»‚Ì‘¼‚ÌŠ§s•¨]
1. Œ´“c“wA¼–{’OAˆÀ•”˜a–çA‚]¾ŽŒAˆÀ“cºmA”‘qNŽ¡FƒtƒH[ƒJƒXƒOƒ‹[ƒv‚Ì‚±‚ê‚܂ł̋OÕ‚Æ¡Œã‚Ì“W–] : ¬Ž™»ÜFG
–òÜŠw, 83, 50-54i2023j
2. ‰Í–{¬•S‡FV”Cˆ¥ŽAu•a‰@–òÜŽt‚¾‚Á‚½Ž„‚ÌV‚½‚ȃXƒ^[ƒgv
ÖòŠw—F‰ï•ñ, 91, 24i2023j
[ŽóÜ]
1. —é–Ø“Þ—YlFŠw¶—DG”•\Üuƒe[ƒv»Ü‚É‚¨‚¯‚éƒAƒgƒ‚ƒLƒZƒ`ƒ“‚Ìin vitro”畆“§‰ß«‚É‹y‚Ú‚·Œo”ç‹zŽû‘£i܂̉e‹¿v
“ú–{–òŠw‰ï‘æ143”N‰ïA2023”N3ŒŽ25“ú`28“ú
2. ŽRú±—MF޵‚¯–òÜŽt§—ãÜu¬Ž™Š³ŽÒ‚ð‘ÎÛ‚Æ‚µ‚½‰@“à»ÜƒXƒ‹ƒtƒ@ƒƒgƒLƒTƒ][ƒ‹EƒgƒŠƒƒgƒvƒŠƒ€”z‡ÜŠÜ—LƒOƒ~»Ü‚ÌŠJ”v
“ú–{–òÜŠw‰ï”N‰ïA2023”N5ŒŽ16“ú`18“ú
3. ŽO‰YŠî–õF—DG”•\ÜuŒûo“à•ö‰óù•ž—p«•]‰¿‚É‚¨‚¯‚éVisual analogue scales‚ÌŒQŠÔ‹y‚ÑŒJ•Ô‚µÄŒ»«‚ÌŒŸ“¢v
‘æ44‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïA2023”N12ŒŽ14“ú`16“ú
4. ”‘qNŽ¡F—ߘa4”N“x‹³ˆõŠˆ“®•]‰¿@Šw’·•\²
ɪŒ§—§‘åŠwA2023”N12ŒŽ18“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
1. Motoyasu Miura, Shimako Tanaka, Masahiko Ikeda, Junichi Kawakami, Hiroshi Watanabe, Noriyuki Namiki, Shinya Uchida: Increased plasma drug concentration and decreased additional insulin secretion following oral administration of glimepiride in Spontaneously Diabetic Torii rats.
Pharmazie, 77, 6-8i2022j
2. Yasuharu Kashiwagura, Akio Hakamata, Masami Shirai, Akira Endoh, Shimako Tanaka, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki, Shinya Uchida: Topical formulations of propranolol for infantile hemangiomas: characteristics of formulations and three cases of infants administered topical propranolol cream.
Chem. Pharm. Bull., 70, 277-282i2022j
3. Eiko Nagata, Yasuharu Kashiwagura, Eisaku Okada, Shimako Tanaka, Shinichiro Sano, Mitsuhiro Nishida, Satoshi Hayano, Satoru Iwashima, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Kazuo Umemura, Shinya Uchida: Efficacy and Safety of Propranolol Cream in Infantile Hemangioma: A Prospective Pilot Study.
J. Pharmacol. Sci., 149, 60-65i2022j
4. ”‘qNŽ¡A’؈äŠG”TA“c’†Ž‡äŽqA•À–Ø“¿”VA“à“cM–çF“ûŽ™ŒŒŠÇŽîŽ¡—Âð–Ú“I‚Æ‚µ‚½‰@“à»Üƒvƒƒvƒ‰ƒmƒ[ƒ‹ƒNƒŠ[ƒ€‚Ì’²»‹y‚ѻ܊w“I•]‰¿
“ú–{•a‰@–òÜŽt‰ïŽGŽ, 58, 937-942i2022j
[‘à]
1. ‰i“cŠGŽqA”‘qNŽ¡A“à“cM–çF“ûŽ™ŒŒŠÇŽî‚ð‘ÎÛ‚Æ‚µ‚½ƒvƒƒvƒ‰ƒmƒ[ƒ‹ƒNƒŠ[ƒ€‚Ì—LŒø«‚¨‚æ‚шÀ‘S«‚ÌŒŸ“¢-‘½Ž{Ý‹¤“¯”ñ–ÓŒŸ”ñ‘ÎÆŽŽŒ±
—Õ°–ò—‚Ìi•à, 43, 33-40i2022j
[Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€]
1. Ž›“c•üŽjA“c’†Ž‡äŽqA…–ìA”‘qNŽ¡A‘D“nŽOŒ‹A•À–Ø“¿”VA—é–Øº•vA—ÑGŽ÷A“à“cM–çF‰@“à»Ü‚Æ‚µ‚Ă̎g—p‚ð‘z’肵‚½ƒXƒ‹ƒtƒ@ƒƒgƒLƒTƒ][ƒ‹-ƒgƒŠƒƒgƒvƒŠƒ€”z‡ÜŠÜ—LƒOƒ~»Ü‚Ì’²»
“ú–{–òŠw‰ï‘æ142”N‰ïi–¼ŒÃ‰®AƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N3ŒŽ25“ú`28“ú
2. ŽR–{xA“c’†Ž‡äŽqAˆ¾”ÑŒ´‚è‚è‚©AŒÑ“cW‰›A’†›¸”ª‹÷A”‘qNŽ¡A—´Œû–œ—¢ŽqA¬“cØŒ\ˆêAX‘PŽ÷A•À–Ø“¿”VAŠ£’¼‹PA“nç³—TŽiA“à“cM–çF¬Ž™‹y‚Ѭl”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚ésildenafil‹y‚Ñbosentan‚Ì•êW’c–ò•¨“®‘Ô‰ðÍ
“ú–{–òŠw‰ï‘æ142”N‰ïi–¼ŒÃ‰®AƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N3ŒŽ25“ú`28“ú
3. ”‘qNŽ¡A—閨аA’؈äŠG”TA“c’†Ž‡äŽqAŽR“àŽÆA‰eŽRT“ñA•À–Ø“¿”VA“à“cM–çFŒŒ‰t“§ÍгŽÒ‚É‚¨‚¯‚郊ƒ“‹z’…–ò‚Éd“_‚ð‚¨‚¢‚½•ž–òŽw“±‚Ì—LŒø«‹y‚Ñ‚»‚Ì—vˆö’Tõ
“ú–{–òŠw‰ï‘æ142”N‰ïi–¼ŒÃ‰®AƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N3ŒŽ25“ú`28“ú
4. âV“¡ŠJA”‘qNŽ¡A“c’†Ž‡äŽqA“à“cM–çF’ˆÓŒ‡”@E‘½“®ÇŽ¡—Âð–Ú“I‚Æ‚µ‚½ƒAƒgƒ‚ƒLƒZƒ`ƒ“ƒe[ƒv»Ü‚É‚¨‚¯‚éin vitro”畆“§‰ß«
“ú–{–òÜŠw‰ï‘æ37”N‰ïi‹ž“sAƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N5ŒŽ26“ú`28“ú
5. ‹{‘‘å‰îA”‘qNŽ¡A’؈äŠG”TA“c’†Ž‡äŽqA•À–Ø“¿”VA“à“cM–çF“ûŽ™ŒŒŠÇŽîŽ¡—Âð–Ú“I‚Æ‚µ‚½‰@“à»Üƒvƒƒvƒ‰ƒmƒ[ƒ‹ƒNƒŠ[ƒ€‚Ì’²»
“ú–{–òÜŠw‰ï‘æ37”N‰ïi‹ž“sAƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N5ŒŽ26“ú`28“ú
6. ”‘qNŽ¡F—Õ°‚ÆŠî‘b‚Ƃ̗Z‡AŠO—p–ò‚Ì“Á«‚̉Ȋw“Iª‹’‚ð’m‚낤IŒ»Ý‚©‚ç–¢—ˆ‚Ö
‘æ4‰ñ”畆åñጊO—p–òŠw‰ïŠwp‘å‰ïi“Œ‹žAŒ»’n{ƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N6ŒŽ10“ú
7. “à“cM–çFf—ÃE‘n–ò‚ɂ‚Ȃª‚錤‹†‚Ì’…Šá“_‚ÆŽÀ‘H\‚Ý‚ñ‚È‚Åì‚éƒGƒrƒfƒ“ƒX
‘æ6‰ñ“ú–{—Õ°–ò—Šw‰ï@ŠÖ“ŒEbM‰z’n•û‰ïiƒIƒ“ƒ‰ƒCƒ“ŠJÃjƒVƒ“ƒ|ƒWƒEƒ€1u‘n–òE–ò•¨Ž¡—ÃŒ¤‹†‚Á‚Ăǂ̂悤‚ÉŽn‚ß‚½‚ç‚¢‚¢‚ñ‚Å‚·‚©-vA2022”N6ŒŽ25“ú
8. “c’†Ž‡äŽqAŽá¼‚µ‚Ì‚ÔAŽR–{xAŽO‰YŠî–õA²“¡—º‘¾A—´Œû–œ—¢ŽqA”‘qNŽ¡A•À–Ø“¿”VA“nç³—TŽiAŠ£’¼‹PA‘Oì—Tˆê˜YA“à“cM–çF’¼ÚŒoŒûR‹ÃŒÅ–ò‚Ì–Ô—…“I‚ÈŒŒŸ÷’†”Z“x’è—Ê–@‚ÌŠJ”‹y‚Ñ•ž—pгŽÒ‚É‚¨‚¯‚錌Ÿ÷’†”Z“x‚Ì•]‰¿
‘æ6‰ñ“ú–{—Õ°–ò—Šw‰ï@ŠÖ“ŒEbM‰z’n•û‰ïiƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N6ŒŽ25“ú
9. ŽO‰YŠî–õAâV“¡ŠJA“c’†Ž‡äŽqA”‘qNŽ¡A_’Jç–¾A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VA“à“cM–çFLimited sampling–@‚ð—p‚¢‚½ƒJƒNƒeƒ‹ŽŽŒ±‚É‚æ‚éƒVƒgƒNƒƒ€P450 ‘jŠQì—p‚Ì•]‰¿
‘æ6‰ñ“ú–{—Õ°–ò—Šw‰ï@“ŒŠCE–k—¤’n•û‰ïiƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N7ŒŽ30“ú
10. ŽR–{xA“c’†Ž‡äŽqAŽO‰YŠî–õAˆ¾”ÑŒ´‚è‚è‚©A’†›¸”ª‹÷A”‘qNŽ¡A—´Œû–œ—¢ŽqA¬“cØŒ\ˆêA•À–Ø“¿”VAŠ£’¼‹PA“nç³—TŽiA“à“cM–çF¬Ž™‹y‚Ѭl‚Ì”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚ésildenafil‹y‚Ñbosentan‚Ì„’茌Ÿ÷’†”Z“x‚Ì”äŠr
‘æ6‰ñ“ú–{—Õ°–ò—Šw‰ï@“ŒŠCE–k—¤’n•û‰ïiƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N7ŒŽ30“ú
11. ŽO‰YŠî–õA•À–Ø“¿”VA“à“cM–çFгŽÒ‚̃AƒhƒqƒAƒ‰ƒ“ƒXŒüã‚ðŽuŒü‚µ‚½»ÜÝŒv‚Ì‚½‚߂̕ž—p«•]‰¿–@
‘æ30‰ñDDSƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXiɪAŒ»’n{ƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N9ŒŽ16“ú
12. “n•Ó“úØŽqA”‘qNŽ¡A‰iˆä“úØAˆ°Œ´‚Ü‚¢‚©A‘åé^—“ÞA“c’†Ž‡äŽqA•À–Ø“¿”VA“à“cM–çF‰@“à»Ü‚Æ‚µ‚Ă̌ûo”S–Œ‰ŠŽ¡—×pƒtƒH[ƒ€»Ü‚Ì’²»
‘æ32‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi‚èAŒ»’n{ƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N9ŒŽ23“ú`9ŒŽ25“ú
13. ”‘qNŽ¡A’؈äŠG”TA“c’†Ž‡äŽqA•À–Ø“¿”VA“à“cM–çF“ûŽ™ŒŒŠÇŽîŽ¡—Âð–Ú“I‚Æ‚µ‚½‰@“à»Üƒvƒƒvƒ‰ƒmƒ[ƒ‹ƒNƒŠ[ƒ€‚Ì’²»‹y‚ѻ܊w“I•]‰¿
‘æ32‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi‚èAŒ»’n{ƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N9ŒŽ23“ú`9ŒŽ25“ú
14. —閨аA¬ì—TŽqA”‘qNŽ¡A“à“cM–çA‰eŽRT“ñAŽR“àŽÆF’¾~’YŽ_ƒJƒ‹ƒVƒEƒ€‚Ì•ž—p«‰ü‘P‚ð–Ú“I‚É•ö‰óŽžŠÔ‚ÉŠî‚»ܕÏX‚ðŒŸ“¢‚µ‚½ŒŒ‰t“§ÍгŽÒ‚Ì 2 Ç—á
‘æ32‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi‚èAŒ»’n{ƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N9ŒŽ23“ú`9ŒŽ25“ú
15. ’†¼”ü—åA”ª–Ø’B–çAΓc‘ì–îAŽR–{’mLAŽO‰Y•¶”üA‘åàVŽu•ÛA‘Š‘]—R‹NŽqA“¡“cˆ¨AŽRŒû‚ê‚ÈAˆÉ“¡—IA‘\•zìŽÀ—¢AŒÑ“c”ü“TAŠÛŽR‘DAŽO‰YŠî–õAìトêF’²Üƒƒ{ƒbƒg‚¨‚æ‚Ñ’²ÜŽx‰‡ƒVƒXƒeƒ€“±“ü‚ª‹y‚Ú‚·’²ÜƒCƒ“ƒVƒfƒ“ƒg‹y‚ш•û‰î“ü‚ւ̉e‹¿
‘æ32‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi‚èAŒ»’n{ƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N9ŒŽ23“ú`9ŒŽ25“ú
16. —閨аA¬ì—TŽqA޽”¨—”¿A“à“cM–çA‰eŽRT“ñAŽR“àŽÆFŒŒ‰t“§ÍгŽÒ‚É‚¨‚¯‚郊ƒ“‹z’…–ò‚Ì•ž—p«‚ÌŒ»ó”cˆ¬‹y‚Ñ‚»‚ÌŒüã‚ð–Ú“I‚Æ‚µ‚½»Ü•ÏX‚Ì—L—p«•]‰¿
‘æ16‰ñ“ú–{t‘Ÿ•a–ò•¨—Ö@Šw‰ïŠwpW‰ïE‘‰ïi’·èjA2022”N10ŒŽ29“ú`10ŒŽ30“ú
17. ”‘qNŽ¡A‰i“cŠGŽqA–Ζؖƒ—¢“ÞA£ŒËì—¤A‰ª“c‰hìA“c’†Ž‡äŽqA²–ìLˆê˜NA¼“cŒõGA‘–ì‘AŠâ“‡ŠoAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA”~‘º˜a•vA“à“cM–çF‰@“à»Üƒvƒƒvƒ‰ƒmƒ[ƒ‹ƒNƒŠ[ƒ€‚̻܊w“I•]‰¿‹y‚Ñ“ûŽ™ŒŒŠÇŽîгŽÒ‚ɑ΂·‚é—Õ°•]‰¿
‘æ49‰ñ“ú–{¬Ž™—Õ°–ò—Šw‰ïŠwpW‰ïi“Œ‹žAŒ»’n{ƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N11ŒŽ3“ú
18. ŽO‰YŠî–õA¬“‡´Ž÷A”‘qNŽ¡A•À–Ø“¿”VA“à“cM–çFŽá”N¬l‚Å‚Ìvisual analogue scales‚É‚æ‚éŒûo“à•ö‰óù•ž—p«•]‰¿–@‚ÌŒŸ“¢
‘æ49‰ñ“ú–{¬Ž™—Õ°–ò—Šw‰ïŠwpW‰ïi“Œ‹žAŒ»’n{ƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N11ŒŽ3“ú
19. ‰i“cŠGŽqA”‘qNŽ¡A‰ª“c‰hìA“c’†Ž‡äŽqA²–ìLˆê˜NA¼“cŒõGA‘–ì‘AŠâ“‡ ŠoAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA”~‘º˜a•vA“à“cM–çF“ûŽ™ŒŒŠÇŽîгŽÒ‚ɑ΂·‚éƒvƒƒvƒ‰ƒmƒ[ƒ‹ƒNƒŠ[ƒ€‚Ì—LŒø«‹y‚шÀ‘S«
‘æ49‰ñ“ú–{¬Ž™—Õ°–ò—Šw‰ïŠwpW‰ïi“Œ‹žAŒ»’n{ƒIƒ“ƒ‰ƒCƒ“ŠJÃjA2022”N11ŒŽ3“ú
20. ŽO‰YŠî–õAâV“¡ŠJA“c’†Ž‡äŽqA”‘qNŽ¡A_’Jç–¾A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VA“à“cM–çFƒJƒNƒeƒ‹ŽŽŒ±‚Å‚Ìlimited sampling–@‚É‚æ‚éƒVƒgƒNƒƒ€P450‚ð‰î‚·‚鑊ŒÝì—p•]‰¿
‘æ43‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi‰¡•ljA2022”N11ŒŽ30“ú`12ŒŽ3“ú
21. —´Œû–œ—¢ŽqA²“¡—º‘¾AH“cŒh‘¾˜YAŽO‰YŠî–õAŽá¼‚µ‚Ì‚ÔA“c’†Ž‡äŽqA_’Jç–¾AˆÀˆäGŽ÷A“à“cM–çA‘Oì—Tˆê˜YAŠ£’¼‹PA“nç³—TŽiFƒoƒ‹[ƒ“”x“®–¬Œ`¬p‘OŒã‚Ì–ò•¨“®‘Ô‚ðŒŸ“¢‚µ‚½–«ŒŒðÇð«”x‚ŒŒˆ³Ç‚Ì4Ç—á
‘æ43‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi‰¡•ljA2022”N11ŒŽ30“ú`12ŒŽ3“ú
[‚»‚Ì‘¼‚ÌŠ§s•¨]
1. ”‘qNŽ¡A¼ìŒ³–çF“ÁWuVŒ^ƒRƒƒiƒEƒCƒ‹ƒXƒƒNƒ`ƒ“ŠJ”‚©‚ç‚Ý‚¦‚Ä‚«‚½‘n–òEˆã—ÃE‹³ˆç‚̉ۑèv
–òÜŠw, 82, 2-3 i2022j
2. ”‘qNŽ¡FVŒ^ƒRƒƒiƒEƒCƒ‹ƒXƒƒNƒ`ƒ“ŠJ”‚©‚ç‚Ý‚¦‚Ä‚«‚½‘n–òEˆã—ÃE‹³ˆç‚̉ۑèi2jVŒ^ƒRƒƒiƒƒNƒ`ƒ“ÚŽí‚ð’Ê‚µ‚Äl‚¦‚é–òÜŽt‚Ì–¢—ˆ@”ªdŠ~ –ql~•½ˆä ‚݂ǂè~“n•” ˆêG
–òÜŠw, 82, 27-31i2022j
3. ŽO‰YŠî–õFV”Cˆ¥ŽAu•êZ‚Å‚ ‚éɪŒ§—§‘åŠw‚Å‚ÌV‚½‚ȃXƒ^[ƒgv
ÖòŠw—F‰ï•ñ, 90, 14i2022j
[ŽóÜ]
1. ŽR–{xFŠw¶—DG”•\Üu¬Ž™‹y‚Ѭl”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚ésildenafil‹y‚Ñbosentan‚Ì•êW’c–ò•¨“®‘Ô‰ðÍv
“ú–{–òŠw‰ï‘æ142”N‰ïA2022”N3ŒŽ25“ú`28“ú
2. “n•Ó“úØŽqFŒœÜ˜_•¶u–ò‚ÆŒ’N‚ÌTŠÔvu“Œ“ú–{‘åkЂ©‚ç10”NCЊQˆã—Âɂ¨‚¯‚題ã‚Ì“W–]‚ɂ‚¢‚Ä\–òŠw¶‚Ì—§ê‚©‚ç\v ‘æ 2 È
“ú–{–òÜŠw‰ïA2022 ”N 5 ŒŽ 26 “ú`28 “ú
3. ŽO‰YŠî–õF—DG‰‰‘èÜuLimited sampling–@‚ð—p‚¢‚½ƒJƒNƒeƒ‹ŽŽŒ±‚É‚æ‚éƒVƒgƒNƒƒ€P450 ‘jŠQì—p‚Ì•]‰¿v
‘æ6‰ñ“ú–{—Õ°–ò—Šw‰ï“ŒŠCE–k—¤’n•û‰ïA2022”N7ŒŽ30“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
1. Motoyasu Miura, Shimako Tanaka, Shinya Uchida, Chiaki Kamiya, Naoki Katayama, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Junichi Kawakami, Hiroshi Watanabe, Noriyuki Namiki: Prediction of the Area under the Curve Using Limited-Point Blood Sampling in a Cocktail Study to Assess Multiple CYP Activities.
Biol Pharm Bull, 44, 762-770 (2021)
2. Marina Oshiro-Sembokuya, Shinya Uchida, Yasuharu Kashiwagura, Maika Ashihara, Shimako Tanaka, Takao Hashimoto, Chiyo Kokubu, Noriyuki Namiki: Evaluation of Disappearance Time and Palatability of Foams in the Oral Cavities of Healthy Volunteers, and Preparation of Drug-Containing Foam Formulations for Use in the Treatment of Oral Mucositis.
Chem Pharm Bull, 69, 400-406 (2021)
3. Yasuharu Kashiwagura, Shinya Uchida, Akio Hakamata, Hiroshi Watanabe, Namiki Namiki. In vitro transdermal permeation and in vivo transdermal absorption of domperidone cream formulations compounded from tablets as a hospital formulation.
Pharmazie, 76, 2-5 (2021)
4. Naoki Katayama, Keiichi Odagiri, Akio Hakamata, Chiaki Kamiya, Shinya Uchida, Shimako Tanaka, Naoki Inui, Noriyuki Namiki, Koichiro Tatsumi, Hiroshi Watanabe: Clinical evaluation of drug-drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers.
Br J Clin Pharmacol, 87, 1903-1911 (2021)
5. Hiroshi Suzuki, Shinya Uchida, Yasuharu Kashiwagura, Shimako Tanaka, Katsuya Yamauchi, Shinji Kageyama, Noriyuki Namiki: Impact of community pharmacist-led intensive education on the control of serum phosphate levels in haemodialysis patients.
Int J Clin Pharm, 43, 220-228 (2021)
6. Yoshiaki Umemoto, Shimako Tanaka, Atsushi Kambayashi, Koki Sugimoto, Yasuharu Kashiwagura, Noriyuki Namiki, Shinya Uchida: Gummi Formulations Comprising Amenamevir Solid Dispersions with Polyvinyl Alcohol.
Chem Pharm Bull., 69, 862-871 (2021)
7. Motoyasu Miura, Shinya Uchida, Shimako Tanaka, Chiaki Kamiya, Naoki Katayama, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Junichi Kawakami, Hiroshi Watanabe, Noriyuki Namiki: Verification of a cocktail approach for quantitative drug-drug interaction assessment: a comparative analysis between the results of a single drug and a cocktail drug.
Xenobiotica, 51, 404-412 (2021)
[‘à]
1. “à“cM–çFŒoŒû“œ”A•a–ò‚Ì”z‡Ü‚ÆT1‰ñ»Ü‚Ì“Á’¥‚ÆŽg—p–@
DM EnsembleA10App.18-25 (2021)
[Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€]
1. ”‘qNŽ¡A–Ζؖƒ—¢“ÞA’؈äŠG”TA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VFƒNƒŒƒƒWƒ“‘¬•öù‚ðD‚Þ–«t‘Ÿ•aгŽÒ‚ɉe‹¿‚ð‹y‚Ú‚·—vˆö‚Ì’Tõ
“ú–{–òŠw‰ï‘æ141”N‰ïiL“‡AƒIƒ“ƒ‰ƒCƒ“ŠJÃjAu‰‰—vŽ|W(WEB) 27P01-229A2021”N3ŒŽ26“ú`29“ú
2. …–ìA“c’†Ž‡äŽqA—閨аAŽ›“c•üŽjA”‘qNŽ¡AŽR“àŽÆA‰eŽRT“ñA“à“cM–çA•À–Ø“¿”VF’nˆæ–ò‹Ç‚É‚¨‚¯‚é|Ž_ƒJƒ‹ƒVƒEƒ€ŠÜ—LƒOƒ~»Ü‚Ì’²»
“ú–{–òÜŠw‰ï‘æ36”N‰ïi“¿“‡AƒIƒ“ƒ‰ƒCƒ“ŠJÃjAu‰‰—vŽ|W pp.248A2021”N5ŒŽ13“ú`15“ú
3. ‰iˆä“úØA”‘qNŽ¡Aˆ°Œ´‚Ü‚¢‚©Aå–k‰®i‘åéj^—“ÞA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VFŒûo”S–Œ‰ŠŽ¡—Âð–Ú“I‚Æ‚µ‚½–ò•¨ŠÜ—LƒtƒH[ƒ€»Ü‚Ì’²»
“ú–{–òÜŠw‰ï‘æ36”N‰ïi“¿“‡AƒIƒ“ƒ‰ƒCƒ“ŠJÃjAu‰‰—vŽ|W pp.211A2021”N5ŒŽ13“ú`15“ú
4. ”‘qNŽ¡A“c’†Ž‡äŽqA‘q“ˆ—_AˆÉ“¡÷A•À–Ø“¿”VA“à“cM–çFŒ’N¬l‚¨‚æ‚Ñ‚—ŽÒ‚É‚¨‚¯‚éƒTƒCƒY‚̈قȂéù܂ɑ΂·‚錒N¬l‚ł̕ž—p«‚¨‚æ‚Ñ‚—ŽÒ‚ł̎戵«‚Ì•]‰¿
‘æ5‰ñ“ú–{—Õ°–ò—Šw‰ïŠÖ“ŒEbM‰z’n•û‰ïi“Œ‹žAWebŠJÃjAu‰‰—vŽ|WA2021”N6ŒŽ20“ú
5. ”‘qNŽ¡A’؈äŠG”TA“c’†Ž‡äŽqA‹àéŽ÷A’©‘q‘¾˜YA•À–Ø“¿”VA“à“cM–çF–«t‘Ÿ•aгŽÒ‚É‚¨‚¯‚éƒNƒŒƒƒWƒ“‘¬•öù‚Ì•ž—p«‹y‚Ñ‚»‚̉e‹¿ˆöŽq
‘æ5‰ñ“ú–{—Õ°–ò—Šw‰ï“ŒŠCE–k—¤’n•û‰ïiŠò•ŒjAu‰‰—vŽ|W pp.22A2021”N7ŒŽ10“ú
6. “c’†Ž‡äŽqA…–ìA”‘qNŽ¡A‘D“nŽOŒ‹A—é–Øº•vA—ÑGŽ÷A•À–Ø“¿”VA“à“cM–çFƒXƒ‹ƒtƒ@ƒƒgƒLƒTƒ][ƒ‹/ƒgƒŠƒƒgƒvƒŠƒ€”z‡ÜŠÜ—LƒOƒ~»Ü‚Ì’²»
‘æ5‰ñ“ú–{—Õ°–ò—Šw‰ï“ŒŠCE–k—¤’n•û‰ïiŠò•ŒjAu‰‰—vŽ|W pp.25A2021”N7ŒŽ10“ú
7. ’؈äŠG”TA”‘qNŽ¡A–Ζؖƒ—¢“ÞA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VF–«t‘Ÿ•aгŽÒ‚É‚¨‚¯‚éƒNƒŒƒƒWƒ“»Ü‚Ì•ž–òƒAƒhƒqƒAƒ‰ƒ“ƒX‚ɉe‹¿‚ð‹y‚Ú‚·—vˆö‚Ì’Tõ
‘æ31‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiŒF–{AWEBŠJÃjAu‰‰—vŽ|WA2021”N10ŒŽ9“ú`10ŒŽ10“ú
8. ˆ¾”ÑŒ´‚è‚è‚©A“c’†Ž‡äŽqA_’Jç–¾A¬“cØŒ\ˆêA—´Œû–œ—¢ŽqA”‘qNŽ¡AŠ£’¼‹PA•À–Ø“¿”VA“nç³—TŽiA“à“cM–çF “ú–{l”x“®–¬«”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚ésildenafil‹y‚Ñbosentan‚Ì•êW’c–ò•¨“®‘Ô‰ðÍ
‘æ31‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiŒF–{AWEBŠJÃjAu‰‰—vŽ|WA2021”N10ŒŽ9“ú`10ŒŽ10“ú
9. »ì—R—A“c’†Ž‡äŽqAŽá¼‚µ‚Ì‚ÔA—´Œû–œ—ŽqA”‘qNŽ¡AH“cŒh‘¾˜YA‘Oì—Tˆê˜YA•À–Ø“¿”VA“nç³—TŽiAŠ£’¼‹PA“à“cM–çF –«ŒŒðÇð«”x‚ŒŒˆ³ÇŽ¡—Öòriociguat‚ÌŒŒ’†”Z“x’è—Ê–@‚ÌŠm—§
‘æ31‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiŒF–{AWEBŠJÃjAu‰‰—vŽ|WA2021”N10ŒŽ9“ú`10ŒŽ10“ú
10. —閨аA¬ì—TŽqA޽”¨—”¿A²‹´‹M”üŽqA”‘qNŽ¡A“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VA‰eŽRT“ñAŽR“àŽÆF »Ü’†ƒŠƒ“ŠÜ—L—ʂɊւ·‚éƒCƒ“ƒ^ƒrƒ…[ƒtƒH[ƒ€‹y‚Ñ»‘¢Œ³‚Ö‚Ì’²¸
‘æ31‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiŒF–{AWEBŠJÃjAu‰‰—vŽ|WA2021”N10ŒŽ9“ú`10ŒŽ10“ú
11. “à“cM–çF f—Âɖ𗧂Œ¤‹†‚Ì’…Šá“_‚ÆŽÀ‘H\ƒGƒrƒfƒ“ƒX‚ð‘n‚肾‚»‚¤
“ú–{•a‰@–òÜŽt‰ï“ŒŠCƒuƒƒbƒNE“ú–{–òŠw‰ï“ŒŠCŽx•”@‡“¯Šwp‘å‰ï2021AƒVƒ“ƒ|ƒWƒEƒ€4u–òÜŽt‚É‹‚ß‚ç‚ê‚錤‹†Šˆ“®F‹³ˆç‚©‚çŽÀ‘H‚Ü‚ÅviWEBŠJÃjAu‰‰—vŽ|W pp.69A2021”N10ŒŽ30“ú`11ŒŽ7“ú
12. —閨аA¬ì—TŽqA޽”¨—”¿A”º–ìˆò—mA“c’†Ž‡äŽqA”‘qNŽ¡A“à“cM–çA•À–Ø“¿”VA‰eŽRT“ñAŽR“àŽÆF |Ž_ƒJƒ‹ƒVƒEƒ€ŠÜ—LƒOƒ~»Ü‚Ì’²»‹y‚Ñ—Õ°“Á«‚Ì•]‰¿
‘æ15‰ñt‘Ÿ•a–ò•¨—Ö@Šw‰ïiWEBŠJÃjAu‰‰—vŽ|W pp.S143A2021”N11ŒŽ6“ú`25“ú
13. “c’†Ž‡äŽqA»ì—R—AŽá¼‚µ‚Ì‚ÔAŽR–{xA”‘qNŽ¡A—´Œû–œ—ŽqA²“¡—º‘¾A•À–Ø“¿”VAŠ£’¼‹PA‘Oì—Tˆê˜YA“nç³—TŽiA“à“cM–çF ’¼ÚŒoŒûR‹ÃŒÅ–ò‚ÌŒŒŸ÷’†”Z“x“¯Žž’è—Ê–@‚ÌŠm—§
‘æ42‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi‹{éjAu‰‰—vŽ|W pp.325A2021”N12ŒŽ9“ú`12ŒŽ11“ú
14. —´Œû–œ—¢ŽqA“c’†Ž‡äŽqAH“cŒh‘¾˜YAˆäã—T‰îA“à“cM–çA‘Oì—Tˆê˜YAŠ£’¼‹PA“nç³—TŽiF ƒŠƒIƒVƒOƒAƒg‚ÌŒŒ’†–ò•¨“®‘Ô‚ðŒŸ“¢‚µ‚½–«ŒŒðÇð«”x‚ŒŒˆ³Ç(CTEPH)‚Ì‚QÇ—á
‘æ42‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi‹{éjAu‰‰—vŽ|W pp.305A2021”N12ŒŽ9“ú`12ŒŽ11“ú
[‚»‚Ì‘¼‚ÌŠ§s•¨]
1. ”‘qNŽ¡, ¼ì Œ³–çF“ÁWu–òÜŠw‚É‚æ‚鎑±‰Â”\‚Ȉã—ÃEŒ¤‹†E‹³ˆç‚Ì”“W‚ð–ÚŽw‚µ‚Ä`ƒ|ƒXƒgEƒRƒƒi/‚±‚ê‚©‚ç‚ ‚é‚ׂ«Žp`v
@–òÜŠw, 81, pp.2-3 i2021j
2. ”‘qNŽ¡, ‹à‘ò‹MŒ›FWeb‘Î’kFSNPEE2020 gDiversity`–òÜŠw‚ÌF‚ñ‚Èw‚©E‚½E‚¿x‚ðŠw‚Ú‚¤`h@V‹‹PŽ÷~ûüŽRK–ç~ˆÀ‰Í“àá~óˆä—•l~åU–ì ~•Ÿ“cŒõ—Ç~ŽR“cK•½~—«i~“cŒ´t“O~‰HΈê‹P~‰Á“¡Ø•ä~ŽR–{ª¶
–òÜŠw, 81, pp.26-33 i2021j
3. ¼ì Œ³–ç, ”‘qNŽ¡F–òÜŠw‚É‚æ‚鎑±‰Â”\‚Ȉã—ÃEŒ¤‹†E‹³ˆç‚Ì”“W‚ð–ÚŽw‚µ‚Ä`ƒ|ƒXƒgEƒRƒƒi/‚±‚ê‚©‚ç‚ ‚é‚ׂ«Žp`i1j ŠÛŽR“O~”öã½—Ç~[…Œ[˜N
–òÜŠw, 81, pp.4-8i2021j
4. ˆÉ“Œr‰ë, ”‘qNŽ¡F–òÜŠw‚É‚æ‚鎑±‰Â”\‚Ȉã—ÃEŒ¤‹†E‹³ˆç‚Ì”“W‚ð–ÚŽw‚µ‚Ä`ƒ|ƒXƒgEƒRƒƒi/‚±‚ê‚©‚ç‚ ‚é‚ׂ«Žp`i2j ç“°”Nº~—ѹ—m~“n•Ó‘PÆ
–òÜŠw, 81, pp.9-20i2021j
5. ”‘qNŽ¡FƒtƒH[ƒJƒXƒOƒ‹[ƒv‚Ì‚±‚ê‚܂ł̋OÕ‚Æ¡Œã‚Ì“W–]FŒoŒû‹zŽûFG@ã—Ñ“Ö~”’â‘P”V~¬›¸—²Žj~A“c Œ\—S
–òÜŠw, 81, pp.122-126i2021j
6. ¼ìŒ³–ç, ”‘qNŽ¡FƒtƒH[ƒJƒXƒOƒ‹[ƒv‚Ì‚±‚ê‚܂ł̋OÕ‚Æ¡Œã‚Ì“W–]FŒo”瓊—^»ÜFG@‹g“cаK~”öã½—Ç~”öŠÖ“N–ç~‹TˆäŒh‘×~‰ª–{_ˆê
–òÜŠw, 81, pp.206-211i2021j
7. ”‘qNŽ¡FƒtƒH[ƒJƒXƒOƒ‹[ƒv‚Ì‚±‚ê‚܂ł̋OÕ‚Æ¡Œã‚Ì“W–]FŒo”瓊—^»ÜFG@™—ÑŒ˜ŽŸ~“¡ˆä‚Ü‚«Žq~“¿—¯‰Ãа~“à–ì’qM
–òÜŠw, 81, pp.264-268i2021j
[ŽóÜ]
1. “c’†Ž‡äŽqF—DG‰‰‘èÜuƒXƒ‹ƒtƒ@ƒƒgƒLƒTƒ][ƒ‹/ƒgƒŠƒƒgƒvƒŠƒ€”z‡ÜŠÜ—LƒOƒ~»Ü‚Ì’²»v
‘æ5‰ñ“ú–{—Õ°–ò—Šw‰ï“ŒŠCE–k—¤’n•û‰ïA2021”N7ŒŽ10“ú
2. ”‘qNŽ¡F“ú–{åñጊw‰ï@—DG¸“ÇÜ
“ú–{åñጊw‰ïA2021”N9ŒŽ9“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
1. Shimako Tanaka, Shinya Uchida, Akio Hakamata, Sachiko Miyakawa, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki: Simultaneous LC-MS Analysis of Plasma Concentrations of Sildenafil, Tadalafil, Bosentan, Ambrisentan, and Macitentan in Patients with Pulmonary Arterial Hypertension
Pharmazie, 75, 236-239 (2020)
2. Homare Kurashima, Shinya Uchida, Yasuharu Kashiwagura, Shimako Tanaka, Noriyuki Namiki: Evaluation of Weight Variation in Mini-Tablets Manufactured by a Multiple-Tip Tool.
Chem Pharm Bul, 68, 981-988 (2020)
3. Shimako Tanaka, Shinya Uchida, Mai Sotoyama, Yasuharu Kashiwagura, Noriyuki Namiki: Combining Powder Formulations of Drugs with Food and Beverages to Improve Palatability.
Biol Pharm Bull., 43, 1954-1959 (2020)
4. Imai H, Morita M, Morita H, Ohyama T, Tanaka S, Uchida S, Namiki N, Uemura N, Ohashi K: The ƒÊ-opioid receptor gene polymorphism 118A>G weakens the pharmacological action of buprenorphine.
Int J Clin Pharmacol Ther, 58, 626-633 (2020)
5. Takashi K Ito, Tomihito Sato, Akio Hakamata , Yuki Onoda, Shumpei Sato,
Fumiyoshi Yamazaki, Makoto Horikawa, Yutaka Takahashi, Takuya Kitamoto,
Masako Suzuki, Shinya Uchida, Keiishi Odagiri, Mitsutoshi Setou: A nonrandomized
study of single oral supplementation within the daily tolerable upper level
of nicotinamide affects blood nicotinamide and NAD- levels in healthy subjects.
Trans. Med. Aging., 4, 45-54 (2020)
[‘à]
1. “à“cM–çFÄl@ŠO—p܂̑I‘ð‚Æ•ž–òŽw“±
’²Ü‚Æî•ñA26App.2234-2238 (2020)
2. ”‘qNŽ¡FÜŒ`•Ê@»Ü“Á«‚Æ•ž–òŽw“±‚̃|ƒCƒ“ƒg@¿Üi’¼’°—p»ÜAäS¿Üj
’²Ü‚Æî•ñA26App.2240-2244i2020j
3. “à“cM–çF•ž–òƒAƒhƒqƒ‰ƒ“ƒXŒüã‚Ì‚½‚ßÜŒ`‘I‘ð|ODù‚Ì—Õ°“I‹@”\«\
ˆã–ò‚Ì–åA60App.2-4i2020j
4. “à“cM–çFŠe˜_‡UD“ÁŽê‚ÈŠ³ŽÒ”wŒi@3D”D•w
ŒŽŠÔ–òŽ–A62App.1914-1920i2020j
5. “à“cM–çA•À–Ø“¿”VFŒûo“à•ö‰óùQ&A
PHARM TECH JAPANA36App.445-454i2020j
[Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€]
1. ”‘qNŽ¡A“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VF‰@“à»ÜƒŒƒ{ƒ`ƒƒLƒVƒ“Œo”ç‹zŽûŒ^»Ü‚ÌŠJ”
“ú–{–òŠw‰ï‘æ140”N‰ïi‹ž“sAŽãŠJÃjAu‰‰—vŽ|W(WEB)@27Q-am099A2020”N3ŒŽ27“ú
2. “c’†Ž‡äŽqAŒ´Ž÷A–L“c—ÉA’†Š_Žj“NA”‘qNŽ¡A“à“cM–çA•À–Ø“¿”VFƒOƒ~»Ü‚ÌŠJ”‚ÉŠÖ‚·‚錤‹† (‘æ7•ñ)|ƒgƒ‰ƒjƒ‰ƒXƒgŠÜ—LƒOƒ~»Ü‚Ì’²»|
“ú–{–òŠw‰ï‘æ140”N‰ïi‹ž“sAŽãŠJÃjAu‰‰—vŽ|W(WEB) 28P-pm092A2020”N3ŒŽ28“ú
3. –L“c—ÉA“c’†Ž‡äŽqAŒ´Ž÷A…–ìA”‘qNŽ¡A“à“cM–çA•À–Ø“¿”VFƒXƒ‹ƒtƒ@ƒƒgƒLƒTƒ][ƒ‹/ƒgƒŠƒƒgƒvƒŠƒ€”z‡ƒOƒ~»Ü‚̈•ûŒŸ“¢
“ú–{–òÜŠw‰ï‘æ35”N‰ïiŒF–{AŽãŠJÃjAu‰‰—vŽ|W pp.40A2020”N5ŒŽ14“ú
4. ˆ°Œ´‚Ü‚¢‚©A”‘qNŽ¡A‘åé^—“ÞA•gì’¼ÆA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VFŒû“à‰ŠŽ¡—Âð–Ú“I‚Æ‚µ‚½‰@“à»ÜƒAƒƒvƒŠƒm[ƒ‹‹y‚у|ƒ‰ƒvƒŒƒWƒ“ƒNƒtƒH[ƒ€»Ü‚Ì’²»
“ú–{–òÜŠw‰ï‘æ35”N‰ïiŒF–{AŽãŠJÃjAu‰‰—vŽ|W pp.46A2020”N5ŒŽ14“ú
5. –Ζؖƒ—¢“ÞA”‘qNŽ¡A—閨аA£ŒËì—¤A“c’†Ž‡äŽqAŽR“àŽÆA‰eŽRT“ñA“à“cM–çA•À–Ø“¿”VFŒŒ‰t“§ÍгŽÒ‚ɓЗ^’†‚̈ã–ò•i‚É‚¨‚¯‚郊ƒ“ŠÜ—Ê‹y‚Ñ‚»‚ÌŒŒ´’†ƒŠƒ“”Z“x‚É‹y‚Ú‚·‰e‹¿
“ú–{–òÜŠw‰ï‘æ35”N‰ïiŒF–{AŽãŠJÃjAu‰‰—vŽ|W pp.46A2020”N5ŒŽ14“ú
6. •½ˆä“ÞXA“c’†Ž‡äŽqAŽsì—SˆËAŒÑ“cW‰›A_’Jç–¾A•ÐŽR’¼‹IA—´Œû–œ—¢ŽqA¬“cØŒ\ˆêAŠ£’¼‹PA“à“cM–çA“nç³—TŽiA•À–Ø“¿”VF”x‚ŒŒˆ³ÇŽ¡—Öòselexipag‚Ìclopidogrel•¹—pŽž‚É‚¨‚¯‚é–ò•¨‘ŠŒÝì—p‚Ì•]‰¿
“ú–{–òÜŠw‰ï‘æ35”N‰ïiŒF–{AŽãŠJÃjAu‰‰—vŽ|W pp.66A2020”N5ŒŽ14“ú
7. ΈäI^A“à“cM–çAˆä–{~ŽqA“c’†Ž‡äŽqA”‘qNŽ¡A•À–Ø“¿”VFƒŒ[ƒU[ƒ‰ƒ}ƒ“Œ°”÷‹¾‚É‚æ‚éƒ~ƒ_ƒ]ƒ‰ƒ€ŠÜ—Lè÷—±ˆ³k•¨‚É‚¨‚¯‚éŒ`‘ÔŠw“I‚¨‚æ‚Ñ’è—Ê•]‰¿
“ú–{–òÜŠw‰ï‘æ35”N‰ïiŒF–{AŽãŠJÃjAu‰‰—vŽ|W pp.69A2020”N5ŒŽ14“ú
8. Žsì—SˆËA“c’†Ž‡äŽqA»ì—R—A”‘qNŽ¡A“à“cM–çA•À–Ø“¿”VF’¼ÚŒoŒûR‹ÃŒÅ–ò‚ÌŒŒŸ÷’†”Z“x“¯Žž’è—Ê–@‚ÌŠm—§
“ú–{–òÜŠw‰ï‘æ35”N‰ïiŒF–{AŽãŠJÃjAu‰‰—vŽ|W pp.74A2020”N5ŒŽ16“ú
9. “c’†Ž‡äŽqA”‘qNŽ¡A“à“cM–çA•À–Ø“¿”VFŽÀÇ—á‚ÉŠî‚¢‚½Problem-based learning(PBL)-ƒ`ƒ…[ƒgƒŠƒAƒ‹‹³ˆçi—Õ°–òŠw‰‰Kj‚ÌŽÀŽ{‹y‚Ñ•]‰¿
‘æ5‰ñ“ú–{–òŠw‹³ˆçŠw‰ï‘å‰ïi“Œ‹žAWEBŠJÃjAu‰‰—vŽ|W pp.178A2020”N9ŒŽ12“ú
10. ”‘qNŽ¡A“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VFŽÀÇ—á‚ÉŠî‚¢‚½Problem-based learning(PBL)-ƒ`ƒ…[ƒgƒŠƒAƒ‹‹³ˆçi—Õ°–òŠw‰‰Kj‚É‚¨‚¯‚éŠw¶‚Ìî•ñŒŸõ‚Ì“®Œü
‘æ5‰ñ“ú–{–òŠw‹³ˆçŠw‰ï‘å‰ïi“Œ‹žAWEBŠJÃjAu‰‰—vŽ|W pp.178A2020”N9ŒŽ12“ú
11. Žsì—SˆËA“à“cM–çA¬”¦—R‰ÀŽqAŽO‰YŠî–õA“c’†Ž‡äŽqA”‘qNŽ¡AŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VF d“xt‹@”\áŠQгŽÒ‚É‚¨‚¯‚é apixaban ‚ÌŒŒŸ÷’†”Z“x‘ª’è‚Æ‘Ì“à“®‘Ô‚Ì„’è
‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi–¼ŒÃ‰®AWEBŠJÃjAu‰‰—vŽ|WApp.925A2020”N10ŒŽ24“ú`11ŒŽ1“ú
12. ”‘qNŽ¡A“à“cM–çA–Ζؖƒ—¢“ÞA£ŒËì—¤A—閨аA“c’†Ž‡äŽqAŽR“àŽÆA‰eŽRT“ñA•À–Ø“¿”VF ŒŒ‰t“§ÍгŽÒ‚Ɉ•û‚³‚ꂽˆã–ò•i‚É‚¨‚¯‚郊ƒ“ŠÜ—ʂɊւ·‚é’²¸
‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi–¼ŒÃ‰®AWEBŠJÃjAu‰‰—vŽ|WApp.1189A2020”N10ŒŽ24“ú`11ŒŽ1“ú
13. Maika Ashihara, Shinya Uchida, Yasuharu Kashiwagura, Naoya Hirukawa, Marina Oshiro, Shimako Tanaka, Saki Watanabe, Noriyuki NamikiFPhysical properties of foam formulations and their disappearance time and palatability in the oral cavities of healthy volunteers
AAPS 2020 PharmSci 360 (NewOrleans, USAAWEBŠJÃ)A2020 ”N10ŒŽ26“ú`11ŒŽ5“ú
14. Marina Mogi, Shinya Uchida, Yasuharu Kashiwagura, Hiroshi Suzuki, Riku Setogawa, Shimako Tanaka, Katsuya Yamauchi, Shinji Kageyama,, Noriyuki NamikiFPhosphorus content of medicines taken by patients on hemodialysis and its relation to serum phosphate concentration
AAPS 2020 PharmSci 360 (NewOrleans, USAAWEBŠJÃ)A2020 ”N10ŒŽ26“ú`11ŒŽ5“ú
15. —´Œû–œ—¢ŽqA_’Jç–¾A¬“cØŒ\ˆêA“à“cM–çA“nç³—TŽiFŒ’í¬l‚É‚¨‚¯‚éclopidogrel•¹—pŽž‚Ìselexipag‚Ì–ò—ÍŠw“I•]‰¿
“ú–{zŠÂŠíŠw‰ï@‘æ156‰ñ“ŒŠCE‘æ141‰ñ–k—¤‡“¯’n•û‰ïiWEBŠJÃjA2020”N10ŒŽ31“ú`11ŒŽ1“ú
16. “c’†Ž‡äŽqA—´Œû–œ—¢ŽqA•½ˆä“ÞXA“à“cM–çA•ÐŽR’¼‹IAŒÑ“cW‰›A_’Jç–¾A¬“cØŒ\ˆêAŠ£’¼‹PA•À–Ø“¿”VA“nç³—TŽiF”x‚ŒŒˆ³ÇŽ¡—Öòselexipag‚Ìclopidogrel•¹—pŽž‚É‚¨‚¯‚錌Ÿ÷’†–ò•¨”Z“x‹y‚ÑŒŒˆ³‚̕ϓ®
‘æ41‰ñ“ú–{—Õ°–ò—Šw‰ï‘‰ïi•Ÿ‰ªAŒ»’nŠJÂÆWEBŠJÃjAu‰‰—vŽ|W pp.S293A2020”N12ŒŽ3“ú
17. —閨аA¬ì—TŽqA޽”¨—”¿A²‹´‹M”üŽqA”‘qNŽ¡A“à“cM–çA•À–Ø“¿”VA‰eŽRT“ñAŽR“àŽÆF@ŒŒ‰t“§ÍгŽÒ‚ÌŒŒ´ƒŠƒ“”Z“x‚É‹y‚Ú‚·»Ü‚©‚ç‚ÌƒŠƒ“ÛŽæ‚̉e‹¿
‘æ14‰ñ“ú–{t‘Ÿ•a–ò•¨—Ö@Šw‰ïiWEBŠJÃjAu‰‰—vŽ|WApp.S132A2020”N12ŒŽ14“ú`28“ú
18. ”‘qNŽ¡FƒXƒ|[ƒc—̈æ‚ł̖ò•¨Žg—p‚ɂ‚¢‚Ä`—«ƒAƒXƒŠ[ƒg‚̘b‘è‚ð’†S‚É`
‘æ15‰ñ“ú–{‹Ö‰Œ‰ÈŠw‰ïŠwpW‰ïiɪAŒ»’nŠJÂÆWEBŠJÃjAƒVƒ“ƒ|ƒWƒEƒ€3A2020”N12ŒŽ20“ú
[‚»‚Ì‘¼‚ÌŠ§s•¨]
1. ”’â‹`”V, ”‘qNŽ¡F“ÁW u•½¬ˆÛV|•½¬30”N‚ðU‚è•Ô‚é|v
–òÜŠw, 80, pp.2-3 i2020j
2. ”‘qNŽ¡F–òÜ‚ª•ø‚¦‚éˆã—ÃŒoÏ‚Ö‚Ì‰Û‘è‚Æ¡Œã‚Ì“W–] ‹´“c ‹œ _ŒËŽs—§ˆã—ÃZƒ“ƒ^[’†‰›Žs–¯•a‰@@‰@’·•â²E–òÜ•”’· ~ ‘åàV F “Œ˜a–ò•iДޮ‰ïŽÐ@Œ³ê–±Žæ’÷–ð
–òÜŠw, 80, pp.229-232i2020j
[ŽóÜ]
1. –L“c—ÉFŠw•”Šw¶Žµ‚¯–òŽt§—ãÜuƒXƒ‹ƒtƒ@ƒƒgƒLƒTƒ][ƒ‹/ƒgƒŠƒƒgƒvƒŠƒ€”z‡ƒOƒ~»Ü‚̈•ûŒŸ“¢v
“ú–{–òÜŠw‰ï‘æ35”N‰ïA2020”N5ŒŽ14“ú`16“ú
2. ΈäI^F‘åŠw‰@¶ƒXƒJƒ‰ƒVƒbƒvuƒŒ[ƒU[ƒ‰ƒ}ƒ“Œ°”÷‹¾‚É‚æ‚éƒ~ƒ_ƒ]ƒ‰ƒ€ŠÜ—Lè÷—±ˆ³k•¨‚É‚¨‚¯‚éŒ`‘ÔŠw“I‚¨‚æ‚Ñ’è—Ê•]‰¿v
“ú–{–òÜŠw‰ï‰iˆäà’cA2020”N5ŒŽ14“ú`16“ú
3. ˆ°Œ´‚Ü‚¢‚©FŒœÜ˜_•¶u–ò‚ÆŒ’N‚ÌTŠÔv@u—ߘaEVŽž‘ã‚É’§‚Þ–òŠwv@‘æ2È
“ú–{–òÜŠw‰ï‰iˆäà’cA2020”N5ŒŽ14“ú`16“ú
4. “c’†Ž‡äŽqF —ߘaŒ³”N“x‹³ˆõŠˆ“®•]‰¿@Šw’·•\²
ɪŒ§—§‘åŠwA2020”N12ŒŽ21“ú
5. —閨аF—DG‰‰‘èÜuŒŒ‰t“§ÍгŽÒ‚ÌŒŒ´ƒŠƒ“”Z“x‚É‹y‚Ú‚·»Ü‚©‚ç‚ÌƒŠƒ“ÛŽæ‚̉e‹¿v
‘æ14‰ñ“ú–{t‘Ÿ•a–ò•¨—Ö@Šw‰ïŠwpW‰ïE‘‰ï2020A2020”N12ŒŽ14“ú`28“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
1. Hidehito Takano, Shinya Uchida, Yasuharu Kashiwagura, Shimako Tanaka, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki: Preparation of Cocoa Powder-Containing Orally Disintegrating Tablets of Rebamipide (Rebamipide Chocolet) and Evaluation of Their Clinical Palatability
Chem Pharm Bull, 67, 112-119 (2019)
2. Mai Sotoyama, Shinya Uchida, Chiaki Kamiya, Shimako Tanaka, Yasuharu Kashiwagura, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki: Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets
Chem Pharm Bull, 67, 540-545 (2019)
3. Chiaki@Kamiya, Naoki Inui, Akio Hakamata, Sachiko Miyakawa, Shimako Tanaka, Shinya Uchida, Noriyuki Namiki, Keiichi Odagiri, Hiroshi Watanabe: Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype
J Pharmacol Sci., 139, 361-366 (2019)
4. Mitsunobu Yoshida, Shinya Uchida, Yasuharu Kashiwagura, Shimako Tanaka, Rakan Matsui, Noriyuki Namiki: Evaluation of in Vitro and in Vivo Transdermal Absorption of Solifenacin Succinate
Chem Pharm Bull, 67, 1225-1231 (2019)
5. Motoyasu Miura, Shinya Uchida, Shimako Tanaka, Naoki Inui, Junichi Kawakami J, Hiroshi Watanabe, Noriyuki Namiki: The Prediction of the Area under the Curve and Clearance of Midazolam from Single-Point Plasma Concentration and Urinary Excretion in Healthy Volunteers
Chem Pharm Bull, 67, 1225-1231 (2019)
6. Norimichi Akiyama, Naoki Inui, Kazutaka Mori, Yutaro Nakamura, Hiroshi Hayakawa, Shimako Tanaka, Shinya Uchida, Noriyuki Namiki, Hiroshi Watanabe, Takafumi Suda: Effect of rifampicin and clarithromycin on the CYP3A activity in patients with Mycobacterium avium complex
J Thorac Dis., 11, 3814-3821 (2019)
7. “à“cM–ç, ‰iˆä»‘å, —閨а, “c’†Ž‡äŽq, ”‘qNŽ¡, ‹àéŽ÷, ’©‘q‘¾˜Y, •À–Ø“¿”V: ƒNƒŒƒƒWƒ“‘¬•öù‚𕞗p’†‚ÌŠ³ŽÒ‚É‚¨‚¯‚镞—p«ƒAƒ“ƒP[ƒg’²¸‚Æ‚»‚Ì•]‰¿
ˆãŠw‚Æ–òŠw, 76, 63-75 (2019)
8. “à“cM–çAŠOŽR^ˆßAXœATŒáA“c’†Ž‡äŽqA”‘qNŽ¡A•À–Ø“¿”VFŒûo“à•ö‰óù‚É•K—v‚Æ‚³‚ê‚é—Õ°»ÜŠw“I“Á«‚ƃ~ƒ`ƒOƒŠƒjƒhEƒ{ƒOƒŠƒ{[ƒX”z‡Œûo“à•ö‰óùiƒOƒ‹ƒxƒX-”z‡ODùj‚̻܌Ÿ“¢
»Ü‹@ŠB‹ZpŠw‰ïŽC110C217-225 (2019)
[Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€]
1. ŠOŽR^ˆßA“à“cM–çA“c’†Ž‡äŽqA’†‘º‹”VA•À–Ø“¿”VFˆùH•¨‚Ƭ‡‚µ‚½•²––»Ü‚Ì•ž—p«‚ɑ΂·‚é“dŽq–¡ŠoƒVƒXƒeƒ€‚Ì—\‘ª«
“ú–{–òŠw‰ï‘æ139”N‰ïiç—tjAu‰‰—vŽ|W4 pp.94A2019”N3ŒŽ21“ú
2. ’†ì“Ä‹BA“c’†Ž‡äŽqA“à“cM–çA²“¡ŽÀ‹GAŒÑ“cW‰›A_’Jç–¾AÎì‹M[A¬“cØŒ\ˆêAŠ£@’¼‹PA“nç³—TŽiA•À–Ø“¿”VF”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚éƒzƒXƒzƒWƒGƒXƒeƒ‰[ƒ[5‘jŠQ–ò‚¨‚æ‚уGƒ“ƒhƒZƒŠƒ“Žó—e‘ÌhR–ò‚ÌŒŒŸ÷’†”Z“x
“ú–{–òŠw‰ï‘æ139”N‰ïiç—tjAu‰‰—vŽ|W4 pp.114A2019”N3ŒŽ21“ú
3. ŽO‰YŠî–õA“à“cM–çA“c’†Ž‡äŽqAŠ£’¼‹PAìトêA“nç³—TŽiA•À–Ø“¿”VFƒ~ƒ_ƒ]ƒ‰ƒ€‹y‚Ñ‘ãŽÓ•¨‚Ìsingle-point sampling‹y‚Ñ”A’†”rŸ•—ʂɂæ‚éCYP3AŠˆ«•]‰¿–@‚ÌŒŸ“¢
“ú–{–òŠw‰ï‘æ139”N‰ïiç—tjAu‰‰—vŽ|W4 pp.146A2019”N3ŒŽ22“ú
4. ”‘qNŽ¡AŠâè—SŽqA‹{è—Y•ãA»ì—zˆêA“â‘׎jAˆäã˜aKA‹{›½–õ‘¥AVˆä‰pˆêA‹ààVа–¾A‡“c•q®A‰êì‹`”VAX–{’B–çF’ni’mj‚Ì‹’“_®”õŽ–‹Æ5”NŠÔ‚ÌɪŒ§—§‘åŠw‚ÌŽæ‚è‘g‚Ý2`ɪŒ§—§‘åŠw‚É‚¨‚¯‚鑽EŽí˜AŒg‹³ˆçƒvƒƒOƒ‰ƒ€‚ɂ‚¢‚Ä`
“ú–{–òŠw‰ï‘æ139”N‰ïiç—tjAu‰‰—vŽ|W4 pp.202A2019”N3ŒŽ23“ú
5. “â‘׎jA”‘qNŽ¡A»ì—zˆêA•‰HŽqF‘¾A“ì@²A‹{è—Y•ãA–ìX–ØGA‰êì‹`”VAX–{’B–çF’ni’mj‚Ì‹’“_®”õŽ–‹Æ5”NŠÔ‚ÌɪŒ§—§‘åŠw‚ÌŽæ‚è‘g‚Ý4`–òŠw•”‚ł̋~‹}‹~–½‹³ˆç‚Ì‹³ˆçŒø‰Ê‚ɂ‚¢‚Ä`
“ú–{–òŠw‰ï‘æ139”N‰ïiç—tjAu‰‰—vŽ|W4 pp.201A2019”N3ŒŽ23“ú
6. ŠOŽR^ˆßA“à“cM–çA_’Jç–¾A“c’†Ž‡äŽqA”‘qNŽ¡AŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒ~ƒ`ƒOƒŠƒjƒhEƒ{ƒOƒŠƒ{[ƒX”z‡Œûo“à•ö‰óù‚É‚¨‚¯‚éˆù‚Ýž‚݂₷‚³‹y‚Ñ•ž—p«‚Ì•]‰¿
“ú–{–òÜŠw‰ï‘æ34”N‰ïi•xŽRjAu‰‰—vŽ|W pp.162A2019”N5ŒŽ16“ú
7. •gì’¼ÆA”‘qNŽ¡A“à“cM–çA’·”ö—º—CA“c’†Ž‡äŽqA•À–Ø“¿”VF‘å—p—ʂ̖ò•¨‚ðŠÜ—L‚·‚éŒoŒû»Ü‚ð‘z’肵‚½ƒ}ƒCƒNƒƒ^ƒuƒŒƒbƒg‚Ì•ž—p«‚Ì•]‰¿
“ú–{–òÜŠw‰ï‘æ34”N‰ïi•xŽRjAu‰‰—vŽ|W pp.162A2019”N5ŒŽ16“ú
8. ™–{Œõ‹PA”~–{‰ÀºA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VF‚¯‚ñ‰»“x‚̈قȂéPVA‚ð—p‚¢‚½ƒAƒƒiƒƒrƒ‹ŒÅ‘Ì•ªŽU‘Ì“Š—^Œã‚Ì–ò•¨“®‘Ô
“ú–{–òÜŠw‰ï‘æ34”N‰ïi•xŽRjAu‰‰—vŽ|W pp.124A2019”N5ŒŽ16“ú
9. £ŒËì—¤A”‘qNŽ¡A‰iˆä¹‘åA—閨аA“c’†Ž‡äŽqA‹àéŽ÷A’©‘q‘¾˜YA“à“cM–çA•À–Ø“¿”VFƒNƒŒƒƒWƒ“‘¬•öù‚𕞗p’†‚ÌŠ³ŽÒ‚É‚¨‚¯‚镞—p«ƒAƒ“ƒP[ƒg’²¸‚Æ‚»‚Ì•]‰¿
“ú–{–òÜŠw‰ï‘æ34”N‰ïi•xŽRjAu‰‰—vŽ|W pp.162A2019”N5ŒŽ16“ú
10. Œ´Ž÷A“c’†Ž‡äŽqA’†Š_Žj“NA™–{àY•FAŠÖG‘¾A”‘qNŽ¡A“à“cM–çA•À–Ø“¿”VFƒgƒ‰ƒjƒ‰ƒXƒgŠÜ—LƒOƒ~»Ü‚ÌŠJ”
“ú–{–òÜŠw‰ï‘æ34”N‰ïi•xŽRjAu‰‰—vŽ|W pp.234A2019”N5ŒŽ16“ú
11. ‰ª“cŒ·‹LA”‘qNŽ¡A‹g“cŒõLA¼ˆä—ÇŠ²A“à“cM–çA•À–Ø“¿”VFƒ\ƒŠƒtƒFƒiƒVƒ“ŠÜ—LŒo”ç‹zŽûŒ^»Ü‚Ì’²»
“ú–{–òÜŠw‰ï‘æ34”N‰ïi•xŽRjAu‰‰—vŽ|W pp.220A2019”N5ŒŽ16“ú
12. •ÐŽR„A“à“cM–çA“c’†Ž‡äŽqA’Å—t—S‹MA”‘qNŽ¡A•À–Ø“¿”VF“dŽq–¡ŠoƒVƒXƒeƒ€‚ð—p‚¢‚½Œûo“à•ö‰óù‚ÌŽÀ—p“I‚È–¡ƒ}ƒXƒLƒ“ƒOŒø‰Ê•]‰¿–@
“ú–{–òÜŠw‰ï‘æ34”N‰ïi•xŽRjAu‰‰—vŽ|W pp.140A2019”N5ŒŽ16“ú
13. Shinya Uchida, Noriyuki NamikiF Evaluations of ease of swallowing and handling tablets of various sizes by healthy volunteers and elderly patients
EuropeanPharma 2019 (Zurich, Switzerland)A2019”N5ŒŽ21“ú
14. Shimako Tanaka, Shinya Uchida, Shuta Seki, Yasuharu Kashiwagura, Chiaki Kamiya, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Noriyuki NamikiF Improved palatability of gummi drug of epinastine hydrochloride@using organoleptic taste-masking methods
EuropeanPharma 2019 (Zurich, Switzerland)A2019”N5ŒŽ21“ú
15. Œ´Ž÷A“c’†Ž‡äŽqA’†Š_Žj“NA™–{àY•FAŠÖG‘¾A“à“cM–çA•À–Ø“¿”VFƒOƒ~»Ü‚Ì•¨«‚Æ•ž—pŠ´‚ÌŠÖŒW
“ú–{—Õ°–ò—Šw‰ï“ŒŠCE–k—¤’n•û‰ïiɪjAu‰‰—vŽ|W pp.24A2019”N6ŒŽ8“ú
16. –L“c—ÉA“c’†Ž‡äŽqAŒ´Ž÷A’†Š_Žj“NA™–{àY•FAŠÖG‘¾A“à“cM–çA•À–Ø“¿”VFƒgƒ‰ƒjƒ‰ƒXƒgŠÜ—LƒOƒ~»Ü‚Ì’²»
“ú–{—Õ°–ò—Šw‰ï“ŒŠCE–k—¤’n•û‰ïiɪjAu‰‰—vŽ|W pp.27A2019”N6ŒŽ8“ú
17. “c’†Ž‡äŽqA“à“cM–çA’†ì“Ä‹BAŒÑ“cW‰›A_’Jç–¾A¬“cØŒ\ˆêAŠ£’¼Ž÷A’†›¸”ª‹÷AX‘PŽ÷A“nç³—TŽiA•À–Ø“¿”VF“ú–{l”x‚ŒŒˆ³Š³ŽÒ‚É‚¨‚¯‚é”x‚ŒŒˆ³ÇŽ¡—Öò‚ÌŒŒ’†”Z“x‚É‹y‚Ú‚·‰e‹¿ˆöŽq‚ÌŒŸ“¢
“ú–{—Õ°–ò—Šw‰ï“ŒŠCE–k—¤’n•û‰ïiɪjAu‰‰—vŽ|W pp.27A2019”N6ŒŽ8“ú
18. •gì’¼ÆA”‘q‘׎¡A“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VFŒ’N¬l‚ð‘ÎÛ‚Æ‚µ‚½ŒoŒû»Ü‚Ì•ž—p«•]‰¿
“ú–{—Õ°–ò—Šw‰ï“ŒŠCE–k—¤’n•û‰ïiɪjAu‰‰—vŽ|W pp.31A2019”N6ŒŽ8“ú
19. Yasuharu Kashiwagura, Shinya Uchida, Akio Hakamada, Ryosuke Nagao, Masami Shirai, Akira Endoh, Noriyuki NamikiF Evaluation of the usability of a newly developed tablet container intended to aid medication intake and enhance patient adherence
ASHP 2019 Summer Meetings and Exhibition (Boston, USA)A2019”N6ŒŽ10“ú
20. Shinya Uchida, Yasuharu Kashiwagura, Shimako Tanaka, Homare Kurashima,
Noriyuki NamikiF What size of tablets are optimal- -Evaluations of ease
of swallowing and handling
ASHP 2019 Summer Meetings and Exhibition (Boston, USA)A2019”N6ŒŽ10“ú
21. ”‘qNŽ¡A“à“cM–çAûü–ìGmA“c’†Ž‡äŽqAŠ£’¼‹PA¬“cØŒ\ˆêA“nç³—TŽiA•À–Ø“¿”VFƒŒƒoƒ~ƒsƒhŒûo“à•ö‰óù‚Ì’²»‚É‚¨‚¯‚éƒRƒRƒAƒpƒEƒ_[‚Ì‘I’è‚Æ•ž—p«•]‰¿
“ú–{ˆã—ÖòŠw‰ï@‘æ3‰ñƒtƒŒƒbƒVƒƒ[ƒYƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi“Œ‹žjAu‰‰—vŽ|W pp.32A2019”N6ŒŽ16“ú
22. ‰ª“cŒ·‹LA”‘qNŽ¡A‹g“cŒõLAˆä–{~ŽqA¼ˆä—ÇŠ²A“à“cM–çA•À–Ø“¿”VFƒ\ƒŠƒtƒFƒiƒVƒ“ŠÜ—LŒo”ç‹zŽûŒ^»Ü‚Ì’²»‚Æ•¨«•]‰¿
“ú–{ˆã—ÖòŠw‰ï@‘æ3‰ñƒtƒŒƒbƒVƒƒ[ƒYƒJƒ“ƒtƒ@ƒ‰ƒ“ƒXi“Œ‹žjAu‰‰—vŽ|W pp.51A2019”N6ŒŽ16“ú
23. “c’†Ž‡äŽqA“à“cM–çA’†ì“Ä‹BAŒÑ“cW‰›A_’Jç–¾A¬“cØŒ\ˆêAŠ£@’¼‹PA“nç³—TŽiA•À–Ø“¿”VF¬l”x‚ŒŒˆ³Š³ŽÒ‚É‚¨‚¯‚é”x‚ŒŒˆ³Ž¡—Öò‚Ì•êW’c–ò•¨“®‘Ô‰ðÍ
‘æ4‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïiɪjAu‰‰—vŽ|W pp.106A2019”N6ŒŽ22“ú
24. _’Jç–¾AŒÑ“cW‰›A•ÐŽR’¼‹IAŠ£@’¼‹PA¬“cØŒ\ˆêA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VA“nç³—TŽiFŒ’íŽÒ‚É‚¨‚¯‚éSelexipag‚ÆClopidogrel•¹—pŽž‚Ì–ò•¨“®‘Ԃɂ‚¢‚Ä
‘æ4‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïiɪjAu‰‰—vŽ|W pp.104A2019”N6ŒŽ22“ú
25. ¬“cØŒ\ˆêA_’Jç–¾AŒÑ“cW‰›AŠ£@’¼‹PA“c’†Ž‡äŽqA“à“cM–çA“nç³—TŽiFƒxƒ‰ƒvƒƒXƒg‚ðƒZƒŒƒLƒVƒpƒO‚É•ÏX‚µ‚½PAHгŽÒ‚ł̖ò•¨”Z“x
‘æ4‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïiɪjAu‰‰—vŽ|W pp.135A2019”N6ŒŽ22“ú
26. Takashi K. Ito, Tomohito Sato, Akio Hakamata, Yuki Onoda, Shumpei Sato, Fumiyoshi Yamazaki, Makoto Horikawa, Takuya Kitamoto, Masako Suzuki, Shinya Uchida, Keiichi Odagiri, Mitsutoshi Setou: A non-randomized study of single oral supplementation of daily tolerable upper level of nicotinamide affects blood nicotinamide and NAD+ levels in healthy subjects
Gordon Research Conference (Newry, USA)A2019”N7ŒŽ14“ú
27. ”‘qNŽ¡FŠw¶‚¨‚æ‚ÑŽáŽè–òÜŽt‚̈笂ɑ΂·‚ég‚ ‚ǂ΂¢‚·h
‘æ29‰ñ“ú–{ˆã—ÖòŠw‰ïi•Ÿ‰ªjAƒVƒ“ƒ|ƒWƒEƒ€38A2019”N11ŒŽ3“ú
28. Koki Sugimoto, Shinya Uchida, Ayae Suzuki, Osamu Yasumuro, Shimako Tanaka, Yasuharu Kashiwagura, Noriyuki Namiki: Effects of grapefruit juice on the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors
Annual Meeting: PharmSci 360 (San Antonio, USA)A2019”N11ŒŽ4“ú
29. Riku Setogawa, Shinya Uchida, Yasuharu Kashiwagura, Hiroshi Suzuki,
Mizuki Kaneshiro, Taro Asakura, Shimako Tanaka, and Noriyuki Namiki: Difference
in palatability among the formulations of Kremezin-, an oral absorbent
of uremic toxins, in chronic kidney disease (CKD) patients.
Annual Meeting: PharmSci 360 (San Antonio, USA)A2019”N11ŒŽ4“ú
30. Naoya Hirukawa, Shinya Uchida, Yasuharu Kashiwagura, Shimako Tanaka, Noriyuki Namiki: The ease of orally taking mini-tablets containing a large amount of drug
Annual Meeting: PharmSci 360 (San Antonio, USA)A2019”N11ŒŽ4“ú
31. Genki Okada, Shinya Uchida, Mitsunobu Yoshida, Jyunko Imoto, Yasuharu Kashiwagura, Shimako Tanaka, Rakan Matsui, and Noriyuki Namiki: In vitro and In vivo Evaluation of Transdermal Absorption of Solifenacin Succinate in Cream and Tape Formulations
Annual Meeting: PharmSci 360 (San Antonio, USA)A2019”N11ŒŽ5“ú
32. Mai Sotoyama, Shinya Uchida, Chiaki Kamiya, Shimako Tanaka, Yasuharu Kashiwagura, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki: Palatability and ease of intake of fixed-dose orally disintegrating tablets
Annual Meeting: PharmSci 360 (San Antonio, USA)A2019”N11ŒŽ6“ú
33. “à“cM–çF—Õ°–òÜŽt‚Ö‚Ì—Õ°–ò—ƒ}ƒCƒ“ƒh‚̈ç¬FƒVƒ“ƒ|ƒWƒEƒ€7@—Õ°–ò—ƒ}ƒCƒ“ƒh‚ðˆç¬‚·‚邽‚߂Ɏ„‚½‚¿‚ª‚·‚ׂ«‚±‚Æ
‘æ40‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi“Œ‹žjAu‰‰—vŽ|WS145A2019”N12ŒŽ4“ú
34. •ÐŽR’¼‹IA_’Jç–¾AŒÑ“cW‰›AŠ£@’¼‹PA¬“cØŒ\ˆêA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VA“nç³—TŽiFŒ’í¬l‚É‚¨‚¯‚éƒVƒgƒNƒƒ€ P450 2C8 ‘jŠQ–òƒNƒƒsƒhƒOƒŒƒ‹•¹—pŽž‚̃ZƒŒƒLƒVƒpƒO‚Ì–ò•¨“®‘Ԃɂ‚¢‚Ä
‘æ40‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi“Œ‹žjAu‰‰—vŽ|WS223A2019”N12ŒŽ5“ú
[‚»‚Ì‘¼‚ÌŠ§s•¨]
1. •À–Ø“¿”VF•ž–òƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚Éd—v‚Ȼ܋Zp
–òŽ–“ú•ñ, ‘æ12164†, pp. 8 (2019)
2. ”’â‹`”V, ”‘qNŽ¡F“ÁW u–òÜŠw‚Æ“ú–{‚Ì–¢—ˆ‚̃~ƒ‰ƒC‚ðl‚¦‚év
–òÜŠw, 79, 4-6 i2019j
3. ”‘qNŽ¡F–òÜŠw‚ªŠ³ŽÒƒxƒlƒtƒBƒbƒg‚ÉvŒ£‚Å‚«‚邱‚ƂƂÍ- ~ˆã—ÃŒ»ê‚Ì—§ê‚©‚ç‚Æ»–òŠé‹Æ‚Ì—§ê‚©‚ç~ ²X–Ø’‰“¿ º˜a‘åŠw“Ї–òÜ•”’·Eº˜a‘åŠw•a‰@–òÜ•”’·
~ ”—˜a”Ž ƒAƒXƒeƒ‰ƒXƒAƒCƒ‹ƒ‰ƒ“ƒhŽÐ’·
–òÜŠw, 79, 12-15 i2019j
4. “à“cM–çA‘O“c˜aÆFƒ‰ƒEƒ“ƒhƒe[ƒuƒ‹4uSpecial population ‚Ì–ò•¨“®‘ÔE–òŒøE•›ì—p—\‘ª‚É‹‚ß‚ç‚ê‚éî•ñE‹Zp‚Æ‚Í-vi“ú–{–òÜŠw‰ï‘æ34
”N‰ïƒ‰ƒEƒ“ƒhƒe[ƒuƒ‹ƒZƒbƒVƒ‡ƒ“•ñj
–òÜŠw, 79, 312-313 i2019j
5. ŒÃ“‡‘厑A“à“cM–çAŽR“c_F‘æ4‰ñ“ú–{—Õ°–ò—Šw‰ï@“ŒŠCE–k—¤’n•û‰ï‚ðI‚¦‚Ä
—Õ°–ò—, 50, 275-278 i2019j
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
1. Tsuyoshi Katayama, Shinya Uchida, Chiaki Kamiya, Shimako Tanaka, Yasuharu Kashiwagura, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki: In vivo drug dissolution in human oral cavity from orally disintegrating tablet and comparability with in vitro testing
Chem Pharm Bull, 66, 999-1005 i2018j
2. Fumiaki Nakagaki, Shinya Uchida, Shimako Tanaka, Noriyuki Namiki: Palatability and preference of gummi formulations with various pharmaceutical characteristics.
Chem Pharm Bull, 66, 452-457 i2018j
3. Osamu Yasumuro, Shinya Uchida, Yasuharu Kashiwagura, Ayae Suzuki, Shimako Tanaka, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki: Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats.
Xenobiotica, 48, 1106-1112 i2018j
4. “à“cM–ç, ’·”ö—º—C, “c’†Ž‡äŽq, ”‘qNŽ¡, •À–Ø“¿”V: ‘å—p—ʂ̖ò•¨‚ðŠÜ—L‚·‚éŒoŒû»Ü‚ð‘z’肵‚½ƒ}ƒCƒNƒƒ^ƒuƒŒƒbƒg‚Ì•ž—p«‚Ì•]‰¿
ˆãŠw‚Æ–òŠw, 75, 1043-1050 i2018j
[‘à]
1. “à“cM–çF¬Ž™E‚—îŽÒE”DŽY•w‚¨‚æ‚Ñ•a‘ÔŽž‚Ì–ò•¨“Š—^Œv‰æ\ƒXƒyƒVƒƒƒ‹ƒ|ƒsƒ…ƒŒ[ƒVƒ‡ƒ“‚Ì–ò•¨Ž¡—Âɂ¨‚¯‚é—¯ˆÓ“_
ˆãŠw‚Ì‚ ‚ä‚Ý, 267, 365-371 i2018j
[’˜‘]
1. “à“cM–çF“œ”A•aŽ¡—ÖòA’É•—E‚”AŽ_ŒŒÇEbó‘B޾гޡ—ÖòAœ‘eé ÇŽ¡—ÖòA’Á’É–òA‚»‚Ì‘¼@
‚È‚ºŒø‚-‚Ç‚¤ˆá‚¤-‚ð—‰ð‚µˆ•û‚·‚邽‚ß‚Ì Ž¡—Öò‚Ì—Õ°–ò—ƒf[ƒ^ƒuƒbƒNi“nç³—TŽi•ÒWA “ú–{ˆãŽ–V•ñŽÐjApp.2-33A314-355A456-471A534-547
(2018)
2. “c’†Ž‡äŽqFœ‘eé ÇŽ¡—ÖòA‚»‚Ì‘¼@
‚È‚ºŒø‚-‚Ç‚¤ˆá‚¤-‚ð—‰ð‚µˆ•û‚·‚邽‚ß‚Ì Ž¡—Öò‚Ì—Õ°–ò—ƒf[ƒ^ƒuƒbƒNi“nç³—TŽi•ÒWA “ú–{ˆãŽ–V•ñŽÐjApp.351-355A534-547
(2018)
[ƒvƒƒV[ƒfƒBƒ“ƒO]
1. “c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VFƒVƒƒhƒVƒ“Œûo“à•ö‰óùiƒ†ƒŠ[ƒt-ODùj‚Ì—Õ°»ÜŠw“I•]‰¿
PLCMik–òjŒ¤‹†‰ï ‘æ 12 ‰ñƒVƒ“ƒ|ƒWƒEƒ€Au‰‰—vŽ|WApp.9-12A2018”N2ŒŽ2“ú
[Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€]
1. “c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VFƒVƒƒhƒVƒ“Œûo“à•ö‰óùiƒ†ƒŠ[ƒt-ODùj‚Ì—Õ°»ÜŠw“I•]‰¿
PLCMik–òjŒ¤‹†‰ï ‘æ 12 ‰ñƒVƒ“ƒ|ƒWƒEƒ€i–¼ŒÃ‰®jA2018”N2ŒŽ2“ú
2. Odagiri K, Miyakawa S, Hakamata A, Inui N, Tanaka S, Uchida S, Namiki N Watanabe H: Different impact of CYP inhibitor and inducer among subjects with different basal CYP activities
ASCPT2016 ANNUAL MEETING (San Diego, USA)A2018”N3ŒŽ11“ú
3. “à“cM–çFƒAƒhƒoƒ“ƒX‹³ˆç‚É‚¨‚¯‚éŠCŠOŒ¤CƒvƒƒOƒ‰ƒ€‚Ö‚ÌŠú‘҂ƉۑèFˆê”ʃVƒ“ƒ|ƒWƒEƒ€S34@‚“x擱“I–òÜŽt‚Ì—{¬‚Æ‚»‚̃Oƒ[ƒJƒ‹‚ÈŠˆ–ô‚ð„i‚·‚éƒAƒhƒoƒ“ƒXƒg‹³ˆçŒ¤‹†ƒvƒƒOƒ‰ƒ€‚Ì‹¤“¯ŠJ”
“ú–{–òŠw‰ï‘æ138”N‰ïi‹à‘òjAu‰‰—vŽ|WA2018”N3ŒŽ27“ú
4. ™–{àY•FA“à“cM–çAŠÖG‘¾A’†Š_Žj“NA“c’†Ž‡äŽqA•À–Ø“¿”VFƒOƒ~»Ü‚ÌŠJ”‚ÉŠÖ‚·‚錤‹† (‘æ6•ñ)|ƒOƒ~»Ü‚Ì•¨«‚Æ•ž—pŠ´‚ÌŠÖŒW|
“ú–{–òŠw‰ï‘æ138”N‰ïi‹à‘òjAu‰‰—vŽ|W4App.53A2018”N3ŒŽ27“ú
5. ”‘qNŽ¡A“c‘ìãÄ‘¾A’r¼N”VA“à“cM–çA•À–Ø“¿”VFˆÙ‚È‚éŽí—Þ‚Ì CoQ10 è÷—±‚ðŠÜ—L‚·‚éŒûo“à•ö‰óù‚Ì—no«‚¨‚æ‚ÑŒoŒû‹zŽû«•]‰¿
“ú–{–òŠw‰ï‘æ138”N‰ïi‹à‘òjAu‰‰—vŽ|W4App.84A2018”N3ŒŽ28“ú
6. XœATŒáA’·”ö—º—CA“à“cM–çA”‘qNŽ¡AÎâ—D‰ÀAˆÉ“¡÷A•À–Ø“¿”VFŒ’N¬l‚¨‚æ‚Ñ‚—ŽÒ‚É‚¨‚¯‚éƒTƒCƒY‚̈قȂéù܂̕ž—p«‚¨‚æ‚ÑŽæ‚舵‚¢«
“ú–{–òŠw‰ï‘æ138”N‰ïi‹à‘òjAu‰‰—vŽ|W4App.84A2018”N3ŒŽ28“ú
7. ²“¡ŽÀ‹GA“c’†Ž‡äŽqA–ì_—DŒŽA_’Jç–¾AŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“à“cM–çA“nç³—TŽiA•À–Ø“¿”VFTDM‚ł̉ž—p‚ð–Ú“I‚Æ‚µ‚½ŒoŒû”x‚ŒŒˆ³ÇŽ¡—Öò‚Ì6Ží“¯Žž’è—Ê–@‚ÌŒŸ“¢
“ú–{–òŠw‰ï‘æ138”N‰ïi‹à‘òjAu‰‰—vŽ|W4App.175A2018”N3ŒŽ28“ú
8. ²X–ØF²A“à“cM–çA—é–Øˆ»ŒbA™–{Œõ‹PA”‘qNŽ¡A“c’†Ž‡äŽqAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒ‰ƒbƒg‚É‚¨‚¯‚éƒOƒŒ[ƒvƒtƒ‹[ƒcƒWƒ…[ƒX‘O“Š—^‚É‚æ‚égefitinibAerlotinib‚¨‚æ‚Ñosimertinib‚Ì‘Ì“à“®‘Ԃ̕ϓ®
“ú–{–òŠw‰ï‘æ138”N‰ïi‹à‘òjAu‰‰—vŽ|W4App.109A2018”N3ŒŽ28“ú
9. ’·”ö—º—CA”‘qNŽ¡AÎâ—D‰ÀAŒÑ“cW‰›A“à“cM–çA“nç³—TŽiA•À–Ø“¿”VF“ûŽ™ŒŒŠÇŽîŽ¡—Âð–Ú“I‚Æ‚µ‚½‰@“à»Üƒvƒƒvƒ‰ƒmƒ[ƒ‹ƒNƒŠ[ƒ€‚ÌŠJ”
“ú–{–òŠw‰ï‘æ138”N‰ïi‹à‘òjAu‰‰—vŽ|W4App.165A2018”N3ŒŽ28“ú
10. ’Å—t—S‹MA“c’†Ž‡äŽqA•ÐŽR„A•gì’¼ÆA_’Jç–¾AŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“à“cM–çA“nç³—TŽiA•À–Ø“¿”VFƒqƒgŒûo“à‚É‚¨‚¯‚éƒAƒ€ƒƒWƒsƒ“Œûo“à•ö‰óù‚©‚ç‚Ì–ò•¨—no
“ú–{–òÜŠw‰ï‘æ33”N‰ïiɪjAu‰‰—vŽ|WApp.68A2018”N5ŒŽ30“ú
11. Akihiro Nagai, Shinya Uchida, Shimako Tanaka, Yasuharu Kashiwagura, Noriyuki NamikiF Evaluation of the usability of a newly developed tablet container intended to aid medication intake and enhance patient adherence
ASHP 2018 Summer Meetings and Exhibition (Denver, USA)A2018”N6ŒŽ4“ú
12. ²“¡ŽÀ‹GA“c’†Ž‡äŽqAŒÑ“cW‰›A–ì_—DŒŽA_’Jç–¾AÎì‹M[A“à“cM–çA¬“cØŒ\ˆêAŠ£@’¼‹PA•À–Ø“¿”VA“nç³—TŽiF”x‚ŒŒˆ³ÇŽ¡—Öò‚Ì“ú–{lгŽÒ‚É‚¨‚¯‚錌Ÿ÷’†”Z“x
‘æ3‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïi‘åãjAu‰‰—vŽ|WApp.108A2018”N6ŒŽ22“ú
13. ŒÑ“cW‰›A“c’†Ž‡äŽqA‘ºã’m—²Aˆäã“ÞA‹àŽqK‰hA’†›¸”ª‹÷AX‘PŽ÷A“à“cM–çA¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiF¬Ž™‚É‚¨‚¯‚é”x‚ŒŒˆ³ÇŽ¡—Öò‚ÌŒŒ’†–ò•¨”Z“x‚̉ðÍ
‘æ3‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïi‘åãjAu‰‰—vŽ|WApp.144A2018”N6ŒŽ23“ú
14. “c’†Ž‡äŽqF•ž–ò‚ðŽx‰‡‚·‚é—Õ°»ÜŠw“IƒAƒvƒ[ƒ`[‚±‚Ç‚à‚Ì–ò‚Ì‚©‚½‚¿‚Æ–¡‚ɂ‚¢‚Ä[
‘æ26‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€i“Œ‹žjAƒVƒ“ƒ|ƒWƒEƒ€4A2018”N6ŒŽ23“ú
15. Shinya Uchida, Shimako Tanaka, Shuta Seki, Sayuri Nakajima, Chiaki Kamiya, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Noriyuki NamikiFEvaluation of palatability of cocoa-flavored gummi drug of aripiprazole developed from commercially available tablets.
The 18th World Congress of Basic and Clinical Pharmacology (Kyoto)A2018”N7ŒŽ1“ú
16. Takaaki Sasaki, Shinya Uchida, Ayae Suzuki, Osamu Yasumuro, Yasuharu Kashiwagura, Shimako Tanaka, Naoki Inui, Hiroshi Watanabe, and Noriyuki NamikiF Relationship between gastric pH and plasma concentrations of gefitinib, erlotinib and osimertinib after oral administrations in rats.
The 18th World Congress of Basic and Clinical Pharmacology (Kyoto)A2018”N7ŒŽ1“ú
17. Chiaki Kamiya, Keiichi Odagiri, Sachiko Miyakawa, Akio Hakamata, Naoki Inui, Shimako Tanaka, Shinya Uchida, Noriyuki Namiki, Hiroshi Watanabe: Genotype-specific effects of cytochrome P450 inducers and inhibitors on CYP2C19 enzyme activity.
The 18th World Congress of Basic and Clinical Pharmacology (Kyoto)A2018”N7ŒŽ1“ú
18. Akio Hakamata, Yasuharu Kashiwagura, Masami Shirai, Akira Endoh, Chiaki Kamiya, Keiichi Odagiri, Shinya Uchida, Naoki Inui and Hiroshi Watanabe: Topical propranolol treatment for infantile hemangioma; A case series
The 18th World Congress of Basic and Clinical Pharmacology (Kyoto)A2018”N7ŒŽ1“ú
19. Jiaxing Tong, Nan Fukudo, Yuto Kudo, Hajime Mizuno, Shinya Uchida, Noriyuki Namiki, Toshimasa Toyo'oka, Kenichiro Todoroki: Development of on-site absorption spectrometry of haloperidol and bromperidol aimed at point-of-care testing.
RSC Tokyo International Conference 2018 (Tokyo)A2018”N9ŒŽ6“ú
20. ”‘qNŽ¡A“à“cM–çAŒÑ“cW‰›A’·”ö—º—CA‘åé^—“ÞA”’ˆäáÁ”üA‰““¡ ²AŠ£ ’¼‹PA“nç³—TŽiA•À–Ø“¿”VF“ûŽ™ŒŒŠÇŽî‚ɑ΂·‚é‰@“à»Üƒvƒƒvƒ‰ƒmƒ[ƒ‹ƒNƒŠ[ƒ€‚Ì’²»‚¨‚æ‚Ñ—Õ°•]
‘æ45‰ñ“ú–{¬Ž™—Õ°–ò—Šw‰ïŠwpW‰ïi“Œ‹žjAu‰‰—vŽ|WApp.66A2018”N10ŒŽ6“ú
21. Ryosuke Nagao, Shinya Uchida, Homare Kurashima, Yuka Ishizaka, Shimako Tanaka, Yasuharu Kashiwagura, Yuzuru Ito, Noriyuki NamikiF Evaluations of ease of swallowing and handling tablets of various sizes by healthy volunteers and elderly patients
Annual Meeting: PharmSci 360 (Washington, USA)A2018”N11ŒŽ7“ú
22. Miohiko Sugimoto, Shinya Uchida, Humiaki Nakagaki, Syuta Seki, Shimako Tanaka, Yasuharu Kashiwagura, and Noriyuki NamikiF Relationships between physical properties and overall palatability of gummi drugs
Annual Meeting: PharmSci 360 (Washington, USA)A2018”N11ŒŽ5“ú
23. Shingo Morihiro, Shinya Uchida, Shuta Seki, Shimako Tanaka, Yasuharu Kashiwagura, Chiaki Kamiya, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki: Improved palatability of gummi drug of epinastine hydrochloride using organoleptic taste-masking methods.
Annual Meeting: PharmSci 360 (Washington, USA)A2018”N11ŒŽ6“ú
24. Akio Hakmata, Shimako Tanaka, Tomotaka, Murakami, Nao Inoue, Sachie Kaneko, Yasumi Nakashima, Yoshiki Mori, Chiaki Kamiya, Shinya Uchida, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe: The analysis of plasma concentration of sildenafil, tadlafil and ambrisentan in japanese children with pulmonary arterial hypertension.
American Heart Association (Chicago, USA)A2018”N11ŒŽ10“ú
25. “à“cM–çF–ò•¨“®‘Ô‚É‚¨‚¯‚é•Ï“®—vˆö‚̃Gƒrƒfƒ“ƒX‚ðì‚éA“`‚¦‚éAŽg‚¤FƒVƒ“ƒ|ƒWƒEƒ€48@–ò•¨“®‘Ô‚É‚¨‚¯‚é•Ï“®—vˆö‚̃Gƒrƒfƒ“ƒX[ƒGƒrƒfƒ“ƒX‚ðì‚éE“`‚¦‚éEŽg‚¤
‘æ28‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi_ŒËjA2018”N11ŒŽ25“ú
26. ‰iˆä»‘åA“à“cM–çA”‘qNŽ¡AŒÑ“cW‰›AÎâ—D‰ÀA“c’†Ž‡äŽqA—閨аAŽR“àŽÆAˆÉ“¡÷A•À–Ø“¿”VFùÜ‚ÌV‹K•ï‘•—eŠíi•ž–òŽx‰‡—eŠíj‚Ì‘€ì«‚Ì•]‰¿
‘æ28‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi_ŒËjA2018”N11ŒŽ25“ú
[‚»‚Ì‘¼‚ÌŠ§s•¨]
1. “à“cM–çA•ÄàV~Fƒ‰ƒEƒ“ƒhƒe[ƒuƒ‹6u–ò•¨‘ŠŒÝì—pEŒÂ•ʉ»ˆã—ÃFG‚Ì¡Œã‚ð–₤\ƒtƒH[ƒJƒXƒOƒ‹[ƒv‚Ö‚ÌŠú‘҂Ɖۑèvi“ú–{–òÜŠw‰ï‘æ33 ”N‰ïƒ‰ƒEƒ“ƒhƒe[ƒuƒ‹ƒZƒbƒVƒ‡ƒ“•ñj
–òÜŠw, 78, 291-292 i2018j
2. “à“cM–çF–òŠw‹³ˆçƒ‚ƒfƒ‹EƒRƒAƒJƒŠƒLƒ…ƒ‰ƒ€‚̉ü’è‚ÆŽÀ–±ŽÀKichange`‰ŒÃ—ˆ¡ •Ï‚í‚Á‚½‚Æ‚±‚ë•Ï‚í‚邯‚±‚ëj
ÖòŠw—F‰ï•ñ, 86, 5 i2018j
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
1. Mai Sotoyama, Shinya Uchida, Shimako Tanaka, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, and Noriyuki Namiki: Citric acid suppresses the bitter taste of olopatadine hydrochloride orally disintegrating tablets
Biol Pharm Bull, 40, 451-457 i2017j
2. Shinya Uchida, Yasuharu Kashiwagura, Yuka Ishizaka, Shimako Tanaka, Hiroshi Suzuki, Katsuya Yamauchi, Yuzuru Ito, Noriyuki Namiki: Evaluation of the usability of a newly developed tablet container to aid medication intake for the enhancement of patient adherence
ˆãŠw‚Æ–òŠw, 74, 1071-1078 i2017j
[‘à]
1. “à“cM–çF»Ü‚Æ•ž–òƒAƒhƒqƒAƒ‰ƒ“ƒX
PRACTICE, 34, 60-62 (2017)
2. “à“cM–çF»Ü‚Æ•ž–òƒAƒhƒqƒAƒ‰ƒ“ƒX|Œûo“à•ö‰óùiODùj\
PRACTICE, 34, 60-62 (2017)
3. “à“cM–çF»Ü‚Æ•ž–òƒAƒhƒqƒAƒ‰ƒ“ƒX|ŒoŒû“œ”A•a–ò‚Ì”z‡Ü\
PRACTICE, 34, 60-62 (2017)
4. ’r¼N”VA“à“cM–çA•À–Ø“¿”VFމ—n«‚̃‚ƒfƒ‹–ò•¨‚Æ‚µ‚ărƒ^ƒ~ƒ“E‚ðŠÜ—L‚µ‚½Œûo“à•ö‰óù‚Ì»ÜÝŒv
PHARM TECH JAPAN, 33, 1865-1874 (2017)
[’˜‘]
1. “à“cM–çF‘æ3Í@–ò•¨ì—p‚Æ“®‘Ô‚ÌŠî–{AC –ò•¨“®‘Ô‚ÌŠî–{A1 –ò•¨‚Ì‹zŽûA2 –ò•¨‚Ì•ª•z
—Õ°–ò—Šw‘æ4”Åiˆê”ÊŽÐ’c–@l“ú–{—Õ°–ò—Šw‰ï•ÒWA¬—Ñ^ˆêA’·’J새êA
“¡‘ºº•vA“nç³—TŽi Ó”C•ÒWAˆãŠw‘‰@jApp.95-105 (2017)
[ƒvƒƒV[ƒfƒBƒ“ƒO]
1. ŠOŽR^ˆßA“à“cM–çA•À–Ø“¿”VF“dŽq–¡ŠoƒVƒXƒeƒ€‚É‚æ‚é–ò܂̕ž—p«—\‘ª
PLCMik–òjŒ¤‹†‰ï ‘æ11‰ñƒVƒ“ƒ|ƒWƒEƒ€Au‰‰—vŽ|WApp.47-50A2017”N2ŒŽ3“ú
[Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€]
1. ŠOŽR^ˆßA“à“cM–çA•À–Ø“¿”VF“dŽq–¡ŠoƒVƒXƒeƒ€‚É‚æ‚é–ò܂̕ž—p«—\‘ª
PLCMik–òjŒ¤‹†‰ï ‘æ11‰ñƒVƒ“ƒ|ƒWƒEƒ€i–¼ŒÃ‰®jA2017”N2ŒŽ3“ú
2. Yasuharu Kashiwagura, Shota Takusagawa, Yasuyuki Ikematsu, Shinya Uchida, Noriyuki NamikiF Preparation and evaluation of characteristics of orally disintegrating tablets containing different types of coenzyme Q10 granules
International Symposium on Drug Delivery and Pharmaceutical Sciences (Kyoto, Japan)A2017”N3ŒŽ9“ú
3. Shimako Tanaka, Mai Sotoyama, Hideshi Nakamura, Shinya Uchida, Noriyuki NamikiFThe prediction of the palatability of combining powder formulations with food and beverages by an electronic gustatory system
International Symposium on Drug Delivery and Pharmaceutical Sciences (Kyoto, Japan)A2017”N3ŒŽ9“ú
4. –ì_—DŒŽA“c’†Ž‡äŽqA“à“cM–çAŽÂŒ´”ü‹IAŽO‰YŠî–õAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒJƒNƒeƒ‹ŽŽŒ±‚Ì–ò•¨‘ŠŒÝì—pŒŸo–@‚Æ‚µ‚Ă̑Ó–«‚ÌŒŸØ
“ú–{–òŠw‰ï‘æ137”N‰ïiå‘äjAu‰‰—vŽ|W4App.62A2017”N3ŒŽ25“ú
5. ŠÖG‘¾A“à“cM–çA“c’†Ž‡äŽqA’†“ˆ¬•S‡AŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒAƒŠƒsƒvƒ‰ƒ][ƒ‹ŠÜ—LƒOƒ~»Ü‚ÌŠJ”‚ÉŠÖ‚·‚錤‹† (‘æ5•ñ)|ƒRƒRƒAƒpƒEƒ_[‚¨‚æ‚уtƒŒ[ƒo[‚ð—p‚¢‚½Š¯”\“Iƒ}ƒXƒLƒ“ƒO|
“ú–{–òŠw‰ï‘æ137”N‰ïiå‘äjAu‰‰—vŽ|W4App.159A2017”N3ŒŽ26“ú
6. Îâ—D‰ÀA“à“cM–çAëƒmX‘ñ¶A‘ì‰À”VA”‘qNŽ¡AˆÉ“¡÷A•À–Ø“¿”VFƒ~ƒjƒ^ƒuƒŒƒbƒg‚Ì•ž—p«‚¨‚æ‚ÑŽæ‚舵‚¢«‚ÉŠÖ‚·‚é•]‰¿
“ú–{–òŠw‰ï‘æ137”N‰ïiå‘äjAu‰‰—vŽ|W4App.154A2017”N3ŒŽ26“ú
7. —é–Øˆ»ŒbA“à“cM–çAˆÀŽºCA“c’†Ž‡äŽqA”‘qNŽ¡AŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒ‰ƒbƒg‚É‚¨‚¯‚éˆÝ“àpH‚Ægefitinib‚¨‚æ‚Ñerlotinib‚ÌŒŒŸ÷’†”Z“x‚Ƃ̊֌W
“ú–{–òŠw‰ï‘æ137”N‰ïiå‘äjAu‰‰—vŽ|W4App.189A2017”N3ŒŽ27“ú
8. Ÿ–”ÂA”‘qNŽ¡AëƒmX‘ñ¶A‚–ìGmA“à“cM–çA•À–Ø“¿”VFƒRƒRƒAƒpƒEƒ_[‚Ì“Y‰Á‚É‚æ‚éŒûo“à•ö‰óù‚ÌùÜ•¨«‚ւ̉e‹¿
“ú–{–òÜŠw‰ï‘æ32”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.112A2017”N5ŒŽ11“ú
9. –ì_—DŒŽAŠOŽR^ˆßA”‘qNŽ¡A“c’†Ž‡äŽqAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“à“cM–çA“nç³—TŽiA•À–Ø“¿”VFƒ~ƒ`ƒOƒŠƒjƒhŒûo“à•ö‰óùiƒOƒ‹ƒtƒ@ƒXƒg-
ODùj‚Ì—Õ°»ÜŠw“I•]‰¿
“ú–{–òÜŠw‰ï‘æ32”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.232A2017”N5ŒŽ11“ú
10. Îâ—D‰ÀA”‘qNŽ¡A‘ì‰À”VAˆÉ“¡÷A“à“cM–çA•À–Ø“¿”VF‘å‚«‚³‚̈قȂéù܂ɂ¨‚¯‚éŽæ‚舵‚¢«‚Ì•]‰¿
“ú–{–òÜŠw‰ï‘æ32”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.234A2017”N5ŒŽ11“ú
11. —é–Øˆ»ŒbAŠOŽR^ˆßA”‘qNŽ¡A“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VFƒVƒƒhƒVƒ“Œûo“à•ö‰óùiƒ†ƒŠ[ƒt-ODùj‚Ì—Õ°»ÜŠw“I•]‰¿
“ú–{–òÜŠw‰ï‘æ32”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.234A2017”N5ŒŽ11“ú
12. ŠÖG‘¾A“c’†Ž‡äŽqA¼ˆä—ÇŠ²A“à“cM–çA•À–Ø“¿”VFН”\“Iƒ}ƒXƒLƒ“ƒO‚É‚æ‚éƒGƒsƒiƒXƒ`ƒ“‰–Ž_‰–ŠÜ—LƒOƒ~»Ü‚Ì•ž—p«‚ÌŒüã
“ú–{–òÜŠw‰ï‘æ32”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.108A2017”N5ŒŽ11“ú
13. “nç²—´–îA“c’†Ž‡äŽqA“à“cM–çAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒJƒNƒeƒ‹ŽŽŒ±‚Ì1ƒ|ƒCƒ“ƒgÌŒŒ‚É‚¨‚¯‚錌Ÿ÷‹y‚Ñ”A’†‘ãŽÓ”䂯AUC”ä‚ÌŠÖŒW
“ú–{–òÜŠw‰ï‘æ32”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.226A2017”N5ŒŽ11“ú
14. “à“cM–çAŒÑ“cW‰›A“c’†Ž‡äŽqA_’Jç–¾AÎì‹M[A¬“cØŒ\ˆêAŠ£’¼Ž÷AX‘PŽ÷A•À–Ø“¿”VA“nç³—TŽiF”x‚ŒŒˆ³ÇŽ¡—Öò‚É‚¨‚¯‚é–ò•¨Ž¡—ƒjƒ^ƒŠƒ“ƒOiTDMj‚ÌŒŸ“¢
‘æ2‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïiŽD–yjAu‰‰—vŽ|WApp.148A2017”N6ŒŽ3“ú
15. ŒÑ“cW‰›AÎì‹M[A“c’†Ž‡äŽqA_’Jç–¾A¬“cØŒ\ˆêA“à“cM–çAŠ£’¼‹PA“nç³—TŽiF–ò•¨‘—Ê‚ÉTDM‚ð—p‚¢‚½ŠÌEt‹@”\áŠQ‡•¹”x‚ŒŒˆ³Ç‚Ì—á
‘æ2‰ñ“ú–{”x‚ŒŒˆ³E”xzŠÂŠw‰ïŠwpW‰ïiŽD–yjAu‰‰—vŽ|WApp.162A2017”N6ŒŽ3“ú
16. Shimako Tanaka, Mai Sotoyama, Hideshi Nakamura, Shinya Uchida, Noriyuki NamikiF The prediction of the palatability of combining powder formulations with food and beverages by an electronic gustatory system
ASHP 2017 Summer Meetings and Exhibition (Minneapolis, USA)A2017”N6ŒŽ3“ú
17. Shinya Uchida, Shimako Tanaka, Akio Hakamata, Hiroshi Watanabe, Noriyuki NamikiF Palatability of cocoa-flavored gummi drug of aripiprazole developed from commercially available tablets
ASHP 2017 Summer Meetings and Exhibition (Minneapolis, USA)A2017”N6ŒŽ4“ú
18. “c’†Ž‡äŽqA“à“cM–çAŒÑ“cW‰›A_’Jç–¾A¬“cØŒ\ˆêAŠ£’¼Ž÷A•À–Ø“¿”VA“nç³—TŽiF”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚é5Ží‚ÌŽ¡—Öò‚ÌTDM‚ÌŒŸ“¢
ˆã—ÖòŠwƒtƒH[ƒ‰ƒ€2017iŽŽ™“‡jAu‰‰—vŽ|WApp.59A2017”N7ŒŽ1“ú
19. –ì_—DŒŽA“c’†Ž‡äŽqA“nç²—´–îA²“¡ŽÀ‹GA¬“cØŒ\ˆêAŒÑ“cW‰›A“à“cM–çA“nç³—TŽiA•À–Ø“¿”VFV‹K”x‚ŒŒˆ³ÇŽ¡—Öòselexipag‹y‚ÑŠˆ«‘ãŽÓ•¨‚ÌŒŒŸ÷’†–ò•¨”Z“x‘ª’è–@‚ÌŠm—§
‘æ34‰ñ“ú–{TDMŠw‰ïEŠwp‘å‰ïi‹ž“sjAu‰‰—vŽ|WApp.134A2017”N9ŒŽ23“ú
20. “c’†Ž‡äŽqAŠOŽR^ˆßA’†‘º‹”VA“à“cM–çA•À–Ø“¿”VF¬Ž™—p»Ü‚ƈùH•¨‚Ƃ̔z‡‚É‚¨‚¯‚镞—pŠ´‚Ì—Õ°“I•]‰¿
‘æ44‰ñ“ú–{¬Ž™—Õ°–ò—Šw‰ïŠwpW‰ïiɪjAu‰‰—vŽ|WApp.114A2017”N10ŒŽ7“ú
21. Shinya Uchida, Hideshi Nakamura, Mai Sotoyama, Shimako Tanaka, Yasuharu Kashiwagura, Noriyuki NamikiF Evaluation and Prediction of the Palatability of Combining Powder Formulations with Food and Beverages by the Human Gustatory Test and Electronic Gustatory System
AAPS 2017 Annural Meeting and Exposition (San Diego, USA)A2017”N11ŒŽ15“ú
22. Hideshi Nakamura, Shinya Uchida, Takashi Sugiura, Noriyuki NamikiF Evaluation of the palatability of orally disintegrating tablets by an electronic gustatory system and its application for formulation development
AAPS 2017 Annural Meeting and Exposition (San Diego, USA)A2017”N11ŒŽ16“ú
23. —é–Øˆ»ŒbA“à“cM–çA”‘qNŽ¡AŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒ‰ƒbƒg‚É‚¨‚¯‚éEGFRƒ`ƒƒVƒ“ƒLƒi[ƒ[‘jŠQÜ‚Ì‘Ì“à“®‘Ô‚É‹y‚Ú‚·ƒOƒŒ[ƒvƒtƒ‹[ƒcƒWƒ…[ƒX‚̉e‹¿
“ú–{–òŠw‰ï“ŒŠCŽx•” ‡“¯Šwp‘å‰ï2017iŽOdjAu‰‰—vŽ|WApp.134A2017”N11ŒŽ26“ú
24. _’Jç–¾A¬“cØŒ\ˆêA‹{ìKŽqAŒÑ“cW‰›AŠ£’¼Ž÷A“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VA“nç³—TŽiF Cytochrome P450‚É‚¨‚¯‚éˆâ“`Žq‘½Œ^‚Æy‘f—U“±/‘jŠQ‚ÌŠÖ˜A
‘æ38‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi‰¡•ljAu‰‰—vŽ|WApp.S255A2017”N12ŒŽ7“ú
25. ‹{ìKŽqA“à“cM–çAŒÑ“cW‰›A–ì_—DŒŽAV—¢·˜NA_’Jç–¾A¬“cØŒ\ˆêAŠ£’¼Ž÷A”~‘º•аA•À–Ø“¿”VA“nç³—TŽiF A Case of Cardiopulmonary Arrest due to Overdose of Mirabegron (Betanis)
‘æ38‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi‰¡•ljAu‰‰—vŽ|WApp.S298A2017”N12ŒŽ7“ú
26. ŒÑ“cW‰›AÎì‹M[A“c’†Ž‡äŽqA_’Jç–¾A¬“cØŒ\ˆêA“à“cM–çAŠ£’¼‹PA“nç³—TŽiFŽ¡—ÓI–ò•¨”Z“xƒ‚ƒjƒ^ƒŠƒ“ƒOiTDMj‚ð—p‚¢‚Ä–òÜ’²®‚ðs‚Á‚½ŠÌEt‹@”\áŠQ‡•¹Ç”x‚ŒŒˆ³Ç‚Ì1—á
‘æ38‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi‰¡•ljAu‰‰—vŽ|WApp.S279A2017”N12ŒŽ9“ú
27. ”‘qNŽ¡FƒŒƒoƒ~ƒsƒhŠÜ—Lƒ`ƒ‡ƒRƒŒƒbƒg‚Ì’²»‚Æ•ž—p«‚Ì•]‰¿
‘æ6‰ñ‘n܃Jƒ“ƒtƒ@ƒŒƒ“ƒXɪiɪjAu‰‰—vŽ|WApp.9-10A2017”N12ŒŽ15“ú
28. “à“cM–çF“dŽq–¡ŠoƒVƒXƒeƒ€‚É‚æ‚é–ò܂̕ž—p«—\‘ª
‘æ6‰ñ‘n܃Jƒ“ƒtƒ@ƒŒƒ“ƒXɪiɪjAu‰‰—vŽ|WApp.11-12A2017”N12ŒŽ15“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
1. Yoshiyuki Hayakawa, Shinya Uchida, Noriyuki Namiki: Evaluation of the ease of taking mini-tablets compared with other tablet formulations in healthy volunteers.
Eur. J. Pharm. Sci, 84, 157-161 i2016j
2. Yohei Koya, Shinya Uchida, Yoshiki Machi, Yuko Shobu, Noriyuki Namiki, Tsutomu Kotegawa: Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs.
Eur. J. Clin. Pharmacol., 72, 1353-1361 i2016j
3. Yuuki Kasashima, Keiichi Yoshihara, Takehiko Yasuji, Kazuhiro Sako, Shinya Uchida, Noriyuki Namiki: Oral sustained release of a hydrophilic drug using the lauryl sulfate salt/complex
Chem. Pharm. Bull., 64, 1304-1309 i2016j
4. Yuuki Kasashima, Shinya Uchida, Keiichi Yoshihara, Takehiko Yasuji, Kazuhiro Sako, Noriyuki Namiki: Oral sustained-release suspension based on a lauryl sulfate salt/complex.
Int. J. Pharm, 515, 677-683 i2016j
5. Shinya Uchida, Yasuharu Kashiwagura, Mai Sotoyama, Shimako Tanaka, Shota
Takusagawa, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe,
Noriyuki Namiki: Improved palatability of orally disintegrating tablets
of mitiglinide calcium hydrate (GLUFAST- OD) by combined masking of organoleptic
taste and physical taste, and assessment of clinical pharmaceutics.
ˆãŠw‚Æ–òŠw, 73, 423-431 i2016j
6. Akio Hakamata, Keiichi Odagiri, Sachiko Miyakawa, Irisawa Hiroshi, Kazuhiko Takeuchi, Naoki Inui, Shimako Tanaka, Shinya Uchida, Watanabe Hiroshi: Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil-Bosentan and Sildenafil-Ambrisentan Combination Therapies for Pulmonary Hypertension.
Clin Transl Sci, 9, 29-35 i2016j
[‘à]
1. “à“cM–ç: ‘ãŽÓ—U“±‚Ì‘ŠŒÝì—p‚͂ǂꂮ‚ç‚¢Ž‘±‚µ‚Ü‚·‚©-|DDI‚ÌŠî–{‚ƃsƒbƒgƒtƒH[ƒ‹IƒGƒLƒXƒp[ƒg‚ª“š‚¦‚éQ&A
–ò‹ÇA 67, pp.2483-2486 i2016j
[ƒvƒƒV[ƒfƒBƒ“ƒO]
1. Shinya UchidaFEvaluation of the ease of taking mini-tablets compared with other tablet formulations in healthy volunteer
J. Pharm. Drug Deliv. Res. 5, pp.53 (2016)
[Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€]
1. ’†“ˆ¬•S‡A“à“cM–çAŽÅØŽáØAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—SŽiA•À–Ø“¿”VFƒAƒŠƒsƒvƒ‰ƒ][ƒ‹ŠÜ—LƒOƒ~»Ü‚ÌŠJ”‚ÉŠÖ‚·‚錤‹†i‘æ4•ñj|ƒOƒ~»Ü‚É‚¨‚¯‚銯”\“Iƒ}ƒXƒLƒ“ƒO‚Ì•]‰¿|
“ú–{–òŠw‰ï‘æ136”N‰ïi‰¡•ljAu‰‰—vŽ|W4App.104A2016”N3ŒŽ27“ú
2. ¬ì°‰ÁAŠOŽR^ˆßA’†‘º‹”VA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VF¬Ž™—pŽU܂ւ̊eŽíˆùH•¨‚Ì”z‡‚ª•ž—pŠ´‚É‹y‚Ú‚·‰e‹¿
“ú–{–òŠw‰ï‘æ136”N‰ïi‰¡•ljAu‰‰—vŽ|W4App.157A2016”N3ŒŽ27“ú
3. ŽÅØŽáØAŽÂŒ´”ü‹IA“à“cM–çA“c’†Ž‡äŽqAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—SŽiA•À–Ø“¿”VFƒJƒNƒeƒ‹ŽŽŒ±‚Å‚Ì1ƒ|ƒCƒ“ƒgÌŒŒ‚É‚¨‚¯‚錌Ÿ÷’†”Z“x‚¨‚æ‚Ñ”A’†‘ãŽÓ”䂯AUC‚Ƃ̊֌W\dextromethorphan‚¨‚æ‚Ñmidazolam‚É‚¨‚¯‚錟“¢\
“ú–{–òŠw‰ï‘æ136”N‰ïi‰¡•ljAu‰‰—vŽ|W4App.173A2016”N3ŒŽ27“ú
4. ŽÂŒ´”ü‹IAŽÅØŽáØA“à“cM–çA“c’†Ž‡äŽqAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—SŽiA•À–Ø“¿”VFƒJƒNƒeƒ‹ŽŽŒ±‚Å‚Ì1ƒ|ƒCƒ“ƒgÌŒŒ‚É‚¨‚¯‚錌Ÿ÷’†”Z“x‚¨‚æ‚Ñ”A’†‘ãŽÓ”䂯AUC‚Ƃ̊֌W\caffeineAlosartan‹y‚Ñomeprazole‚É‚¨‚¯‚錟“¢\
“ú–{–òŠw‰ï‘æ136”N‰ïi‰¡•ljAu‰‰—vŽ|W4App.173A2016”N3ŒŽ27“ú
5. •À–Ø“¿”VFƒVƒ“ƒ|ƒWƒEƒ€uÜŒ`‚Ì‘½—l«‚ÍŠ³ŽÒƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚Æˆã—ÃŒoÏ‚ÉvŒ£‚Å‚«‚é‚©-v•ž–òƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚ð–ÚŽw‚µ‚½ÜŒ`ŠJ”‚Ìd—v«
“ú–{–òŠw‰ï‘æ136”N‰ïiƒI[ƒKƒiƒCƒU[•ƒVƒ“ƒ|ƒWƒXƒgA‰¡•ljA
u‰‰—vŽ|W1App.130-131A2016”N3ŒŽ27“ú
6. ŠOŽR^ˆßA“à“cM–çA“c’†Ž‡äŽqAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—SŽiA•À–Ø“¿”VFƒIƒƒpƒ^ƒWƒ“‰–Ž_‰–Œûo“à•ö‰óù‚ÌŠ¯”\“Iƒ}ƒXƒLƒ“ƒO‚ð—p‚¢‚½•ž—p«‚̉ü‘P
“ú–{–òŠw‰ï‘æ136”N‰ïi‰¡•ljAu‰‰—vŽ|W4App.62A2016”N3ŒŽ28“ú
7. ŽR‰º‚Ђ©‚èA“à“cM–çA‹´–{çqA”‘qNŽ¡A¼ˆä—ÇŠ²A•À–Ø“¿”VFƒ\ƒŠƒtƒFƒiƒVƒ“ŠÜ—LƒNƒŠ[ƒ€»Ü‚¨‚æ‚уe[ƒv»Ü‚É‚¨‚¯‚éin vitro”畆“§‰ß«
“ú–{–òŠw‰ï‘æ136”N‰ïi‰¡•ljAu‰‰—vŽ|W4App.71A2016”N3ŒŽ28“ú
8. X–{’B–çA“â‘׎jA‹{›½–õ‘¥Aˆäã˜aKA’Ò‘åŽ÷A’JàVNŒºA»ì—zˆêA”‘qNŽ¡A—é–Ø”üŠóA•‰HŽqF‘¾A–ìŒû”ŽŽiA‰êì‹`”VAVˆä‰pˆêAŽ®Žç°ŽqA•yˆÀáÁ—A’JŒû’ʉpA“Œ–ì’è—¥A”ä—¯ŠÔ—mˆêAX–ì’qŽqA‡“c•q®F’nˆæƒj[ƒY‚Ƀ}ƒbƒ`‚µ‚½ˆã—Ãlވ笃VƒXƒeƒ€‚ÌŠJ”
“ú–{–òŠw‰ï‘æ136”N‰ïi‰¡•ljAu‰‰—vŽ|W4App.212A2016”N3ŒŽ28“ú
9. ˆî–ع–îA“c’†Ž‡äŽqA“à“cM–çAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VF”x‚ŒŒˆ³ÇŽ¡—Öò‚É‚¨‚¯‚é“¯Žž’è—Ê–@‚ÌŒŸ“¢‚Æ•êW’c–ò•¨“®‘Ô‰ðÍ
“ú–{–òÜŠw‰ï‘æ31”N‰ïiŠò•ŒjAu‰‰—vŽ|WApp.231A2016”N5ŒŽ19“ú
10. ŽÅØŽá“ÞA“à“cM–çA’†“ˆ¬•S‡AëƒmX‘ñ¶A‘ì‰À”VA•À–Ø“¿”VFŒ’íl‚É‚¨‚¯‚éƒ~ƒjƒ^ƒuƒŒƒbƒg‚Ì•ž—p«•]‰¿
“ú–{–òÜŠw‰ï‘æ31”N‰ïiŠò•ŒjAu‰‰—vŽ|WApp.202A2016”N5ŒŽ19“ú
11. ‹´–{çqA“à“cM–çAŽR‰º‚Ђ©‚èA¼ˆä—ÇŠ²A”‘qNŽ¡A•À–Ø“¿”VFƒ\ƒŠƒtƒFƒiƒVƒ“Œo”ç‹zŽûŒ^»Ü‚̃‰ƒbƒg‚É‚¨‚¯‚éin vivo”畆“§‰ß«•]‰¿
“ú–{–òÜŠw‰ï‘æ31”N‰ïiŠò•ŒjAu‰‰—vŽ|WApp.210A2016”N5ŒŽ19“ú
12. “c‘ìãÄ‘¾A”‘qNŽ¡A’r¼N”VA“à“cM–çA•À–Ø“¿”VFƒ†ƒrƒfƒJƒŒƒmƒ“iCoQ10jŒûo“à•ö‰óù‚̻ܓÁ«
“ú–{–òÜŠw‰ï‘æ31”N‰ïiŠò•ŒjAu‰‰—vŽ|WApp.201A2016”N5ŒŽ19“ú
13. ‘]ª‘DAŠOŽR^ˆßA“c’†Ž‡äŽqA’†‘º‹”VA“à“cM–çA•À–Ø“¿”VFˆùH•¨‚Æ”z‡‚µ‚½•²––»Ü‚Ì“dŽq–¡ŠoƒVƒXƒeƒ€‚É‚æ‚镞—p«—\‘ª
“ú–{–òÜŠw‰ï‘æ31”N‰ïiŠò•ŒjAu‰‰—vŽ|WApp.267A2016”N5ŒŽ21“ú
14. ëƒmX‘ñ¶A“à“c^–çA’†“ˆ¬•S‡AŽÅØŽá“ÞA‘ì‰À”VA•À–Ø“¿”VFƒ~ƒjƒ^ƒuƒŒƒbƒg‚ÌŽæ‚舵‚¢‚â‚·‚³‚ÉŠÖ‚·‚é•]‰¿
“ú–{–òÜŠw‰ï‘æ31”N‰ïiŠò•ŒjAu‰‰—vŽ|WApp.265A2016”N5ŒŽ21“ú
15. ’†‘º‹”VAŠOŽR^ˆßA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VF“dŽq–¡ŠoƒVƒXƒeƒ€‚ð—p‚¢‚½•²––»Ü‚ƈùH•¨‚Ƃ̔z‡‚É‚¨‚¯‚镞—pŠ´‚Ì•]‰¿
“ú–{–òÜŠw‰ï‘æ31”N‰ïiŠò•ŒjAu‰‰—vŽ|WApp.139A2016”N5ŒŽ21“ú
16. –ì_—DŒŽA“à“cM–çA“nç²—´–îA“c’†Ž‡äŽqAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA¬”¦—R‰ÀŽqA“nç³—TŽiA•À–Ø“¿”VFS•s‘S‚Ì‹}«‘ˆ«‚𗈂µ‚½”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚éƒtƒƒZƒ~ƒh‚ÌŒŒŸ÷’†”Z“x‚Æ–ò•¨“®‘ÔŠw“Iƒpƒ‰ƒ[ƒ^‚Ì„’è
‘æ33‰ñ“ú–{TDMŠw‰ïEŠwp‘å‰ïi‰F“s‹{jAu‰‰—vŽ|WApp.160A2016”N5ŒŽ29“ú
17. “nç²—´–îA“à“cM–çA–ì_—DŒŽA“c’†Ž‡äŽqAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA¬”¦—R‰ÀŽqA“nç³—TŽiA•À–Ø“¿”VFS•s‘S‚Ì‹}«‘ˆ«‚𗈂µ‚½”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚éƒ^ƒ_ƒ‰ƒtƒBƒ‹ƒ^ƒ_ƒ‰ƒtƒBƒ‹‚¨‚æ‚уAƒ“ƒuƒŠƒZƒ“ƒ^ƒ“‚ÌŒŒŸ÷’†–ò•¨”Z“x‚̕ϓ®
‘æ33‰ñ“ú–{TDMŠw‰ïEŠwp‘å‰ïi‰F“s‹{jAu‰‰—vŽ|WApp.161A2016”N5ŒŽ29“ú
18. Yasuharu Kashiwagura, Shinya Uchida, Takuya Murao, Hidehito Takano, Noriyuki NamikiF Cocoa-flavored orally disintegrating rebamipide tablets for patient benefit
ASHP 2016 Summer Meetings and Exhibition (Bartimore, USA)A2016”N6ŒŽ13“ú
19. Shinya Uchida, Sayuri Nakajima, Yoshiyuki Hayakawa, Noriyuki NamikiFAre
mini-tablets easy to take- - A clinical trial for evaluating the ease of
taking mini-tablets in healthy volunteers
ASHP 2016 Summer Meetings and Exhibition (Bartimore, USA)A2016”N6ŒŽ14“ú
20. ”‘qNŽ¡A“à“cM–çAŽÄ“chŠóA¼ˆä—ÇŠ²A•À–Ø“¿”VF‰@“à»Ü‚Æ‚µ‚Ä»‚µ‚½ƒhƒ“ƒyƒŠƒhƒ“Œo”ç‹zŽûŒ^»Ü‚̔畆“§‰ß«•]‰¿
‘æ32‰ñ“ú–{DDSŠw‰ïŠwpW‰ïiɪjAƒvƒƒOƒ‰ƒ€—\eWApp.208A2016”N6ŒŽ30“ú
21. “à“cM–çA‹´–{çqAŽR‰º‚Ђ©‚èA¼ˆä—ÇŠ²A”‘qNŽ¡A•À–Ø“¿”VFƒ\ƒŠƒtƒFƒiƒVƒ“Œo”ç‹zŽûŒ^»Ü‚Ì’²»‚ÆŒo”ç‹zŽû«•]‰¿
‘æ32‰ñ“ú–{DDSŠw‰ïŠwpW‰ïiɪjAƒvƒƒOƒ‰ƒ€—\eWApp.209A2016”N6ŒŽ30“ú
22. Shinya UchidaFEvaluation of the ease of taking mini-tablets compared with other tablet formulations in healthy volunteer
5th Annual European Pharma Congress (Berlin, Germany)A2016”N7ŒŽ19“ú
23. ŠOŽR^ˆßA“à“cM–çA“c’†Ž‡äŽqAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒNƒGƒ“Ž_‚É‚æ‚éƒIƒƒpƒ^ƒWƒ“Œûo“à•ö‰óù‚̋ꖡ—}§Œø‰Ê
‘æ135‰ñ“ú–{–ò—Šw‰ïŠÖ“Œ•”‰ïi•l¼jA2016”N10ŒŽ8“ú
24. “à“cM–çFH•iEƒTƒvƒŠƒƒ“ƒg‚ƈã–ò•i‚Ì‘ŠŒÝì—pFƒVƒ“ƒ|ƒWƒEƒ€19@–ò•¨‘ŠŒÝì—p‚Ì‰Û‘è‚Æ‰ñ”ð‚ÖŒü‚¯‚Ă̓W–]
‘æ135‰ñ“ú–{—Õ°–ò—Šw‰ïŠwpW‰ï‘‰ïi•ÄŽqjAu‰‰—vŽ|WApp.S157A2016”N12ŒŽ2“ú
25. “à“cM–çA–ì_—DŒŽA“nç²—´–îA“c’†Ž‡äŽqAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA¬”¦—R‰ÀŽqA“nç³—TŽiA•À–Ø“¿”VFS•s‘S‹}«‘ˆ«Šú‚Ì”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚錌Ÿ÷’†ƒtƒƒZƒ~ƒh”Z“x‚ð—p‚¢‚½–ò•¨“®‘ÔŠw“I‰ðÍ
‘æ135‰ñ“ú–{—Õ°–ò—Šw‰ïŠwpW‰ï‘‰ïi•ÄŽqjAu‰‰—vŽ|WApp.S253A2016”N12ŒŽ2“ú
26. ŒÑ“cW‰›A”‘qNŽ¡A‚–ìGmA‘º”ö‘ìÆA“à“cM–çA¬“cØŒ\ˆêAŠ£’¼‹PA•À–Ø“¿”VA“nç³—TŽiFƒŒƒoƒ~ƒsƒhŒûo“à•ö‰óù‚É‚¨‚¯‚éƒJƒJƒIƒpƒEƒ_[‚Ì–¡ƒ}ƒXƒLƒ“ƒOŒø‰Ê
‘æ135‰ñ“ú–{—Õ°–ò—Šw‰ïŠwpW‰ï‘‰ïi•ÄŽqjAu‰‰—vŽ|WApp.S294A2016”N12ŒŽ3“ú
[‚»‚Ì‘¼‚ÌŠ§s•¨]
1. ”‘qNŽ¡F‘æ40‰ñ»ÜE‘n܃Zƒ~ƒi[•ñ
–òÜŠw, 76, 58-59 i2016j
2. “à“cM–çF»Ü‹Zp¡Ì•¨Œê\ƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚ð–ÚŽw‚µ‚Ä\
ƒƒfƒBƒJƒ‹ƒrƒ…[ƒ|ƒCƒ“ƒgA2016”N2ŒŽ10“úA3ŒŽ10“úA5ŒŽ10“úA7ŒŽ10“úA8ŒŽ10“úA
9ŒŽ10“úA10ŒŽ10“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
1. Shin-ichiro@Kimura, Shinya Uchida, Ken Kanada, Noriyuki Namiki: Effect
of granule properties on rough mouth feel and palatability of orally disintegrating
tablets.
Int. J. Pharm., 484, 156-162 (2015)
2. Rakan Matsui, Shinya Uchida, Noriyuki Namiki: Combination effect of
physical and qustatory taste masking for propiverine hydrochloride orally
disintegrating tablets on palatability.
Biol. Pharm. Bull., 38, 17-22 (2015)
3. Yasuyuki Ikematsu, Shinya Uchida, Noriyuki Namiki: Preparation and evaluation of orally disintegrating tablets containing vitamin E as a model fat-soluble drug.
Chem. Pharm. Bull., 63, 156-163 (2015)
4. Shinya Uchida, Shogo Hiraoka, Noriyuki Namiki: Development of gummi
drugs of aripiprazole as hospital formulations.
Chem. Pharm. Bull., 63, 354-360 (2015)
5.Hideshi Nakamura, Shinya Uchida, Takeshi Sugiura, Noriyuki Namiki: The
prediction of palatability of orally disintegrating tablets by an electronic
gustatory system.
Int. J. Pharm., 484, 156-162 (2015)
6. Yasunori Iwao, Shin-ichiro@Kimura, Masayuki Ishida, Ryohei Mise, Masaki
Yamada, Noriyuki Namiki, Shuji Noguchi, Shigeru Itai: Preparation and evaluation
of highly drug-loaded fine globular granules using a multi-functional rotor
processor.
Chem. Pharm. Bull., 63, 95-101 (2015)
7.“à“cM–çA•À–Ø“¿”VFƒVƒƒhƒVƒ“Œûo“à•ö‰óùiƒ†ƒŠ[ƒtRODùj‚Ì—Õ°»ÜŠw“I•]‰¿
»Ü‹@ŠB‹ZpŠw‰ïŽ., 24, 483-491 (2015)
[‘à]
1. Noriyuki Namiki: Clinical functionality required for orally disintegrating
tablets selected as the next generation type.
Yakugaku Zasshi., 135, 237-243 (2015)
2. “c’†Ž‡äŽq: ‚P“H‚ÌŒŒ‚Å–ò•¨‘ãŽÓy‘fŠˆ«‚ð•]‰¿
ƒtƒ@ƒ‹ƒ}ƒVƒA, 51, pp.163 (2015)
[’˜‘]
1. “à“cM–çF‘æ3Í—Õ°–ò—ŠwAB. —Õ°–ò•¨“®‘ÔŠwAH.ˆ•û‚Æ’²Ü
•W€–ò—Šw@‘æ7”Åi¡ˆä³A‹{–{‰p޵ŠÄCA”і쳌õA—é–ØG“T•ÒWAˆãŠw‘‰@jA
pp.35-38, 56-59 (2015)
[ƒvƒƒV[ƒfƒBƒ“ƒO]
1. ŠOŽR^ˆßA“à“cM–çA•À–Ø“¿”VF“dŽq–¡ŠoƒVƒXƒeƒ€‚É‚æ‚éŒûo“à•ö‰óù‚Ì•ž—pŠ´‚Ì—\‘ª
PLCMik–òjŒ¤‹†‰ï@‘æ9‰ñƒVƒ“ƒ|ƒWƒEƒ€i–¼ŒÃ‰®jAu‰‰—vŽ|WApp.5-8 (2015)
2. Shinya UchidaFSimultaneous evaluation of the activity of five cytochrome
P450 enzymes by a cocktail study in healthy volunteers
Clin Pharmacol Biopharm, 4, pp.28 (2015)
3. Shinya UchidaFDevelopment of gummi drugs of aripiprazole
J Pharm Drug Deliv Res, 3, pp.60 (2015)
[Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€]
1. ŠOŽR^ˆßA“à“cM–çA•À–Ø“¿”VF“dŽq–¡ŠoƒVƒXƒeƒ€‚É‚æ‚éŒûo“à•ö‰óù‚Ì•ž—pŠ´‚Ì—\‘ª
PLCMik–òjŒ¤‹†‰ï@‘æ9‰ñƒVƒ“ƒ|ƒWƒEƒ€i–¼ŒÃ‰®jA2015”N1ŒŽ30“ú
2. ŠOŽR^ˆßA“c’†Ž‡äŽqA¬àV”ü‹IA¬ì°‰ÁA‡Œ´‰ÃŽõA“à“cM–çA•À–Ø“¿”VFƒAƒWƒXƒƒ}ƒCƒVƒ“×—±¬Ž™—p10“uƒg[ƒv‚ƈùH•¨‚Ƃ̔z‡‚É‚¨‚¯‚镞—pŠ´‚ÌŒŸ“¢
“ú–{–òŠw‰ï‘æ135”N‰ïi_ŒËjAu‰‰—vŽ|W4App.155A2015”N3ŒŽ26“ú
3. ŽR‰º‚Ђ©‚èA’r“c‘ñ–¢A¼ˆä—ÇŠ²A”‘qNŽ¡A“à“cM–çA“nç³—TŽiA•À–Ø“¿”VFƒhƒ“ƒyƒŠƒhƒ“Œo”ç‹zŽûŒ^»Ü‚ÌŠJ”‚ð–Ú“I‚Æ‚µ‚½Šî‘b“IŒŸ“¢
“ú–{–òŠw‰ï‘æ135”N‰ïi_ŒËjAu‰‰—vŽ|W4App.127A2015”N3ŒŽ26“ú
4. ¬àV”ü‹IA“à“cM–çA‘O“c’mA’†“ˆ¬•S‡A•½‰ªËŒáA•À–Ø“¿”VFƒAƒŠƒsƒvƒ‰ƒ][ƒ‹ŠÜ—LƒOƒ~»Ü‚ÌŠJ”‚ÉŠÖ‚·‚錤‹†i‘æ2•ñj
“ú–{–òŠw‰ï‘æ135”N‰ïi_ŒËjAu‰‰—vŽ|W4App.139A2015”N3ŒŽ26“ú
5. ‘º”ö‘ìÆA“à“cM–çA‘O“c’mAŒÑ“cW‰›AŠ£@’¼‹PA¬“cØŒ\ˆêA“nç³—TŽiA•À–Ø“¿”VFƒŒƒoƒ~ƒsƒhEƒ`ƒ‡ƒRƒŒƒbƒg‚ÌŠJ”
“ú–{–òŠw‰ï‘æ135”N‰ïi_ŒËjAu‰‰—vŽ|W4App.105A2015”N3ŒŽ26“ú
6. “c’†Ž‡äŽqA¬àV”ü‹IA¬ì°‰ÁAŠOŽR^ˆßA‡Œ´‰ÃŽõA“à“cM–çA•À–Ø“¿”VFƒJƒ‹ƒ{ƒVƒXƒeƒCƒ“DS50%uƒg[ƒv‚ƈùH•¨‚Ƃ̔z‡‚É‚¨‚¯‚镞—pŠ´‚ÌŒŸ“¢
“ú–{–òŠw‰ï‘æ135”N‰ïi_ŒËjAu‰‰—vŽ|W4App.155A2015”N3ŒŽ26“ú
7. ŽÄ“chŠóA”‘qNŽ¡AŽR‰º‚Ђ©‚èAˆî–ع–îA¼ˆä—ÇŠ²A“à“cM–çA“nç³—SŽiA•À–Ø“¿”VF‰@“à»Üƒhƒ“ƒyƒŠƒhƒ““îp‚¨‚æ‚уNƒŠ[ƒ€‚É‚¨‚¯‚é”畆“§‰ß«‚ÌŒŸ“¢
“ú–{–òÜŠw‰ï‘æ30”N‰ïi’·èjAu‰‰—vŽ|WApp.64A2015”N5ŒŽ21“ú
8. ¬ì°‰ÁA“à“cM–çA—é–ØqA–Ø‘ºWˆê˜YA•À–Ø“¿”VFŒûo“à•ö‰óù‚̃Uƒ‰ƒcƒLŠ´‚É‹y‚Ú‚·ŠÜ—Lè÷—±‚Ì—±ŽqŒa‚̉e‹¿
“ú–{–òÜŠw‰ï‘æ30”N‰ïi’·èjAu‰‰—vŽ|WApp.39A2015”N5ŒŽ21“ú
9. ’†“ˆ¬•S‡A“à“cM–çA‘O“c’mAŽÅØŽá“ÞA•½‰ªËŒáA•À–Ø“¿”VFƒAƒŠƒsƒvƒ‰ƒ][ƒ‹ŠÜ—LƒOƒ~»Ü‚ÌŠJ”‚ÉŠÖ‚·‚錤‹†i‘æ3•ñj
“ú–{–òÜŠw‰ï‘æ30”N‰ïi’·èjAu‰‰—vŽ|WApp.64A2015”N5ŒŽ21“ú
10. •À–Ø“¿”VFгŽÒƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚Ì–O‚–³‚«’Ç‹iƒ‰ƒEƒ“ƒhƒe[ƒuƒ‹4j@
“ú–{–òÜŠw‰ï‘æ30”N‰ïiƒI[ƒKƒiƒCƒU[A’·èjA2015”N5ŒŽ22“ú
11. Haruka Ogawa, Shinya Uchida, Hideshi Nakamura, Shimako Tanaka, Noriyuki
NamikiFCombining powder formulations of drugs with food and beverages to
improve palatability
ASHP 2015 Summer Meetings and Exhibition (Denver, USA)A2015”N6ŒŽ9“ú
12. Miki Ozawa, Shinya Uchida, Hiromitsu Imai, Kyoichi Ohashi, Noriyuki
NamikiFRelationship between plasma concentration and salivary flow rate
after single-dose oral administration of propiverine in healthy volunteers
ASHP 2015 Summer Meetings and Exhibition (Denver, USA)A2015”N6ŒŽ9“ú
13. Sayuri Nakajima, Shinya Uchida, Tomoka Maeda, Shogo Hiraoka, Noriyuki
NamikiFCompounding of aripiprazole as a gummy drug using commercially available
products
ASHP 2015 Summer Meetings and Exhibition (Denver, USA)A2015”N6ŒŽ9“ú
14. Shinya UchidaFDevelopment of gummi drugs of aripiprazole
World Drug Delivery Summit (Houston, USA)A2015”N8ŒŽ17“ú
15. •À–Ø“¿”VF‘n܂̖²•‘‘äEƒnƒCƒuƒŠƒbƒh‰»‚·‚éˆã—ÂɌü‚¯‚ÄE–ò•i‚ðŽè‚ɂƂÁ‚Ä“ú Žv‚¤‚±‚Æ
“ú–{–òÜŠw‰ï‘æ40‰ñ»ÜƒZƒ~ƒi[iÀ’·A•ºŒÉjA2015”N8ŒŽ20“ú
16. Shinya Uchida, Rakan Matsui, Noriyuki NamikiFIn vitro and In vivo transdermal
absorption of oil-in-water type emulsified formulation of propiverine hydrochloride
Pharma+Bio Asia 2015iKuala LumpurAMalaysiajA2015”N9ŒŽ4“ú
Yasuharu Kashiwagura, Shinya Uchida, Hiroki Shibata, Shimako Tanaka, Hiroshi Watanabe, Tadanori Sasaki, Noriyuki NamikiFPharmacokinetics of Thyroxine after Administration of Levothyroxine Suppository in Thyroidectomized Rat
Pharma+Bio Asia 2015iKuala LumpurAMalaysiajA2015”N9ŒŽ4“ú
“à“cM–çF‰@“à»Ü‚̉Ȋw“Iª‹’‚ÉŠî‚ÂŽg—pŠm—§‚ð–ÚŽw‚µ‚½—Õ°»ÜŠwE—Õ°–òŠw“IŒŸ“¢
USƒtƒH[ƒ‰ƒ€2015iɪŒ§—§‘åŠwŠwpƒtƒH[ƒ‰ƒ€jiɪjAu‰‰—vŽ|WApp.20A2015”N9ŒŽ29“ú
”‘qNŽ¡FгŽÒƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚ð–Ú“I‚Æ‚µ‚½ƒvƒƒsƒxƒŠƒ“‰–Ž_‰–ODù‚È‚ç‚тɌo”ç‹zŽûŒ^»Ü‚ÌŠJ”
USƒtƒH[ƒ‰ƒ€2015iɪŒ§—§‘åŠwŠwpƒtƒH[ƒ‰ƒ€jiɪjAu‰‰—vŽ|WApp.55A2015”N9ŒŽ29“ú
“c’†Ž‡äŽqA“à“cM–çAŽÂŒ´”ü‹IA¬àV”ü‹IAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VF”x‚ŒŒˆ³ÇŽ¡—Öò‚ÌŒŒŸ÷’†”Z“x‘ª’è‚ÌŒŸ“¢
‘æ4‰ñ“ú–{”xzŠÂŠw‰ïE‘æ3‰ñ“ú–{”x‚ŒŒˆ³Šw‰ï@‡“¯ŠwpW‰ïi“Œ‹žjAu‰‰—vŽ|WA
2015”N10ŒŽ10“ú
Shinya Uchida, Shin-ichiro Kimura, Haruka Ogawa, Noriyuki NamikiFEffect of Granule Size on Rough Mouth Feel and Palatability of Orally Disintegrating Tablets
2015 AAPS Annural Meeting and ExpositioniOrlando, USAjA2015”N10ŒŽ26“ú
Mai Sotoyama, Shinya Uchida, Shimako Tanaka, Akio Hakamata, Keiichi Odagiri, Naoki Inui, Hiroshi Watanabe, Noriyuki NamikiFCitric Acid Suppresses the Bitter Taste of Olopatadine Hydrochloride Orally Disintegrating Tablets
2015 AAPS Annural Meeting and ExpositioniOrlando, USAjA2015”N10ŒŽ27“ú
Hikari Yamashita, Shinya Uchida, Yasuharu Kashiwagura, Hiroki Shibata, Rakan Matsui, Akio Hakamata, Hiroshi Watanabe, and Noriyuki NamikiFIn Vitro and In Vivo Evaluation of Transdermal Absorption of Domperidone in Cream Formulations
2015 AAPS Annural Meeting and ExpositioniOrlando, USAjA2015”N10ŒŽ28“ú
“à“cM–çFR‹Û‰»Šw—Ö@‚É‚¨‚¯‚éTDM‚ðÄl‚·‚é
“ú–{•a‰@–òÜŽt‰ï“ŒŠCƒuƒƒbƒNE“ú–{–òŠw‰ï“ŒŠCŽx•”@‡“¯Šwp‘å‰ï2015Au‰‰—vŽ|WA
pp.21A2015”N11ŒŽ1“ú
”‘qNŽ¡A”Ñ’Ë—YŽŸA¬’rÊŽqAX–{”ŽqA–{àV—t—¯”üA”Ñ’Ë‹vŽuAž¥‘¥–¾Fç—tŒ§–òÜŽt‰ï/•a‰@–òÜŽt‰ï‡“¯uåñ጖ò•¨Ž¡—ÃŒ¤C‰ïvŠˆ“®‚É‚¨‚¯‚é3”NŠÔ‚Ì•à‚Ý
‘æ25‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi‰¡•ljAu‰‰—vŽ|WApp.245A2015”N11ŒŽ22“ú
Shinya Uchida,FSimultaneous evaluation of the activity of five cytochrome P450 enzymes by a cocktail study in healthy volunteers
3rd International Summit on Clinical Pharmacy 2015iAtlanta, USAjA2015”N12ŒŽ7“ú
¬“cØŒ\ˆêAŒÑ“cW‰›A•ÐŽR’¼‹IA‹{ìKŽqAŠ£’¼‹PA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VA“nç³—TŽiFCYP1A2, CYP2C9, 2C19, 2D6‚¨‚æ‚Ñ3A‚̊–ò‚ÌŒŒ’†”Z“x‚Æ, –ò•¨‚É‚æ‚é—U“±E‘jŠQ‚̉e‹¿‚ÌŠÖ˜A«
‘æ36‰ñ“ú–{—Õ°–ò—Šw‰ïŠwpW‰ïi“Œ‹žjAu‰‰—vŽ|WApp.134A2015”N12ŒŽ9“ú
¬“cØŒ\ˆêAŒÑ“cW‰›A•ÐŽR’¼‹IA‹{ìKŽqAŠ£’¼‹PA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VA“nç³—TŽiFCYP1A2, CYP2C9, 2C19, 2D6‚¨‚æ‚Ñ3A‚̊–ò‚ÌŒŒ’†”Z“x‚Æ, –ò•¨‚É‚æ‚é—U“±E‘jŠQ‚̉e‹¿‚ÌŠÖ˜A«
‘æ36‰ñ“ú–{—Õ°–ò—Šw‰ïŠwpW‰ïi“Œ‹žjAu‰‰—vŽ|WApp.134A2015”N12ŒŽ9“ú
ŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA¬”¦—R‰ÀŽqA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VA“nç³—TŽiF”x‚ŒŒˆ³Ç‚É‹Nˆö‚·‚éS•s‘S‘ˆ«Ž–‚Ì•a‘Ԃ̕ω»‚ƃtƒƒZƒ~ƒhAƒ^ƒ_ƒ‰ƒtƒBƒ‹AƒAƒ“ƒuƒŠƒZƒ“ƒ^ƒ“‚ÌŒŒ’†”Z“x‚Ì„ˆÚ‚Ƃ̊֘A«
‘æ36‰ñ“ú–{—Õ°–ò—Šw‰ïŠwpW‰ïi“Œ‹žjAu‰‰—vŽ|WApp.137A2015”N12ŒŽ9“ú
“à“cM–çFŽ„‚͂ǂ±‚Å—Õ°–ò—Šw‚ðŠw‚ñ‚¾‚©
‘æ36‰ñ“ú–{—Õ°–ò—Šw‰ïŠwpW‰ïi“Œ‹žjAu‰‰—vŽ|WApp.55A2015”N12ŒŽ11“ú
“c’†Ž‡äŽqA•lç—ŽqAŠ£’¼‹PA“nç³—TŽiA“à“cM–çA•À–Ø“¿”VFƒJƒNƒeƒ‹ŽŽŒ±‚É‚¨‚¯‚éŠîŽ¿–ò•¨‚ÌŒŒŸ÷’†”Z“x‚ÆAUC‚Æ‚Ì‘ŠŠÖ«
‘æ36‰ñ“ú–{—Õ°–ò—Šw‰ïŠwpW‰ïi“Œ‹žjAu‰‰—vŽ|WApp.237A2015”N12ŒŽ11“ú
ŠOŽR^ˆßA“c’†Ž‡äŽqA“à“cM–çAŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒIƒƒpƒ^ƒWƒ“‰–Ž_‰–Œûo“à•ö‰óù‚É‚¨‚¯‚éƒNƒGƒ“Ž_‚̋ꖡ—}§Œø‰Ê
‘æ36‰ñ“ú–{—Õ°–ò—Šw‰ïŠwpW‰ïi“Œ‹žjAu‰‰—vŽ|WApp.263A2015”N12ŒŽ11“ú
‚»‚Ì‘¼‚ÌŠ§s•¨
“à“cM–çF»Ü‹Zp¡Ì•¨Œê\ƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚ð–ÚŽw‚µ‚Ä\
ƒƒfƒBƒJƒ‹ƒrƒ…[ƒ|ƒCƒ“ƒgA2015”N1ŒŽ10“úA2ŒŽ10“úA3ŒŽ10“úA4ŒŽ10“úA5ŒŽ10“úA
6ŒŽ10“úA7ŒŽ10“úA10ŒŽ10“úA11ŒŽ10“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
Hirokazu Wakuda, Shinya Uchida, Masahiko Ikeda, Masaki Tabuchi, Yasumitsu
Akahoshi, Kazumasa Shinozuka, Shizuo Yamada: Is hyperuricemia a risk factor
for arteriosclerosis- Uric Acid and arteriosclerosis in apolipoprotein
e-deficient mice.
Biol. Pharm. Bull., 37(12), 1866-1871 (2014)
Rakan Matsui, Shinya Uchida, Noriyuki Namiki: In Vitro and in Vivo Evaluation under Finite Conditions of a Transdermal Oil-in-Water Type Emulsified Formulation of Propiverine Hydrochloride.
Biol. Pharm. Bull., 37(10), 1661-1667 (2014)
Shogo Hiraoka, Shinya Uchida, Noriyuki Namiki: Preparation and characterization of high-content aripiprazole-loaded core-shell structure microsphere for long-release injectable formulation.
Chem. Pharm. Bull., 62(7), 654-60 (2014)
Rakan Matsui, Shinya Uchida, Noriyuki Namiki: Transdermal absorption of natural progesterone from alcoholic gel formulations with hydrophilic surfactant.
Drug. Dev. Ind. Pharm, 1, 1-4 (2014)
Shin-ichiro Kimura, Yasunori Iwao, Masayuki Ishida, Shuji Noguchi, Shigeru Itai, Shinya Uchida, Masaki Yamada, Noriyuki Namiki: Evaluation of the physicochemical properties of fine globular granules prepared by a multi-functional rotor processor.
Chem. Pharm. Bull., 62(4):309-315 (2014)
Yasuharu Kashiwagura, Shinya Uchida, Shimako Tanaka, Hiroshi Watanabe, Masahiro Masuzawa, Tadanori Sasaki, Noriyuki Namik: Clinical efficacy and pharmacokinetics of levothyroxine suppository in patients with hypothyroidism.
Biol. Pharm. Bull., 37(4), 666-670 (2014)
Shinya Uchida, Shimako Tanaka, Noriyuki Namiki: Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
Biopharm. Drug Dispos., 35(4), 228-236 (2014)
Shimako Tanaka, Shinya Uchida, Naoki Inui, Kazuhiko Takeuchi, Hiroshi Watanabe, Noriyuki Namiki: Simultaneous LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 substrate drugs and their metabolites.
Biol. Pharm. Bull., 37(1), 18-25 (2014)
‘à
•À–Ø“¿”VFƒƒ“ƒOƒZƒ‰[–ò—ñ“`-””„Œã25”N‚ªŒo‰ßA¡‚ài‰»‚µ‘±‚¯‚éRŒŒ¬”–ò
“úŒoƒƒfƒBƒJƒ‹”N––”NŽn“Á•Ê”ÅA62-63 (2014)
”‘qNŽ¡A²X–Ø’‰“¿F(4)•¡”‚̿܂ðŽg—p‚·‚éۂ̇˜‚ÆŠÔŠu
–ò‹Ç, 65, 2415-2419 (2014)
ƒvƒƒV[ƒfƒBƒ“ƒO
“c’†Ž‡äŽqA“à“cM–çAŠ£ ’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒJƒNƒeƒ‹ŽŽŒ±‚ð—p‚¢‚½–ò•¨‘ŠŒÝì—p‚Ì–Ô—…“I‰ðÍ–@‚ÌŠm—§‚Ɖž—p
PROGRESS IN DRUG DELIVERY SYSTEM, XXIII, 21-26 (2014)
Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€
Shinya Uchida, Shimako Tanaka, Sachiko Miyakawa, Naoki Inui, Kazuhiko Takeuchi, Hiroshi Watanabe, Noriyuki NamikiFComparison of inhibitory duration of grapefruit juice on organic anion-transporting polypeptide and CYP3A4
ASCPT 2014 Annual meeting (Atlanta, USA)A2014”N3ŒŽ18“ú
•À–Ø“¿”VF’m‚Á‚Ä“¾‚·‚é”][ÇŽ¡—Â̓¤’mޝ
“ú–{–òŠw‰ï‘æ134”N‰ïiŒF–{jAu‰‰—vŽ|W1App.300A2014”N3ŒŽ29“ú
‡Œ´‰ÃŽõA“à“cM–çA¬ì°‰ÁA’|‰ºˆ¤”üA“c’†Ž‡äŽqA•À–Ø“¿”VFƒtƒFƒLƒ\ƒtƒFƒiƒWƒ“‰–Ž_‰–DS6%uƒg[ƒv‚ƈùH•¨‚Ƃ̔z‡‚É‚¨‚¯‚镞—pŠ´‚ÌŒŸ“¢
“ú–{–òŠw‰ï‘æ134”N‰ïiŒF–{jAu‰‰—vŽ|W4App.142A2014”N3ŒŽ30“ú
ù–ì’mŠCA“c’†Ž‡äŽqA‹{ìKŽqA÷“c‚Ȃ‚«AŒÑ“cW‰›A¬“cØŒ\ˆêAŠ£’¼‹PA“à“cM–çA•À–Ø“¿”VA“nç³—TŽiFƒJƒNƒeƒ‹ŽŽŒ±‚É‚æ‚é5Ží‚̃`ƒgƒNƒ[ƒ€P450Šˆ«‚Ì“¯Žž•]‰¿
“ú–{–òŠw‰ï‘æ134”N‰ïiŒF–{jAu‰‰—vŽ|W4App.128A2014”N3ŒŽ30“ú
‘º”ö‘ìÆA“à“cM–çAŽR‰º‚Ђ©‚èA”ª–Ør•ãA•À–Ø“¿”VFƒsƒ^ƒoƒXƒ^ƒ`ƒ“Œûo“à•ö‰óùiƒŠƒoƒ(R)ODùj‚Ì—Õ°»ÜŠw“I“Á«‚Æ•ž—p«‚ÌŒŸ“¢
“ú–{–òŠw‰ï‘æ134”N‰ïiŒF–{jAu‰‰—vŽ|W4App.142A2014”N3ŒŽ30“ú
Shimako Tanaka, Shinya Uchida, Naoki Inui, Kazuhiko Takeuchi, Hiroshi Watanabe, Noriyuki NamikiFSimultaneous LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 substrate drugs and their metabolites
5th FIP Pharmaceutical Sciences World Congress 2014 (Melbourne, Australia)A2014”N4ŒŽ16“ú
Shinya Uchida, Shimako Tanaka, Noriyuki NamikiFSimultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats
5th FIP Pharmaceutical Sciences World Congress 2014 (Melbourne, Australia)A2014”N4ŒŽ16“ú
‡Œ´‰ÃŽõA“à“cM–çA’†‘º‹”VA•À–Ø“¿”VF“dŽq–¡ŠoƒVƒXƒeƒ€‚É‚æ‚éŒûo•ö‰óù‚Ì•ž—pŠ´‚Ì—\‘ª
“ú–{–òÜŠw‰ï‘æ29”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.106A2014”N5ŒŽ20“ú
“c’†Ž‡äŽqA”Ñ‘º’q–çAŽÄ“chŠóA”‘qNŽ¡A“à“cM–çA“nç³—TŽiA²X–Ø’‰“¿A•À–Ø“¿”VFbó‘B“Eoƒ‰ƒbƒg‚É‚¨‚¯‚郌ƒ{ƒ`ƒƒLƒVƒ“¿Ü‚Ì‘Ì“à“®‘Ô
“ú–{–òÜŠw‰ï‘æ29”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.128A2014”N5ŒŽ20“ú
”‘qNŽ¡A“à“cM–çA“c’†Ž‡äŽqA‰iˆä~ŽqA–‘àVLA²X–Ø’‰“¿A•À–Ø“¿”VF‰@“à»ÜƒŒƒ{ƒ`ƒƒLƒVƒ“¿Ü‚Ì—Õ°Œø‰Ê‚ÌŒŸ“¢
“ú–{–òÜŠw‰ï‘æ29”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.129A2014”N5ŒŽ20“ú
‘º”ö‘ìÆA“à“cM–çA—é–ØqA—é–Ø—TA•À–Ø“¿”VF•¨—“I‹y‚ÑŠ¯”\“Iƒ}ƒXƒLƒ“ƒO‚É‚æ‚éƒvƒƒsƒxƒŠƒ“ODù‚Ì•ž—p«•]‰¿
“ú–{–òÜŠw‰ï‘æ29”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.198A2014”N5ŒŽ20“ú
—é–ØqA“à“cM–çA‘º”ö‘ìÆA—é–Ø—TA•À–Ø“¿”VFƒvƒƒsƒxƒŠƒ“ODù‚Ì–¡ƒ}ƒXƒLƒ“ƒO»Ü‚ÌŠJ”
“ú–{–òÜŠw‰ï‘æ29”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.199A2014”N5ŒŽ20“ú
‘O“c’mA“à“cM–çAù–ì’mŠCA¬àV”ü‹IA•½‰ªËŒáA•À–Ø“¿”VFƒAƒŠƒsƒvƒ‰ƒ][ƒ‹ŠÜ—LƒOƒ~»Ü‚ÌŠJ”
“ú–{–òÜŠw‰ï‘æ29”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.200A2014”N5ŒŽ20“ú
’r“c‘ñ–¢AŽR‰º‚Ђ©‚èA•½“c^–çA“à“cM–çA•À–Ø“¿”VFƒvƒƒsƒxƒŠƒ“Œo”ç‹zŽû»Ü‚ÌŠJ”
“ú–{–òÜŠw‰ï‘æ29”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.205A2014”N5ŒŽ20“ú
ŽR‰º‚Ђ©‚èA’r“c‘ñ–¢A•½“c^–çA“à“cM–çA•À–Ø“¿”VFƒvƒƒsƒxƒŠƒ“Œo”ç‹zŽû»Ü‚É‚¨‚¯‚éin vivoŒo”ç‹zŽû«•]‰¿
“ú–{–òÜŠw‰ï‘æ29”N‰ïi‘å‹{jAu‰‰—vŽ|WApp.205A2014”N5ŒŽ20“ú
Takumi Ikeda, Yasuharu Kashiwagura, Shinya Uchida, Masahiro Masuzawa, Tadanori Sasaki, Noriyuki NamikiFClinical efficacy of a levothyroxine suppository in patients with hypothyroidism
ASHP 2014 Summer Meetings and Exhibition (Las Vegas, USA)A2014”N6ŒŽ3“ú
Shinya Uchida, Noriyuki NamikiFUsefulness of drug information website accessed by cell phone data connection via two-dimensional matrix barcode
ASHP 2014 Summer Meetings and Exhibition (Las Vegas, USA)A2014”N6ŒŽ3“ú
Yoshihisa Gohara, Shinya Uchida, Shimako Tanaka, Noriyuki NamikiFEffects on the palatability of the dry-syrup formulation of fexofenadine when taken in combination with food and beverages
ASHP 2014 Summer Meetings and Exhibition (Las Vegas, USA)A2014”N6ŒŽ3“ú
ù–ì’mŠCA“à“cM–çA•À–Ø“¿”VFƒŒƒxƒ`ƒ‰ƒZƒ^ƒ€V‹Kƒhƒ‰ƒCƒVƒƒbƒv܂̒²Ü‚É‚¨‚¯‚镪•ïŒë·
ˆã—ÖòŠwƒtƒH[ƒ‰ƒ€2014 ‘æ22‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€i“Œ‹žjAu‰‰—vŽ|WApp. 193A2014”N6ŒŽ28“ú
“c’†Ž‡äŽqA“à“cM–çAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒJƒNƒeƒ‹ŽŽŒ±‚ð—p‚¢‚½–ò•¨‘ŠŒÝì—p‚Ì–Ô—…“I‰ðÍ–@‚ÌŠm—§‚Ɖž—p
‘æ23‰ñ DDSƒJƒ“ƒtƒ@ƒ‰ƒ“ƒX 2014iɪjAu‰‰—vŽ|WApp. 8-9A2014”N9ŒŽ5“ú
“à“cM–çFƒJƒNƒeƒ‹ŽŽŒ±‚É‚æ‚é5Ží‚̃`ƒgƒNƒ[ƒ€P450Šˆ«‚Ì“¯Žž•]‰¿
USƒtƒH[ƒ‰ƒ€ 2014iɪŒ§—§‘åŠwŠwpƒtƒH[ƒ‰ƒ€jiɪjAu‰‰—vŽ|WApp. 23A2014”N9ŒŽ25“ú
•À–Ø“¿”VF•ž–òƒAƒhƒqƒAƒ‰ƒ“ƒX‚𑣂·Œûo“à•ö‰óù‚Ì—Õ°“I‹@”\«
‘æ24‰ñ“ú–{ˆã—ÖòŠw‰ïƒVƒ“ƒ|ƒWƒEƒ€iƒVƒ“ƒ|ƒWƒXƒgAƒI[ƒKƒiƒCƒU[A–¼ŒÃ‰®jA2014”N9ŒŽ28“ú
Takuya Murao, Rakan Matsui, Shinya Uchida, Noriyuki NamikiFCombination effect of physical and gustatory masking for propiverine hydrochloride orally disintegrating tablets on their palatability
2014 AAPS Annural Meeting and ExpositioniSan Diego, USAjA2014”N11ŒŽ4“ú
Rakan Matsui, Shinya Uchida, Noriyuki NamikiFIn Vitro and In Vivo under Finite Conditions of a Transdermal Oil-in-Water Type Emulsified Formulation of Propiverine Hydrochloride
2014 AAPS Annural Meeting and ExpositioniSan Diego, USAjA2014”N11ŒŽ3“ú
Shinya Uchida,FReduction in the volume of water for ingesting and the clinical disintegration time of orally disintegrating tablets of solifenacin (Vesicare(R) OD)
2nd International Summit on Clinical Pharmacy 2014iSan FranciscoAUSAjA2014”N12ŒŽ2“ú
“à“cM–çAŠ£’¼‹PA“c’†Ž‡äŽqA¬“cØŒ\ˆêAŒÑ“cW‰›A“nç³—TŽiA•À–Ø“¿”VFLC-MS/MS‚ð—p‚¢‚½ƒJƒNƒeƒ‹ŽŽŒ±‚É‚æ‚é–ò•¨‘ŠŒÝì—p‚Ì“¯Žž‰ðÍ
‘æ35‰ñ“ú–{–ò—Šw‰ïŠwp‘‰ïiˆ¤•QjAu‰‰—vŽ|WApp.S179A2014”N12ŒŽ5“ú
Š£’¼‹PA“à“cM–çA“nç³—TŽiFƒVƒgƒNƒƒ€P450y‘f—U“±‚ÌŒoŽž“I•ω»
‘æ35‰ñ“ú–{–ò—Šw‰ïŠwp‘‰ïiˆ¤•QjAu‰‰—vŽ|WApp.S183A2014”N12ŒŽ5“ú
”‘qNŽ¡F‰@“à»ÜƒŒƒ{ƒ`ƒƒLƒVƒ“¿Ü‚Ì’²»‚Æ—Õ°•]‰¿
‘æ3‰ñ‘n܃Jƒ“ƒtƒ@ƒŒƒ“ƒXɪiɪjAu‰‰—vŽ|WApp.24-25A2014”N12ŒŽ12“ú
‚»‚Ì‘¼‚ÌŠ§s•¨
“à“cM–çF»Ü‹Zp¡Ì•¨Œê\ƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚ð–ÚŽw‚µ‚Ä\
ƒƒfƒBƒJƒ‹ƒrƒ…[ƒ|ƒCƒ“ƒgA2014”N1ŒŽ10“úA2ŒŽ10“úA3ŒŽ10“úA4ŒŽ10“úA5ŒŽ10“úA6ŒŽ10“ú
7ŒŽ10“úA8ŒŽ10“úA9ŒŽ10“úA10ŒŽ10“úA11ŒŽ10“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
Yoshinori Nakano, Arisa Maeda, Shinya Uchida, Noriyuki Namiki: Preparation and evaluation of unpleasant taste-masked pioglitazone orally disintegrating tablets.
Int. J. Pharm., 446, 160-165 (2013)
Shinya Uchida, Tomohiro Yoshita, Noriyuki Namiki: Reduction in the volume of water for ingesting orally disintegrating tablets of solifenacin (VesicareR OD), and the clinical disintegration time of VesicareR OD after unit-dose packaging.
Int. J. Pharm., 446, 1-5 (2013)
Kazutoshi Ban, Ritsu Sonohara, Mitsunobu Yoshida, Kazuhiro Sako, Sinya Uchida, Noriyuki Namiki.: Pharmaceutical development of a parenteral formulation of conivaptan hydrochloride.
PDA J. Pharm. Sci. Technol., 67, 336-353 (2013)
•À–Ø“¿”V: V‹KƒvƒŒƒ^[ƒ‹ODùiHybr IDTABj‚Ì—Õ°Žg—p‚É‚¨‚¯‚é—L—p«
PHARM TECH JAPAN, 29, 1971-1975 (2013)
Naoki Inui, Taisuke Akamatsu, Shinya Uchida, Shimako Tanaka, Noriyuki Namiki, Masato Karayama, Kingo Chida, Hiroshi Watanabe: Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.
Clin. Pharmacol. Ther., 94, 702-708 (2013)
Tomohiro Yoshita, Shinya Uchida, Noriyuki Namiki: Clinical disintegration time of orally disintegrating tablets clinically available in Japan in healthy volunteers.
Biol. Pharm. Bull., 36, 1488-1493 (2013)
“à“cM–çA“c’†Ž‡äŽqA•À–Ø“¿”V:ƒtƒFƒLƒ\ƒtƒFƒiƒWƒ“‰–Ž_‰–DS6“uƒg[ƒv‚ƈùH•¨‚Ƃ̔z‡‚É‚¨‚¯‚镞—pŠ´‚ÌŒŸ“¢
ƒAƒŒƒ‹ƒM[‚Ì—Õ°, 33, 71-75 (2013)
“à“cM–çA•À–Ø“¿”V: ƒsƒ^ƒoƒXƒ^ƒ`ƒ“Œûo“à•ö‰óùiƒŠƒoƒODùj‚Ì—Õ°»ÜŠw“I“Á«‚Æ•ž—p«‚ÌŒŸ“¢
f—ÂÆV–ò, 50, 1087-1094 (2013)
Shimako Tanaka, Shinya Uchida, Sachiko Miyakawa, Naoki Inui, Kazuhiko Takeuchi, Hiroshi Watanabe, Noriyuki Namiki: Comparison of inhibitory duration of grapefruit juice on organic anion-transporting polypeptide and cytochrome P450 3A4.
Biol. Pharm. Bull., 36, 1936-1941 (2013)
Sachiko Miyakawa, Keiichi Odagiri, Naoki Inui, Akio Hakamata, Takahiro Goto, Shimako Tanaka, Shinya Uchida, Noriyuki Namiki, Hiroshi Watanabe: Short-term drug-drug interaction between sildenafil and bosentan under long-term use in patients with pulmonary arterial hypertension.
Pharmacology & Pharmacy, 4, 542-548 (2013)
“à“cM–çC“nç³—TŽiC•À–Ø“¿”VF–ò•¨‘ŠŒÝì—p‚ÌŒŸo‚ð–Ú“I‚Æ‚µ‚½ƒ‰ƒbƒg‚¨‚æ‚уqƒg‚ð‘ÎÛ‚Æ‚µ‚½ƒJƒNƒeƒ‹ŽŽŒ±\‘ãŽÓy‘f‚¨‚æ‚уgƒ‰ƒ“ƒXƒ|[ƒ^[‚ð‰î‚·‚é–ò•¨‘ŠŒÝì—p‚̉ðÍ\
—Õ°–ò—‚Ìi•àA17-25 (2013)
‘à
•À–Ø“¿”VFh—Õ°“I‹@”\«h‚ð–ž‚½‚µ‚½Œûo“à•ö‰óiODjù‚̃ƒŠƒbƒg
“úŒoƒhƒ‰ƒbƒOƒCƒ“ƒtƒHƒ[ƒVƒ‡ƒ“A32-33 (2013)
•À–Ø“¿”VF”z‡Ü‚Ì—Õ°“I‹@”\«
–òŽ–A55, 1101-1108 (2013)
•À–Ø“¿”VF•ž–òƒAƒhƒqƒAƒ‰ƒ“ƒX‚ð‚‚߂邽‚߂ɂ͖ò܂̈ù‚݂₷‚³‚ÌŽ‹“_‚à•K—v
“úŒoƒhƒ‰ƒbƒOƒCƒ“ƒtƒHƒ[ƒVƒ‡ƒ“ExpressA1-4 (2013)
Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€
’|’†—»ˆêAê –ì³A“à“cM–çA•À–Ø“¿”VFŒûo“à•ö‰óù‰»‚É‚æ‚éˆù…•K—v—ʂ̌¸
PLCMŒ¤‹†‰ï‘æ7‰ñƒVƒ“ƒ|ƒWƒEƒ€¢Œûo“à•ö‰óù“™‚ÌŒ»ó‚Æ“W–]£i–¼ŒÃ‰®jA2013”N1ŒŽ31“ú
’|‰ºˆ¤”üA’rã“Þ•äA¬“‡´Ž÷A“à“cM–çA•À–Ø“¿”VFVisual@analog@scale‚ð—p‚¢‚½Œûo“à•ö‰óù‚Ì•ž—p«•]‰¿–@‚ÌŒŸ“¢
“ú–{–òŠw‰ï‘æ133”N‰ïi‰¡•ljA2013”N3ŒŽ28“ú
”ª–Ør•ãAŽR“cŒ’“ñ˜YA‹g“c—FGA“à“cM–çA•À–Ø“¿”VFŒûo“à•ö‰óù‚ÌùÜ•¨«‚É‹y‚Ú‚·‘SŽ©“®•ª•ï‹@‚É‚æ‚镪•ï‚ÆPTPƒV[ƒg‚©‚ç‚̉Ÿ‚µo‚µ‚̉e‹¿
“ú–{–òŠw‰ï‘æ133”N‰ïi‰¡•ljA2013”N3ŒŽ29“ú
‘å‰Yç’ßA“à“cM–çA[ˆäKŒbA‘º”ö‘ìÆA“c’†Ž‡äŽqA‰Á“¡•q–¾AŽÂ“¹OA•À–Ø“¿”VF‰@“à»Üƒrƒ^ƒ~ƒ“K1ƒNƒŠ[ƒ€‚Ì’²»‚ƕۑ¶ˆÀ’è«‚Ì•]‰¿
“ú–{–òŠw‰ï‘æ133”N‰ïi‰¡•ljA2013”N3ŒŽ30“ú
÷“c‚Ȃ‚«A“c’†Ž‡äŽqAŽR‘º¹‹IAù–ì’mŠCA“à“cM–çA•À–Ø“¿”VFƒ‰ƒbƒgƒJƒNƒeƒ‹ŽŽŒ±‚É‚æ‚éƒ`ƒgƒNƒ[ƒ€P450‚ð‰î‚µ‚½–ò•¨‘ŠŒÝì—p‚ÌŒŸo
“ú–{–òÜŠw‰ï‘æ28”N‰ïi–¼ŒÃ‰®jAu‰‰—vŽ|WApp.357A2013”N5ŒŽ25“ú
‘º”ö‘ìÆA”ª–Ør•ãA“à“cM–çA•À–Ø“¿”VFƒVƒƒXƒ^ƒ][ƒ‹ODùiƒvƒŒƒ^[ƒ‹ODùjV‹K»Ü‚Ì—Õ°Žg—p‚É‚¨‚¯‚éùÜ•¨«
“ú–{–òÜŠw‰ï‘æ28”N‰ïi–¼ŒÃ‰®jAu‰‰—vŽ|WApp.238A2013”N5ŒŽ23“ú
’|‰ºˆ¤”üA’rã“Þ•äA¬“‡´Ž÷A“à“cM–çA•À–Ø“¿”VFVisual analog scale‚ð—p‚¢‚½Œûo“à•ö‰óù‚Ì•ž—p«•]‰¿–@‚ÌŒŸ“¢
“ú–{–òÜŠw‰ï‘æ28”N‰ïi–¼ŒÃ‰®jAu‰‰—vŽ|WApp.309A2013”N5ŒŽ25“ú
”ª–Ør•ãA‘º”ö‘ìÆAŽR“cŒ’“ñ˜YA’|’†—ɈêAê –ì³A“à“cM–çA•À–Ø“¿”VFˆù…•K—v—Ê‹y‚Ñ•ž—p«‚É‹y‚Ú‚·Œûo“à•ö‰óù‚ÌùÜŒa‚Æù”‚̉e‹¿
“ú–{–òÜŠw‰ï‘æ28”N‰ïi–¼ŒÃ‰®jAu‰‰—vŽ|WApp.238A2013”N5ŒŽ23“ú
•½“c^–çA’‡–ìŒc‘¥AŽž”C³˜aA—é–Ø—TA‘º”ö‘ìÆA“à“cM–çA•À–Ø“¿”VFLudiflash‚ð—p‚¢‚½ƒsƒIƒOƒŠƒ^ƒ]ƒ“Œûo“à•ö‰óù‚ÌŠJ”
“ú–{–òÜŠw‰ï‘æ28”N‰ïi–¼ŒÃ‰®jAu‰‰—vŽ|WApp.309A2013”N5ŒŽ23“ú
—é–Ø—TA’‡–ìŒc‘¥A’rã“Þ•äA•½“c^–çA‘º”ö‘ìÆA“à“cM–çA•À–Ø“¿”VFƒtƒŒ[ƒo[‚̬‡‚É‚æ‚éƒsƒIƒOƒŠƒ^ƒ]ƒ“Œûo“à•ö‰óù‚Ì–¡ƒ}ƒXƒLƒ“ƒO
“ú–{–òÜŠw‰ï‘æ28”N‰ïi–¼ŒÃ‰®jAu‰‰—vŽ|WApp.198A2013”N5ŒŽ23“ú
Shinya Hirata, Shunsuke Yagi, Takuya Murao, Shinya Uchida, Noriyuki NamikiFReduction in the volume of water required for ingesting orally disintegrating tablets
2013 ASHP Summer Meeting and Exhibition (Minneapolis, USA)A2013”N6ŒŽ2“ú
Shinya Uchida, Tomohiro Yoshita, Noriyuki NamikiFClinical disintegration time of orally disintegrating tablets clinically available in Japan in healthy volunteers
2013 ASHP Summer Meeting and Exhibition (Minneapolis, USA)A2013”N6ŒŽ2“ú
Shinya Uchida, Tomohiro Yoshita, Shunsuke Yagi, Shinya Hirata, Takuya Murao, Shimako Tanaka, Noriyuki NamikiFClinical disintegration time and volume of water required for orally disintegrating tablets in healthy volunteers
11th EACPT Congress 2013 (Geneva, Switzerlad)A2013”N8ŒŽ28“ú
Shimako Tanaka, Shinya Uchida, Sachiko Miyakawa, Naoki Inui, Kazuhiko Takeuchi, Hiroshi Watanabe, Noriyuki NamikiFComparison of Duration of inhibitory effect of grapefruit juice on organic anion-transporting polypeptide
11th EACPT Congress 2013 (Geneva, Switzerlad)A2013”N8ŒŽ30“ú
“à“cM–çA‹g“c—FGA•À–Ø“¿”VFƒ\ƒŠƒtƒFƒiƒVƒ“Œûo“à•ö‰óùiƒxƒVƒPƒAODj‚É‚¨‚¯‚éˆù…•K—v—ʂ̌¸‚ƈê•’²Ü‚̉e‹¿
‘æ20‰ñ“ú–{”r”A‹@”\Šw‰ïiɪjA´˜^WApp. 278A2013”N9ŒŽ19“ú
‡Œ´‰ÃŽõA’|‰ºˆ¤”üA’†‘º‹”VA™‰YŒ’A“à“cM–çA•À–Ø“¿”VF“dŽq–¡ŠoƒVƒXƒeƒ€‚É‚æ‚éƒtƒ@ƒ‚ƒ`ƒWƒ“Œûo“à•ö‰óù‚Ì•ž—pŠ´‚Ì—\‘ª
‘æ23‰ñ“ú–{ˆã—ÖòŠw‰ïiå‘äjAu‰‰—vŽ|WApp. 301A2013”N9ŒŽ21“ú
÷“c‚Ȃ‚«A“c’†Ž‡äŽqAù–ì’mŠCA“à“cM–çA•À–Ø“¿”VFƒ‰ƒbƒgƒJƒNƒeƒ‹ŽŽŒ±‚É‚¨‚¯‚é§“f–ò‚É‚æ‚é–ò•¨‘ŠŒÝì—p‚ÌŒŸ“¢
‘æ23‰ñ“ú–{ˆã—ÖòŠw‰ïiå‘äjAu‰‰—vŽ|WApp. 220A2013”N9ŒŽ21“ú
”Ñ‘º’q–çA”ª–Ør•ãA“à“cM–çA•À–Ø“¿”VFŒûo“à•ö‰óùŽŽŒ±ŠíƒgƒŠƒR[ƒvƒeƒXƒ^‚Ì•ö‰óŽžŠÔ‚É‹y‚Ú‚·ŽŽŒ±‰t‰·“x‚̉e‹¿
‘æ23‰ñ“ú–{ˆã—ÖòŠw‰ïiå‘äjAu‰‰—vŽ|WApp. 406A2013”N9ŒŽ22“ú
ˆÉ“¡–M•FAˆäã˜aKA’Ò‘åŽ÷A‰êì‹`”VAŽR“c_Aó‘qŒóŽqAˆäã’BGA–k‘ºCAâ–{’Bˆê˜YAŽÄŽR–F”VA›’JƒŽqA—é–Ø’‘ãA’†–ì^”ÄA•À–Ø“¿”VA¼ŽR‘ÏŽŠAX–{’B–çAŽR“c×YAŽR–{Ÿ‰›A¡ˆäN”VFɪŒ§—§‘åŠwE•a‰@E’nˆæ–ò‹Ç˜AŒg‚É‚æ‚é–ò•¨—Ö@Œ¤C‰ï‚ÌŒ»‹µ
‘æ23‰ñ“ú–{ˆã—ÖòŠw‰ïiå‘äjAu‰‰—vŽ|WApp. 367A2013”N9ŒŽ22“ú
Tsutomu Kotegawa, In-Jin Jang, Ichiro Ieiri, Shinya Uchida, Hiromitsu Imai, Seokuee Kim, Masato Fukae, Tetsuji Ohyama, Hajime Hamasaki, Kimiko Tsutsumi, Eiji Uchida, Kyoichi OhashiFEffects of the OATP2B1 C1457T polymorphism and apple juice on the pharmacokinetics of acebutolol in humans
‘æ34‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi“Œ‹žjA—Õ°–ò—, 44(Suppl), S253, 2013A2013”N12ŒŽ3“ú
“à“cM–çFŒûo“à•ö‰óù‚Ì—Õ°“I‹@”\«‚Ì•]‰¿
‘æ2‰ñ‘n܃Jƒ“ƒtƒ@ƒŒƒ“ƒXɪiɪjAu‰‰—vŽ|WAP12-13A2013”N12ŒŽ13“ú
‚»‚Ì‘¼‚ÌŠ§s•¨
“à“cM–çF»Ü‹Zp¡Ì•¨Œê\ƒAƒhƒqƒAƒ‰ƒ“ƒXŒüã‚ð–ÚŽw‚µ‚Ä\
ˆê‚ÌŠª@»Ü‚Æ‚ÍA“ñ‚ÌŠª@‚‚·‚è‚Æ»Ü‚Ì—ðŽj@\‚‚·‚è‚ðŽg‚¢‚â‚·‚‚·‚邽‚ß‚É\A
ŽO‚ÌŠª@»Ü‚Ì”’B„Ÿ20¢‹I‚©‚ç21¢‹I‚Ö„Ÿ
ƒƒfƒBƒJƒ‹ƒrƒ…[ƒ|ƒCƒ“ƒgA2013”N10ŒŽ10“úA11ŒŽ10“úA12ŒŽ10“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
Takeshi Sugiura, Shinya Uchida, Noriyuki Namiki:Taste-masking effect of physical and organoleptic methods on peppermint-scented orally disintegrating tablet of famotidine based on suspension spray-coating method.
Chem. Pharm. Bull., 60, 315-319 (2012)
Tsutomu Kotegawa, Kimiko Tsutsumi, Hajime Morita, Hiromistu Imai, Misaki Morita, Tsuneaki Yoshizato, Tesuji Ohyama, Shinya Uchida, Hiroshi Watanabe, Noriyuki Namiki, Kyoichi Ohashi: Effects of dosing interval on the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam in humans.
Eur. J. Clin.Pharmacol., 68, 1605-1610 (2012)
Chise Kodaira, Shinya Uchida, Mihoko Yamade, Masafumi Nishino, Mutsuhiro Ikuma, Noriyuki Namiki, Mitsushige Sugimoto, Hiroshi Watanabe, Akira Hishida, Takahisa Furuta: Influence of Different Proton Pump Inhibitors on Activity of Cytochrome P450 Assessed by [13C]-Aminopyrine Breath Test.
J. Clin. Pharmacol., 52, 432-439 (2012)
Naoki Inui, Tatsuhisa Kato, Shinya Uchida, Kingo Chida, Kazuhiko Takeuchi, Takahito Kimura, Hiroshi Watanabe: Novel Patch for Transdermal Administration of Morphine.
J. Pain Symptom Manag., 44, 479-485 (2012)
Toshihiro Yoshikawa, Hiroshi Yamada, Katsuhiko Matsuda, Hitoshi Niino, Yuko M. Sagesaka, Takami Kakuda, Kiichiro Toyoizumi, Keiji Matsumoto, Kazuhiro Kosuge, Shinya Uchida, Satomi Onoue, Shizuo Yamada, Keizo Umegaki: Effects of short-term consumption of a large amount of tea catechins on chromosomal damage, oxidative stress markers, serum lipid, folic acid, and total homocysteine levels: a randomized, double-blind, controlled study.
Jpn. J. Clin. Pharmacol., 43, 11-18 (2012)
•À–Ø“¿”VFƒAƒŒƒƒbƒNODù‚Ì—Õ°“IùÜ•¨«
PHARM TECH JAPAN, 28, 519-522 (2012)
•À–Ø“¿”VFƒAƒŒƒ‹ƒM[«Ž¾Š³Š³Ž™‚Ìe‚ð‘ÎÛ‚Æ‚µ‚½Œûo“à•ö‰óù‚ɑ΂·‚éˆÓޝ’²¸
Prog. Med., 32, 737-741 (2012)
‘à
•À–Ø“¿”VF“ÁWu‰@“à»Üv
–òÜŠw, 72, 2-8 (2012)
•À–Ø“¿”VFODù‚Í”][ÇŠ³ŽÒ‚³‚ñ‚̂悫ƒp[ƒgƒi[
Medical Tribune, pp. 1-3 (2012)
’˜‘
•À–Ø“¿”VFŒûo“à•ö‰óù‚Ì—Õ°•]‰¿AƒAƒJƒfƒ~ƒA‚É‚¨‚¯‚錤‹†“WŠJ‚»‚Ì3
‚·‚ׂĂª‚í‚©‚éŒûo“à•ö‰óùƒnƒ“ƒhƒuƒbƒNi‚¶‚Ù‚¤j, pp.50-56, 77-80 (2012)
•À–Ø“¿”VFƒWƒFƒlƒŠƒbƒNˆã–ò•i
V‚µ‚¢–òŠwŽ–“Ti’©‘q‘“Xj, pp.174-177 (2012)
•À–Ø“¿”VF¢—Õ°‚ª‹‚ß‚é»Ü‹ZpE—±ŽqÝŒv‚Ìi•à‚ÍŒûo“à•ö‰óù‚Ìi•à£
»Ü‹@ŠB‹ZpŠw‰ïŽiŒûo“à•ö‰ó»Ü“ÁW†ji»Ü‹@ŠB‹ZpŠw‰ïj, pp.6-12 (2012)
•À–Ø“¿”VF¢—Õ°“I‹@”\«‚ð‚‚ß‚é»Ü‹Zp£
ˆã–ò•i»ÜŠJ”‚Ì‚½‚߂̎Ÿ¢‘ã”÷—±ŽqƒR[ƒeƒBƒ“ƒO‹ZpiŒûo“à•ö‰ó»Ü“ÁW†j
iƒV[ƒGƒ€ƒV[o”Åj, pp.191-197 (2012)
“à“cM–çAŽR“c×YF‘æ12Í 4.ƒZƒ“ƒgƒWƒ‡[ƒ“ƒYƒ[ƒgA5.ƒCƒ`ƒ‡ƒE—tƒGƒLƒXA7.ƒGƒ]ƒEƒRƒM
ƒXƒgƒŒƒX‚ÌŠî–{—‰ð‚ÆRƒXƒgƒŒƒXH•i‚ÌŠJ”i‰¡‰z‰p•FŠÄAƒV[ƒGƒ€ƒV[o”Åj, pp.227-231,pp.232-237,pp.243-245 (2012)
•À–Ø“¿”VF‘˜_8@–ò•¨“Š—^ÝŒv‚ÆTDM
޾г‚©‚ç‚Ý‚½—Õ°–ò—Šw@‘æ3”Åi‘å‹´‹žˆêA“¡‘ºº•vA“nç³—TŽi•ÒA‚¶‚Ù‚¤j, pp.64-81 (2012)
ƒvƒƒV[ƒfƒBƒ“ƒO
“à“cM–çA“c’†Ž‡äŽqAŠ£’¼‹PA’|“à˜a•FA“nç³—TŽiA‘å‹´‹žˆêA•À–Ø“¿”VF–ò•¨‘ŠŒÝì—pŒŸo‚Ì‚½‚ß‚Ìin vivo‚ł̃‰ƒbƒg‚¨‚æ‚ÑŒ’íl‘ÎÛŽŽŒ±
Jpn. J. Clin. Pharmacol. Ther., 43, 263-264 (2012)
Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€
•À–Ø“¿”VFODù‚Í”][ÇŠ³ŽÒ‚³‚ñ‚̂悫ƒp[ƒgƒi[
²‰êŒ§ˆãŽt‰ïŠwpu‰‰‰ï”]‘²’†’nˆæ˜AŒgƒvƒƒWƒFƒNƒgSCRUMi²‰êjA2012”N1ŒŽ12“ú
•À–Ø“¿”VFODù‚͂悫ƒp[ƒgƒi[
PLCMŒ¤‹†‰ï‘æ6‰ñƒVƒ“ƒ|ƒWƒEƒ€¢Œûo“à•ö‰óù“™‚ÌŒ»ó‚Æ“W–]£i–¼ŒÃ‰®jA2012”N1ŒŽ30“ú
‰Á“¡ˆÀGA“¡’JŒ›ˆêA–k‘ºCA‰êì‹`”VF–ò܃AƒŒƒ‹ƒM[i•›ì—pjƒJ[ƒh‚ð—p‚¢‚½•›ì—p‰ð̓VƒXƒeƒ€Šm—§‚Ì‚½‚߂̗\”õ“I‰ðÍ
‘æ25‰ñɪŒ§•a‰@–òÜŽt‰ïŠwp‘å‰ïiɪjAu‰‰—vŽ|WApp. 25-26A2012”N2ŒŽ12“ú
¬›˜amA¡ˆäN”VAHŽR‹ÓŽOAó‘qŒòŽqAˆÉ“¡–M•FAˆäã’BGA‰êì‹`”VAâ–{’Bˆê˜YAŽÄŽR–F”VA›’JƒŽqA—é–Ø’‘ãA’†–ìáÁ”ÄA•À–Ø“¿”VA–ì–шê˜YA¼ŽR‘ÏŽŠAX–{’B–çAŽR“c×YAŽR“c_FɪŒ§—§‘åŠwE•a‰@E’nˆæ–ò‹Ç˜AŒg‚É‚æ‚é–ò•¨—Ö@Œ¤C‰ï‚ÌŒ»‹µ
“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yjAu‰‰—vŽ|W4Ap.353A2012”N3ŒŽ29“ú
•À–Ø“¿”VFODù‚Í”][ÇŠ³ŽÒ‚³‚ñ‚̂悫ƒp[ƒgƒi[Aƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yjAu‰‰—vŽ|W4App.292A2012”N3ŒŽ29“ú
‘ˆä’¼“oA“à“cM–çAŽO‰YŠî–õA’|‰ºˆ¤”üA[ˆäKŒbA“c’†Ž‡äŽqAˆäã’BGA•À–Ø“¿”VAŽR“c@_FƒJƒ‹ƒVƒEƒ€hR–òŽ¡—Ã’†‚Ì‚ŒŒˆ³Š³ŽÒ‚̉ƒ댌ˆ³‚É‹y‚Ú‚·ƒOƒŒ[ƒvƒtƒ‹[ƒcƒWƒ…[ƒX‚̉e‹¿
“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yjAu‰‰—vŽ|W4App.192A2012”N3ŒŽ30“ú
•À–Ø“¿”VFODù‚Í”][ÇŠ³ŽÒ‚³‚ñ‚̂悫ƒp[ƒgƒi[
“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yjAu‰‰—vŽ|W1App.192A2012”N3ŒŽ30“ú
•À–Ø“¿”VFŽŸ¢‘ãŒ^ŒoŒû»Ü‚É‹‚ß‚ç‚ê‚é—Õ°“I‹@”\«AƒVƒ“ƒ|ƒWƒEƒ€
“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yjAu‰‰—vŽ|W1App.261A2012”N3ŒŽ31“ú
“c’†Ž‡äŽqA“à“cM–çA[ˆäKŒbAŽO‰YŠî–õAŽR‘º¹‹IA“nç³—TŽiA•À–Ø“¿”VFƒ‰ƒbƒg‚É‚¨‚¯‚éƒOƒŒ[ƒvƒtƒ‹[ƒcƒWƒ…[ƒX‚É‚æ‚éOATP‘jŠQŽ‘±ŽžŠÔ‚ÌŒŸ“¢
“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yjAu‰‰—vŽ|W4App.222A2012”N3ŒŽ31“ú
’rã“Þ•äA™‰YŒ’A“à“cM–çA•À–Ø“¿”VFRACTAB ‹Zp‚ð—p‚¢‚½ƒAƒ€ƒƒWƒsƒ“ODù‚Ì–¡‚â‚É‚¨‚¢‚É‹y‚Ú‚·•¨—“I‹y‚ÑŠ¯”\“Iƒ}ƒXƒLƒ“ƒO‚ÌŒø‰Ê
“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yjAu‰‰—vŽ|W4App.314A2012”N3ŒŽ31“ú
’|’†—»ˆêAŽR“cŒ’“ñ˜YA“à“cM–çA•À–Ø“¿”VFƒIƒƒpƒ^ƒWƒ“ODùiƒAƒŒƒƒbƒNODùj‚Ì—Õ°Žg—p‚É‚¨‚¯‚éùÜ•¨«
“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yjAu‰‰—vŽ|W4App.314A2012”N3ŒŽ31“ú
ŽR“cŒ’“ñ˜YA’|’†—»ˆêA“à“cM–çA•À–Ø“¿”VFƒxƒVƒPƒA‚ÌODù‰»‚É‚æ‚éˆù…•K—v—ʂ̌¸
“ú–{–òŠw‰ï‘æ132”N‰ïiŽD–yjAu‰‰—vŽ|W4App.315A2012”N3ŒŽ31“ú
“c’†Ž‡äŽqA“à“cM–çA’|“à˜a•FA[ˆäKŒbA‹{ìKŽqAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒOƒŒ[ƒvƒtƒ‹[ƒcƒWƒ…[ƒX‚Ì–ò•¨ƒgƒ‰ƒ“ƒXƒ|[ƒ^[‘jŠQì—p‚ÌŽ‘±ŠúŠÔ
“ú–{–òÜŠw‰ï‘æ27”N‰ïi_ŒËjA—vŽ|WApp.112A2012”N5ŒŽ24“ú
’rã“Þ•äA’‡–ìŒc‘¥A’|‰ºˆ¤”üAŽž”C³˜aA’|’†—»ˆêA“à“cM–çA•À–Ø“¿”VFƒsƒIƒOƒŠƒ^ƒ]ƒ“Œûo“à•ö‰óù‚Ì–¡ƒ}ƒXƒLƒ“ƒO‚ð–Ú“I‚Æ‚µ‚½ƒtƒŒ[ƒo[‚Ì–Ô—…“IŒŸ“¢
“ú–{–òÜŠw‰ï‘æ27”N‰ïi_ŒËjA—vŽ|WApp.130A2012”N5ŒŽ24“ú
[ˆäKŒbA“c’†Ž‡äŽqAŽR‘º¹‹IA÷“c‚Ȃ‚«A“à“cM–çA•À–Ø“¿”VFƒ‰ƒbƒg‚É‚¨‚¯‚éƒ`ƒgƒNƒ[ƒ€P450Šˆ«•]‰¿‚Ì‚½‚߂̃JƒNƒeƒ‹ŽŽŒ±‚ÌŒŸ“¢
“ú–{–òÜŠw‰ï‘æ27”N‰ïi_ŒËjA—vŽ|WApp.212A2012”N5ŒŽ24“ú
ŽR‘º¹‹IA“c’†Ž‡äŽqA÷“c‚Ȃ‚«A[ˆäKŒbA“à“cM–çA•À–Ø“¿”VFƒ‰ƒbƒgƒJƒNƒeƒ‹ŽŽŒ±‚ð—p‚¢‚½ŠeŽíƒ`ƒgƒNƒ[ƒ€P450—U“±‹y‚Ñ‘jŠQ–ò‚̉e‹¿‚ÌŒŸo
“ú–{–òÜŠw‰ï‘æ27”N‰ïi_ŒËjA—vŽ|WAp.212A2012”N5ŒŽ24“ú
ŽR“cŒ’“ñ˜YA”ª–Ør•ãA‘ˆä’¼“oAŽR‘º¹‹IAŽž”C³˜aA“à“cM–çA•À–Ø“¿”VFƒqƒg‚É‚¨‚¯‚éŒûo“à•ö‰óù‚Ì•ö‰óŽžŠÔ‹y‚шù…•K—v—Ê‘ª’è–@‚ÌŒŸ“¢
“ú–{–òÜŠw‰ï‘æ27”N‰ïi_ŒËjA—vŽ|WApp.220A2012”N5ŒŽ24“ú
Žž”C³˜aA’‡–ìŒc‘¥A’rã“Þ•äA’|’†—»ˆêA“à“cM–çA•À–Ø“¿”VFLudiflash‚ð—p‚¢‚½ƒsƒIƒOƒŠƒ^ƒ]ƒ“Œûo“à•ö‰óù‚ÌŠJ”‚ƃtƒŒ[ƒo[‚É‚æ‚é–¡ƒ}ƒXƒLƒ“ƒOŒø‰Ê
“ú–{–òÜŠw‰ï‘æ27”N‰ïi_ŒËjA—vŽ|WAp.221A2012”N5ŒŽ24“ú
’‡–ìŒc‘¥A‘O“c‚ ‚肳A’rã“Þ•äA“à“cM–çA•À–Ø“¿”VFƒAƒNƒgƒX-ODù‚É‚¨‚¯‚é•s‰õ‚È–¡‚ɑ΂·‚éƒ}ƒXƒLƒ“ƒOŒø‰Ê
“ú–{–òÜŠw‰ï‘æ27”N‰ïi_ŒËjA—vŽ|WApp.221A2012”N5ŒŽ24“ú
ŽR‘º¹‹IA“à“cM–çA•À–Ø“¿”VF—Õ°‚ւ̉ž—p‚ð–ÚŽw‚µ‚½–ò•¨‘ŠŒÝì—p‚ÌŒŸ“¢
“ú–{–òÜŠw‰ï‘æ27”N‰ïi_ŒËjAŠw¶ŽåÃVƒ“ƒ|ƒWƒEƒ€ iSNPEE2012juŠî‘b–òÜŠw‚©‚çŽÀ‘H–òÜŠw‚ւ̃Aƒvƒ[ƒ`@- Ž•ž‚·‚ׂ«‰Û‘è‚͉½‚©‚ðl‚¦‚é-v—vŽ|WApp.87A2012”N5ŒŽ25“ú
•À–Ø“¿”VFƒAƒŒƒ‹ƒM[Ž¡—Âɂ¨‚¯‚éODù‚Ì—L—p«i—Õ°“I‹@”\«j
‘æ6‰ñ‚’m‚悳‚±‚¢”畆ƒAƒŒƒ‹ƒM[Œ¤‹†‰ïi‚’mjA2012”N6ŒŽ15“ú
•À–Ø“¿”VF»Ü‚ƈã–ò•iî•ñiƒVƒ“ƒ|ƒWƒEƒ€2Fˆã–ò•iî•ñ‚Ìì‚è•ûAŠˆ‚©‚µ•ûj
ˆã—ÖòŠwƒtƒH[ƒ‰ƒ€2012‘æ20‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€i•Ÿ‰ªjAu‰‰—vŽ|WApp.92A2012”N7ŒŽ14“ú
“c’†Ž‡äŽqA“à“cM–çA’|“à˜a•FA[ˆäKŒbA‹{ìKŽqAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒOƒŒ[ƒvƒtƒ‹[ƒcƒWƒ…[ƒX‚É‚æ‚é—L‹@ƒAƒjƒIƒ“ƒgƒ‰ƒ“ƒXƒ|[ƒ^[‘jŠQì—p‚ÌŽ‘±
ˆã—ÖòŠwƒtƒH[ƒ‰ƒ€2012‘æ20‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€i•Ÿ‰ªjAu‰‰—vŽ|WApp.65A2012”N7ŒŽ14“ú
‹{ìKŽqA“c’†Ž‡äŽqA“üàVаA“à“cM–çA’|“à˜a•FAŠ£’¼‹PA•À–Ø“¿”VA“nç³—TŽiF”x‚ŒŒˆ³Ç‚É‚¨‚¯‚éV‹K–ò܂ɂæ‚鑽ܕ¹—p—Ö@‚ÌŒø‰Ê‚¨‚æ‚Ñ–ò•¨‘ŠŒÝì—pFƒVƒ‹ƒfƒiƒtƒBƒ‹Aƒ{ƒZƒ“ƒ^ƒ“AƒAƒ“ƒuƒŠƒZƒ“ƒ^ƒ“‚ɂ‚¢‚Ă̌Ÿ“¢
PHƒTƒ~ƒbƒg2012i‰ªŽRjAu‰‰—vŽ|WApp.38A2012”N7ŒŽ29“ú
•À–Ø“¿”VFˆã–ò•i‚̈À‘S‚ÉŠÖ‚·‚éŠî‘b’mޝ
ɪŒ§ŠÅŒì‹¦‰ïEˆã—ÈÀ‘SŠÇ—ŽÒ—{¬Œ¤CiɪjA2012”N8ŒŽ1“ú
•À–Ø“¿”VFˆã—ÃŒ»ê‚É‚¨‚¯‚éODù‚Ìd—v«‚Ɖۑè
“ú–{–òÜŠw‰ï“`³uK‰ïi•l¼jA2012”N9ŒŽ21“ú
“à“cM–çA•À–Ø“¿”VAˆäã’BGAŽR“c_FƒOƒŒ[ƒvƒtƒ‹[ƒcƒWƒ…[ƒX‚É‚æ‚é—L‹@ƒAƒjƒIƒ“ƒgƒ‰ƒ“ƒXƒ|[ƒ^[‘jŠQì—p‚ÌŽ‘±
‘æ35‰ñ“ú–{‚ŒŒˆ³Šw‰ï‘‰ïi–¼ŒÃ‰®jAu‰‰—vŽ|WApp.511A2012”N9ŒŽ22“ú
•À–Ø“¿”VFŽŸ¢‘ãŒ^ŒoŒû»Ü‚É‹‚ß‚ç‚ê‚é—Õ°“I‹@”\«
‘æ45‰ñ“ú–{–òÜŽt‰ïŠwp‘å‰ïi•l¼jAu‰‰—vŽ|WApp. 87A2012”N10ŒŽ7“ú
Yoshinori Nakano, Naho Ikegami, Shinya Uchida, Noriyuki NamikiFEffects of flavors on taste sensation of pioglitazone orally disintegrating tablet
2012 AAPS Annual Meeting and Exposition (Chicago, USA)A2012”N10ŒŽ14“ú
Shinya Uchida, Seiki Kojima, Noriyuki NamikiFVisual analog scale-based evaluation of taste and scent of famotidine orally disintegrating tablets in healthy volunteers
2012 AAPS Annual Meeting and Exposition (Chicago, USA)A2012”N10ŒŽ14“ú
Takeshi Sugiura, Shinya Uchida, Naho Ikegami, Noriyuki NamikiFTaste Masking Analysis in Development of Orally Disintegrating Amlodipine Tablet using Human Gustatory Sensation Test and Taste Sensor Test
2012 AAPS Annual Meeting and Exposition (Chicago, USA)A2012”N10ŒŽ14“ú
•À–Ø“¿”VFODù‚Í”][ÇŠ³ŽÒ‚³‚ñ‚̂悫ƒp[ƒgƒi[
‘æ6‰ñ“ú–{–ò‹ÇŠw‰ïŠwp‘‰ïi•Ÿ‰ªjA2012”N10ŒŽ27“ú
“c’†Ž‡äŽqA“à“cM–çA‹{ìKŽqCŠ£’¼‹PC’|“à˜a•FC“nç³—TŽiC•À–Ø“¿”VF”x“®–¬«”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚ésildenafil, bosentan, tadalafil‹y‚Ñambrisentan‚ÌŒŒŸ÷’†”Z“x‚Ì“¯Žž’è—Ê–@‚ÌŒŸ“¢
‘æ22‰ñ“ú–{ˆã—ÖòŠw‰ïiVŠƒjAu‰‰—vŽ|WApp. 442A2012”N10ŒŽ28“ú
•À–Ø“¿”VFƒAƒŒƒ‹ƒM[Ž¡—Âɂ¨‚¯‚éODù‚Ì—L—p«i—Õ°“I‹@”\«j
“Œ–kƒAƒŒƒ‹ƒM[ƒtƒH[ƒ‰ƒ€A2012”N11ŒŽ3“ú
•À–Ø“¿”VF»Ü‹Zp‚ªø¬‚·‚é—Õ°“I‹@”\«
‘æ12‰ñ»Ü‹@ŠB‹ZpŒ¤‹†‰ïi‘åã•{—§‘åjA—vŽ|WAp.207A2011”N11ŒŽ11“ú
“c’†Ž‡äŽqA“à“cM–çA’|“à˜a•FA[ˆäKŒbA‹{ìKŽqAŠ£’¼‹PA“nç³—TŽiA•À–Ø“¿”VFƒOƒŒ[ƒvƒtƒ‹[ƒcƒWƒ…[ƒX‚Ì–ò•¨ƒgƒ‰ƒ“ƒXƒ|[ƒ^[‘jŠQì—p‚ÌŽ‘±ŠúŠÔ‚̉ð–¾
‘æ33‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi“ß”ejAu‰‰—vŽ|WAS.255A2012”N11ŒŽ29“ú
‹{ìKŽqA“c’†Ž‡äŽqA“üàVаA“à“cM–çA’|“à˜a•FAŠ£’¼‹PA•À–Ø“¿”VA“nç³—TŽiF”x“®–¬«‚ŒŒˆ³Ç‚É‚¨‚¯‚éV‹K–ò܂ɂæ‚鑽ܕ¹—p—Ö@‚ÌŒø‰Ê‚¨‚æ‚Ñ–ò•¨‘ŠŒÝì—pFƒVƒ‹ƒfƒiƒtƒBƒ‹Aƒ{ƒZƒ“ƒ^ƒ“AƒAƒ“ƒuƒŠƒZƒ“ƒ^ƒ“‚ɂ‚¢‚Ă̌Ÿ“¢
‘æ33‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ïi“ß”ejAu‰‰—vŽ|WAS.217A2012”N11ŒŽ29“ú
“à“cM–çFƒsƒIƒOƒŠƒ^ƒ]ƒ“‚Ì–¡ƒ}ƒXƒLƒ“ƒO‚ð–Ú“I‚Æ‚µ‚½ƒtƒŒ[ƒo[‚Ì–Ô—…“IŒŸ“¢
‘æ1‰ñ‘n܃Jƒ“ƒtƒ@ƒŒƒ“ƒXɪiɪjAu‰‰—vŽ|WAP20-21A2012”N12ŒŽ14“ú
‚»‚Ì‘¼‚ÌŠ§s•¨
‰Á“¡ˆÀGA‰êì‹`”VF–ò܃AƒŒƒ‹ƒM[i•›ì—pjƒJ[ƒh‚ð—p‚¢‚½•›ì—p‰ð̓VƒXƒeƒ€\’z‚Ì‚½‚߂̗\”õ“I‰ðÍ
ɪŒ§•a‰@–òÜŽt‰ï‰ï•ñA61App.62-63 (2012)
•y‰ªŒª“ñA“¡’JŒ›ˆêA‰Á“¡ˆÀGFƒAƒŒƒ‹ƒM[î•ñ‚ÌŠÇ—‚Æ’²Ü@–ò܃AƒŒƒ‹ƒM[i•›ì—pjƒJ[ƒh‚É‚æ‚éƒAƒŒƒ‹ƒM[î•ñŠÇ—
’²Ü‚Æî•ñA18App.677-680 (2012)
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
Tatsumi Kawai, Shinya Uchida, Noriyuki Namiki: Usefulness of Drug Information Website Accessed by Cell Phone Data Connection via Two-dimensional Matrix Barcode.
Jpn. J. Parm. Health Care Sci., 37, 241-251 (2011)
‰êì‹`”VA–ìŒû”ŽŽiA•À–Ø“¿”VA—ÑGŽ÷A¬›˜amF’nˆæˆã—ÂðŽx‚¦A–òÜŽt‚̈ӗ~‚ð‚‚߂郊ƒJƒŒƒ“ƒg‹³ˆç‚Æ‘åŠw‚Ì–ðŠ„
YAKUGAKU ZASSHI, 131, 41-44 (2011)
“à“cM–çA•À–Ø“¿”VFƒAƒ€ƒƒWƒsƒ“ODùuƒPƒ~ƒtƒ@v‚Ì—Õ°Žg—p‚É‚¨‚¯‚éùÜ•¨«
ˆãŠw‚Æ–òŠw, 65, 395-398 (2011)
Shingen Misaka, Reiko Nakamura, Shinya Uchida, Kazuhiko Takeuchi, Norio Takahashi, Naoki Inui, Kazuhiro Kosuge, Shizuo Yamada, Hiroshi Watanabe: Effect of 2 weeks' consumption of pomegranate juice on the pharmacokinetics of a single dose of midazolam: an open-label, randomized, single-center, 2-period crossover study in healthy Japanese volunteers.
Clin. Ther., 33, 246-252 (2011)
Kazuki Mimura, Ken Kanada, Shinya Uchida, Masaki Yamada, Noriyuki Namiki: Formulation Study for Orally Disintegrating Tablet.
Chem. Pharm. Bull., 59, 959-964 (2011)
Junya Hatanaka, Yukiko Shinme, Kazuki Kuriyama, Atsushi Uchida, Keitatsu Kou, Shinya Uchida, Shizuo Yamada, Satomi Onoue: In Vitro and In Vivo characterization of New Formulations of St. John's Wort Extract with Improved Pharmacokinetics and Anti-nociceptive Effect.
Drug. Metab. Pharmacokinet., 26:551-558 (2011)
‘à
•À–Ø“¿”VFODù‚Ì—Õ°Žsꫂɂ‚¢‚Ä
–òÜŠwA71A39-42 (2011)
•À–Ø“¿”VFˆã—ª‹‚߂鎟¢‘ãŒ^ƒ‰ƒCƒtƒTƒCƒNƒ‹ƒ}ƒlƒWƒƒ“ƒg»Ü
ƒtƒ@ƒ‹ƒ}ƒVƒAA47A37-41 (2011)
•À–Ø“¿”VFƒKƒXƒƒ“NEODù‚̃qƒ…[ƒ}ƒ“ƒtƒB[ƒ‹
PHARM TECH JAPAN, 27A1755-1758 (2011)
•À–Ø“¿”VFƒ{ƒmƒeƒIù 50 mg»Üê—pƒpƒbƒP[ƒWMVPiMonthly Viewable ProtectjBOX‚Ì—Õ°“I—L—p«
PHARM TECH JAPAN, 27A2029-2033 (2011)
’˜‘
•À–Ø“¿”VF3.2.3@‘ã•\“I‚È™•ú»Ü‚É‚¨‚¯‚陕ú‰»‚ÌŽè’iA
»Ü‰»‚̃TƒCƒGƒ“ƒXAŠî‘b‚ÆCMCi‰iˆäPŽiA‰€•”®•ÒA‚¶‚Ù‚¤jApp.244-249A(2010)
Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€
•À–Ø“¿”VFODù‚Í”][ÇŠ³ŽÒ‚̂悫ƒp[ƒgƒi[Aƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[
“ú–{–òŠw‰ï‘æ131”N‰ïiɪjAu‰‰—vŽ|W1App.281A2011”N3ŒŽ29“ú
ŽO‰YŠî–õA“à“cM–çA“à“c‹g˜YA’rã“Þ•äA’|’†—»ˆêA“c’†Ž‡äŽqA‰Á“¡ˆÀGA•À–Ø“¿”VFŒûo“à•ö‰óù‚̃tƒŒ[ƒo[‚̋ꖡƒ}ƒXƒLƒ“ƒOŒø‰Ê
“ú–{–òŠw‰ï‘æ131”N‰ïiɪjAu‰‰—vŽ|W4App.245A2011”N3ŒŽ29“ú
’|’†—»ˆêAŽR“cŒ’“ñ˜YAŽO‰YŠî–õA“à“c‹g˜YA“c’†Ž‡äŽqA‰Á“¡ˆÀGA“à“cM–çA•À–Ø“¿”VFŒûo“à•ö‰óù‚Ì•ö‰ó«‚ÉŠÖ‚·‚éˆê”ÊŽŽŒ±–@‚ÌŒŸ“¢
“ú–{–òŠw‰ï‘æ131”N‰ïiɪjAu‰‰—vŽ|W4App.245A2011”N3ŒŽ29“ú
ŽR“cŒ’“ñ˜YA’|’†—»ˆêAŽO‰YŠî–õA“à“c‹g˜YA“c’†Ž‡äŽqA‰Á“¡ˆÀGA“à“cM–çA•À–Ø“¿”VFŒûo“à•ö‰óù‚Ì‹qŠÏ“I•ö‰óŽžŠÔ‚Æd“x‚É‹y‚Ú‚·‘SŽ©“®ùÜ•ª•ï‹@‚É‚æ‚镪•ï‚̉e‹¿
“ú–{–òŠw‰ï‘æ131”N‰ïiɪjAu‰‰—vŽ|W4App.245A2011”N3ŒŽ29“ú
’rã“Þ•äA“à“c‹g˜YAŽO‰YŠî–õA’|’†—»ˆêA“c’†Ž‡äŽqA‰Á“¡ˆÀGA“à“cM–çA•À–Ø“¿”VFƒtƒ@ƒ‚ƒ`ƒWƒ“Œûo“à•ö‰óù‚É‚¨‚¯‚éƒtƒŒ[ƒo[‚ÌL‚¢‹y‚ыꖡ‚̃}ƒXƒLƒ“ƒOŒø‰Ê
“ú–{–òŠw‰ï‘æ131”N‰ïiɪjAu‰‰—vŽ|W4App.245A2011”N3ŒŽ29“ú
™‰Y@Œ’A“à“cM–çA’rã“Þ•äAŽR“cŒ’“ñ˜YA•À–Ø“¿”VFƒtƒ@ƒ‚ƒ`ƒWƒ“Œûo“à•ö‰óù‚̋ꖡ‚É‹y‚Ú‚·ƒ}ƒXƒLƒ“ƒOŒø‰Ê
“ú–{–òŠw‰ï‘æ131”N‰ïiɪjAu‰‰—vŽ|W4App.245A2011”N3ŒŽ29“ú
ŒI–عŠóŒbA’rã“Þ•äA“c’†Ž‡äŽqA‰Á“¡ˆÀGA“à“cM–çAìˆä—´”üA•À–Ø“¿”VFQR ƒR[ƒh‚ð—˜—p‚µ‚½Œg‘Ñ“d˜b‚É‚æ‚éˆã–ò•iî•ñ’ñ‹ŸƒVƒXƒeƒ€‚Ì—L—p«‚ÌŒŸ“¢
“ú–{–òŠw‰ï‘æ131”N‰ïiɪjAu‰‰—vŽ|W4App.264A2011”N3ŒŽ29“ú
“c’†Ž‡äŽqAŽO‰YŠî–õA“à“cM–çA‹{ìKŽqAŒã“¡‹M—TA’|“à˜a•FAŠ£’¼‹PAŽR“c_A•À–Ø“¿”VA“nç³—TŽiF”x“®–¬«”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚ésildenafil‚¨‚æ‚Ñbosentan‚ÌŒŒŸ÷’†”Z“x‚Ì“¯Žž’è—Ê–@
“ú–{–òŠw‰ï‘æ131”N‰ïiɪjAu‰‰—vŽ|W4Ap.267A2011”N3ŒŽ29“ú
“à“cM–çFƒ`ƒgƒNƒ[ƒ€P450iCYPj2C9ˆâ“`Žq‘½Œ^‚ƃxƒ“ƒYƒuƒƒ}ƒƒ“‚Ì–ò•¨“®‘ÔE–òŒø‚ւ̉e‹¿AƒVƒ“ƒ|ƒWƒEƒ€u’É•—E‚”AŽ_ŒŒÇFŋ߂Ìi•àv
“ú–{–òŠw‰ï‘æ131”N‰ïiɪjAu‰‰—vŽ|W1App.180A2011”N3ŒŽ30“ú
•À–Ø“¿”VFLUTSŽ¡—Öò‚ÌŒûo“à•ö‰óù‚ÍOABгŽÒ‚³‚ñ‚̂悫ƒp[ƒgƒi[
‘æ24‰ñ“ú–{˜V”N”å”AŠí‰ÈŠw‰ïi–¼ŒÃ‰®jAu‰‰—vŽ|WAp.50A2011”N5ŒŽ29“ú
’|’†—»ˆêAŽR“cŒ’“ñ˜YA“à“c‹g˜YAŽO‰YŠî–õA“c’†Ž‡äŽqA‰Á“¡ˆÀGA“à“cM–çA•À–Ø“¿”VFŒûo“à•ö‰óù‚ÌV‹K•ö‰óŽŽŒ±–@‚ÌŒŸ“¢‚Æ‘SŽ©“®ùÜ•ª•ï‹@‚É‚æ‚镪•ï‚̉e‹¿
“ú–{–òÜŠw‰ï‘æ26”N‰ïi“Œ‹žjA—vŽ|WAp.112A2011”N5ŒŽ29“ú
ŽRèÊA“à“cM–çAŽž”C³˜aA‘ˆä’¼“oAŽR‘º¹‹IA“c’†Ž‡äŽqA‰Á“¡ˆÀGA•À–Ø“¿”VFV‹KODùŠîÜLudiflash‚ð—p‚¢‚½ƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“ƒ`ƒ‡ƒRƒŒƒbƒg‚ÌŠJ”
“ú–{–òÜŠw‰ï‘æ26”N‰ïi“Œ‹žjA—vŽ|WAp.201A2011”N5ŒŽ29“ú
”ä‰ÃŸA“à“cM–çA“à“c‹g˜YA’rã“Þ•äAŽO‰YŠî–õA’|’†—»ˆêA“c’†Ž‡äŽqA•À–Ø“¿”VFƒCƒ‹ƒ\ƒOƒ‰ƒWƒ“Œûo“à•ö‰óù‚ÌL‚¢‹y‚Ñ–¡‚É‹y‚Ú‚·ƒtƒŒ[ƒo[‚̉e‹¿
“ú–{–òÜŠw‰ï‘æ26”N‰ïi“Œ‹žjA—vŽ|WAp.203A2011”N5ŒŽ29“ú
ŽO‰YŠî–õA“à“cM–çA’rã“Þ•äA“à“c‹g˜YA’|’†—»ˆêA“c’†Ž‡äŽqA‰Á“¡ˆÀGA•À–Ø“¿”VF—Õ°ŽŽŒ±‹y‚Ñ“dŽq–¡ŠoƒZƒ“ƒT[‚É‚æ‚é‹ê–¡ƒ}ƒXƒLƒ“ƒOŒø‰Ê‚ÌŒŸ“¢
“ú–{–òÜŠw‰ï‘æ26”N‰ïi“Œ‹žjA—vŽ|WAp.206A2011”N5ŒŽ29“ú
™–{Ê–çA™‰YŒ’A’rã“Þ•äAŽR“cŒ’“ñ˜YA“à“cM–çA•À–Ø“¿”VFRACTAB‹Zp‚ð—p‚¢‚½ƒtƒ@ƒ‚ƒ`ƒWƒ“Œûo“à•ö‰óù‚̋ꖡƒ}ƒXƒLƒ“ƒOŒø‰Ê
“ú–{–òÜŠw‰ï‘æ26”N‰ïi“Œ‹žjA—vŽ|WAp.201A2011”N5ŒŽ31“ú
“c’†Ž‡äŽqAŽO‰YŠî–õA“à“cM–çA‹{ìKŽqAŒã“¡‹M—TA’|“à˜a•FAŠ£’¼‹PAŽR“c_A•À–Ø“¿”VA“nç³—TŽiF”x“®–¬«”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚ésildenafil‚¨‚æ‚Ñbosentan‚ÌŒŒŸ÷’†”Z“x‚Ì‘ª’è
‘æ28‰ñ“ú–{TDMŠw‰ïEŠwp‘å‰ïiL“‡jATDMŒ¤‹†, 28(Suppl), s193, 2011A2011”N6ŒŽ19“ú
[ˆäKŒbA“c’†Ž‡äŽqA“à“cM–çAŽR‘º¹‹IAŽO‰YŠî–õAŠ£’¼‹PA’|“à˜a•FA“nç³—TŽiA•À–Ø“¿”VFƒJƒNƒeƒ‹ŽŽŒ±‚É‚¨‚¯‚é5–ò•¨‚Æ‚»‚ê‚ç‚Ì‘ãŽÓ•¨‚ÌLC/MS/MS‚É‚æ‚é“¯Žž’è—Ê–@‚ÌŠm—§
‘æ28‰ñ“ú–{TDMŠw‰ïEŠwp‘å‰ïiL“‡jATDMŒ¤‹†, 28(Suppl), s217, 2011A2011”N6ŒŽ19“ú
•À–Ø“¿”VFƒWƒFƒlƒŠƒbƒNˆã–ò•i‚É‹‚ß‚ç‚ê‚é—Õ°“I‹@”\«
“ú–{ƒWƒFƒlƒŠƒbƒNˆã–ò•iŠw‰ï‘æ5‰ñŠw‰ïŠwp‘å‰ïi“Œ‹žjAu‰‰—vŽ|WAp.54A2011”N6ŒŽ19“ú
ŽR“cŒ’“ñ˜YA’|’†—»ˆêAŽž”C³˜aA‘ˆä’¼“oAŽR‘º¹‹IA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VFƒqƒg‚É‚¨‚¯‚éŒûo“à•ö‰óù‚Ì•ö‰óŽžŠÔ‹y‚шù…•K—v—Ê‘ª’è–@‚ÌŒŸ“¢
‘æ21‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi_ŒËjA—vŽ|WAp.269A2011”N10ŒŽ2“ú
ŽR‘º¹‹IAŽO‰YŠî–õA“c’†Ž‡äŽqA[ˆäKŒbAŽž”C³˜aA“à“cM–çA•À–Ø“¿”VFƒ‰ƒbƒg‚É‚¨‚¯‚éCYPŠˆ«•]‰¿‚Ì‚½‚߂̃JƒNƒeƒ‹ŽŽŒ±‚ÌŒŸ“¢
‘æ21‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi_ŒËjA—vŽ|WAp.321A2011”N10ŒŽ2“ú
•À–Ø“¿”VF’m‚Á‚Ä“¾‚·‚éODù‚Ì“¤’mޝ
‘æ65‰ñ‘—§•a‰@‘‡ˆãŠw‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[i‰ªŽRju‰‰—vŽ|WAp.228A2011”N10ŒŽ7“ú
•À–Ø“¿”VF»Ü‹Zp‚ªø¬‚·‚é—Õ°“I‹@”\«
‘æ12‰ñ»Ü‹@ŠB‹ZpŒ¤‹†‰ïi‘åã•{—§‘åjA—vŽ|WAp.207A2011”N11ŒŽ11“ú
—ÑGŽ÷A’Ò‘åŽ÷A“à“cM–çA¬›˜amA‰êì‹`”VA•À–Ø“¿”VAŽR“c_A›•qKA‰œ’¼lAˆÉ“¡–M•FF“Œ“ú–{‘åkЂɂ¨‚¯‚é–òŠw•”‹³ˆõ‚ÌЊQˆã—ʈ“®
“ú–{•a‰@–òÜŽt‰ï“ŒŠCƒuƒƒbƒNE“ú–{–òŠw‰ï“ŒŠCŽx•”‡“¯Šwp‘å‰ïi–¼ŒÃ‰®j
Shimako Tanaka, Shinya Uchida, Masaki Yamamura, Motoyasu Miura, Yukie Fukai, Noriyuki Namiki : The simultaneous evaluation of activities of cytochrome P450 enzymes using a five-drug cocktail in rats.
‘æ5‰ñŽŸ¢‘ã‚ð’S‚¤ŽáŽèˆã—Öò‰ÈŠwƒVƒ“ƒ|ƒWƒEƒ€i–¼ŒÃ‰®jA—vŽ|WAp.30A2011”N11ŒŽ26“ú
’rã“Þ•äA¬“‡´Ž÷A“à“cM–çA•À–Ø“¿”VFƒtƒ@ƒ‚ƒ`ƒWƒ“Œûo“à•ö‰óù‚É‚¨‚¯‚é–¡‹y‚тɂ¨‚¢‚Ì—Õ°–ò—Šw“I•]‰¿
‘æ32‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi•l¼jA—Õ°–ò—, 42(Suppl), S274, 2011A2011”N12ŒŽ1“ú
Žž”C³˜aA™‰YŒ’A’rã“Þ•äA“à“cM–çA•À–Ø“¿”VF—Õ°ŽŽŒ±‚¨‚æ‚Ñ“dŽq–¡ŠoškŠoƒVƒXƒeƒ€‚É‚æ‚éƒtƒ@ƒ‚ƒ`ƒWƒ“Œûo“à•ö‰óù‚Ì–¡‹y‚тɂ¨‚¢‚Ì•]‰¿
‘æ32‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi•l¼jA—Õ°–ò—, 42(Suppl), S274, 2011A2011”N12ŒŽ1“ú
“c’†Ž‡äŽqAŽO‰YŠî–õA“à“cM–çA‹{ìKŽqAŒã“¡‹M—TA’|“à˜a•FAŠ£’¼‹PAŽR“c_A•À–Ø“¿”VA“nç³—TŽiF“ú–{l”x“®–¬«”x‚ŒŒˆ³ÇгŽÒ‚É‚¨‚¯‚ésildenafil‚¨‚æ‚Ñbosentan‚ÌŒŒŸ÷’†”Z“x‚Ì‘ª’è
‘æ32‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi•l¼jA—Õ°–ò—, 42(Suppl), S281, 2011A2011”N12ŒŽ1“ú
“à“cM–çA“c’†Ž‡äŽqAŠ£’¼‹PA’|“à˜a•FA“nç³—TŽiA‘å‹´‹žˆêA•À–Ø“¿”VF–ò•¨‘ŠŒÝì—pŒŸo‚Ì‚½‚ß‚Ìin vivo‚ł̃‰ƒbƒg‚¨‚æ‚ÑŒ’íl‘ÎÛŽŽŒ±AƒVƒ“ƒ|ƒWƒEƒ€S13u‘½—l‚È–ò•¨‘ŠŒÝì—p‚Ö‚Ì’§í‚Æ“W–]v
‘æ32‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi•l¼jA—Õ°–ò—, 42(Suppl), S159, 2011A2011”N12ŒŽ2“ú
¡ˆä_ŒõAX“c”üçAX“cŒ³A‘åŽR“NŽiAˆÉ“¡“c‰lŽqA{è—F‹IAX–{‘ìÆA¬Žèì‹ÎA“c’†Ž‡äŽqA“à“cM–çA•À–Ø“¿”VA‘å‹´‹žˆêFƒuƒvƒŒƒmƒ‹ƒtƒBƒ“‚Ì–ò—ì—p‚É‚¨‚¯‚éƒIƒsƒIƒCƒhƒÊ1Žó—e‘̈â“`Žq‘½Œ^i118A>Gj‚̉e‹¿
‘æ32‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi•l¼jA—Õ°–ò—, 42(Suppl), S352, 2011A2011”N12ŒŽ3“ú
‚»‚Ì‘¼‚ÌŠ§s•¨
•À–Ø“¿”VF»ÜH•v‚É•s‰ÂŒ‡‚È¢Š³ŽÒƒxƒlƒtƒBƒbƒg£‚ÌŽ‹“_
PHARMACY DIGESTA4A2-4 (2011)
•À–Ø“¿”VA‚‹´@ŒåFŒûo“à•ö‰óù‚ª‰ßŠˆ“®äNã÷Ž¡—Ã‚É‚à‚½‚ç‚·ƒƒŠƒbƒg
Astellas SquareA7A4-10 (2011)
•À–Ø“¿”VF¢–ò£‚ðŒê‚ê‚é–òÜŽt‚ª‚¢‚È‚¢I-
PHARMACY DIGESTA5A2-4 (2011)
•À–Ø“¿”VF–¾“ú‚É‚©‚¯‚é
»Ü‹@ŠB‹ZpŒ¤‹†‰ïŽA20A329-332 (2011)
•À–Ø“¿”VF¢ODù£”á”»‚Í“–‚½‚ç‚È‚¢
ˆã—ÃŒoÏA1398A3 (2011)
•À–Ø“¿”VFƒWƒFƒlƒŠƒbƒNˆã–ò•i‚É‹‚ß‚ç‚ê‚é—Õ°“I‹@”\«
ƒWƒFƒlƒŠƒbƒNŒ¤‹†A5A54 (2011)
•À–Ø“¿”VA¼‰Y@ŠóAˆÉ¨—Y–çF‚¢‚Ü—Õ°‚Å‹‚ß‚ç‚ê‚é»Ü‚Æ‚ÍiгŽÒ‚̃xƒlƒtƒBƒbƒg‚©‚ç’T‚éj
–òŽ–A53A95-102 (2011)
•À–Ø“¿”VA¼‰Y@ŠóAˆÉ¨—Y–çF‚¢‚Ü—Õ°‚Å‹‚ß‚ç‚ê‚é»Ü‚Æ‚ÍiгŽÒ‚̃xƒlƒtƒBƒbƒg‚©‚çj
PHARM TECH JAPANA27A7-15 (2011)
“à“cM–çFR‹Û–òˆ•ûŽž‚Ì’ˆÓ“_C‰ºÜE§Ž_܂Ƃ̓¯Žž•ž—p‚Å‹zŽû‘jŠQAɪŒ§—§‘åŠw–òŠw•”E“à“cM–玂ɕ·‚
MTPro‹LŽ–A2011”N3ŒŽ25“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
Shinya Uchida, Kayoko Shimada, Shingen Misaka, Hiromitu Imai, Yasuhiro Katoh, Naoki Inui, Kazuhiko Takeuchi, Takashi Ishizaki, Shizuo Yamada, Kyoichi Ohashi, Noriyuki Namiki, Hiroshi Watanabe: Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes.
Drug Metab Pharmacokinet, 25, 605-610 (2010)
Yasuhiro Katoh, Shinya Uchida, Masayoshi Kawai, Noriyoshi Takei, Norio Mori, Junichi Kawakami, Yoshiyuki Kagawa, Shizuo Yamada, Noriyuki Namiki, Hisakuni Hashimoto: Onset of Clinical Effects and Plasma Concentration of Fluvoxamine in Japanese.
Biol. Pharm. Bull., 33, 1999-2002 (2010)
Yoshihisa Kato, Hiroshi Suzuki, Koichi Haraguchi, Shinichi Ikushiro, Yoshihiko Ito, Shinya Uchida, Shizuo Yamada, Masakuni Degawa: A possible mechanism for the decrease in serum thyroxine level by Phenobarbital in rodents.
Toxicol Appl Pharmacol., 249, 238-246 (2010)
Junya Hatanakaa, Hina Chikamoria, Hideyuki Satoa, Shinya Uchidaa, Kazuhiro Debaric, Satomi Onouea, Shizuo Yamada: Physicochemical and pharmacological characterization of alpha-tocopherol-loaded nano-emulsion system.
Int J Pharm., 396, 188-193 (2010)
Yasuhiro Katoh, Shinya Uchida, Masayoshi Kawai, Noriyoshi Takei, Norio Mori, Junichi Kawakami, Yoshiyuki Kagawa, Shizuo Yamada, Noriyuki Namiki, Hisakuni Hashimoto: Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.
Biol. Pharm. Bull., 33, 285-288 (2010)
Norio Takahashi, Naoki Inui, Hiroshi Morita, Kazuhiko Takeuchi, Shinya Uchida, Hiroshi Watanabe, Hirotoshi Nakamura: Effect of thyroid hormone on the activity of CYP3A enzyme in humans.
J Clin Pharmacol., 50, 88-93 (2010)
Shingen Misaka, Shinya Uchida, Hiromitsu Imai, Naoki Inui, Shinichiro Nishio, Kyoichi Ohashi, Hiroshi Watanabe, Shizuo Yamada: Pharmacokinetics and pharmacodynamics of midazolam administered intravenously and orally at low doses to healthy volunteers.
Clin. Exp. Pharmacol. Physiol., 37, 290-295 (2010)
‘à
•À–Ø“¿”VF‰@“à»ÜE’²ÜƒtƒH[ƒJƒXƒOƒ‹[ƒv‚ÌŠˆ“®‚ɂ‚¢‚Ä
–òÜŠwA70A255-257 (2010)
•À–Ø“¿”VFƒvƒŒƒ^[ƒ‹‚n‚cù‚Æ‚»‚Ì—Õ°“I‹@”\«
PHARM TECH JAPAN, 26A2087-2091 (2010)
•À–Ø“¿”VF”z‡ÜƒJƒfƒ…ƒGƒbƒg‚Ì—Õ°»ÜŠw“I—L—p«
PHARM TECH JAPANA26A2491-2495 (2010)
Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€
•À–Ø“¿”VF2010”N–â‘è‚̃sƒ“ƒ`‚ÆODù‚̃`ƒƒƒ“ƒX
PLCM(k–ò)Œ¤‹†‰ï(–¼ŒÃ‰®) ‘æ4‰ñƒVƒ“ƒ|ƒWƒEƒ€¢Œûo“à•ö‰óù‚ÌŒ»ó‚Æ“W–]£ u‰‰—vŽ|Wpp. 1-4A2010”N1ŒŽ27“ú
•À–Ø“¿”VFˆã–ò•i‚ÌLCM‚Í^‚ÉŠ³ŽÒEˆã—ÂÉvŒ£‚Å‚«‚é‚©- ˆã—ÂŖ]‚Ü‚ê‚鎟¢‘ãŒ^‚ÌLCM»ÜAƒVƒ“ƒ|ƒWƒEƒ€ƒI[ƒKƒiƒCƒU[EƒVƒ“ƒ|ƒWƒXƒg
“ú–{–òŠw‰ï‘æ130”N‰ïi‰ªŽRjAu‰‰—vŽ|W1App.207A2010”N3ŒŽ30“ú
“à“c‹g˜NA“à“cM–çAŽO‰YŠî–õA’|’†—»ˆêA‰Á“¡ˆÀGA•À–Ø“¿”VFŒûo“à•ö‰óù‚̃tƒŒ[ƒo[‚̋ꖡƒ}ƒXƒLƒ“ƒOŒø‰Ê
“ú–{–òŠw‰ï‘æ130”N‰ïi‰ªŽRjAu‰‰—vŽ|W4Ap.220A2010”N3ŒŽ28“ú
ŽO‰YŠî–õA“à“cM–çAŽOâáÁŒ³A‰Á“¡ˆÀGAŽR“c×YA‘å‹´‹žˆêA“nç³—TŽiA•À–Ø“¿”VFƒ~ƒ_ƒ]ƒ‰ƒ€‹y‚Ñ‘ãŽÓ•¨‚Ì”A’†”rŸ•—ʂƌŒŸ÷’†”Z“xŽžŠÔ‹Èü‰º–ÊςƂ̊֌W
“ú–{–òŠw‰ï‘æ130”N‰ïi‰ªŽRjAu‰‰—vŽ|W4Ap.202A2010”N3ŒŽ30“ú
’|’†—»ˆêA“à“cM–çAŽO‰YŠî–õA“à“c‹g˜NA‰Á“¡ˆÀGA•À–Ø“¿”VFŒûo“à•ö‰óù‚Ì‹qŠÏ“I•ö‰óŽžŠÔ‚Æ’²Ü‹“x
“ú–{–òŠw‰ï‘æ130”N‰ïi‰ªŽRjAu‰‰—vŽ|W4Ap.227A2010”N3ŒŽ28“ú
Œã“¡‹M—TA‹{ìKŽqA’|“à˜a•FA“à“cM–çA¬›˜amAŠ£’¼‹PA•À–Ø“¿”VA“nç³—TŽiAŽR“c_F”x“®–¬«”x‚ŒŒˆ³ÇгŽÒ‚ɑ΂·‚ébosentan•¹—p“Š—^ƒ^ƒCƒ~ƒ“ƒO‚É‚æ‚ésildenafilŒŒ’†”Z“x•ω»‚Ì—Õ°“IŒŸ“¢
“ú–{–òŠw‰ï‘æ130”N‰ïi‰ªŽRjAu‰‰—vŽ|W4Ap.192A2010”N3ŒŽ29“ú
—ÑGŽ÷AHŽR‹ÓŽOAÎìŽ •FAˆäã’BGA‰œ’¼lA‰êì‹`”VAìトêA‰ÍŒ´è‹M”ŒA›’JƒŽqA’†–ìáÁ”ÄA•À–Ø“¿”VA–ì–шê˜YA¼ŽR‘ÏŽŠAX–{’B–çAŽR“c×YAŽR“c_AˆÉ“¡–M•FFɪŒ§—§‘åŠwE•a‰@E’nˆæ–ò‹Ç˜AŒg‚É‚æ‚é–ò•¨—Ö@Œ¤C‰ï‚ÌŒ»‹µ
“ú–{–òŠw‰ï‘æ130”N‰ïi‰ªŽRjAu‰‰—vŽ|W4Ap.351A2010”N3ŒŽ28“ú
—é–Ø@‹§A‰ª“c_”üA“y‰®Æ—YA‰êì‹`”VA–Ø‘º˜a“NA™ŽR@³A•À–Ø“¿”VA•½“ˆ®‰pA’†‘ºŒõ_A¬›˜amA‘O“c@“OA—Ñ@GŽ÷A–ìŒû”ŽŽiA¬–ìGŽ÷A“¡ˆä@‘FŽOŒö—§˜AŒg–òÜŽt¶ŠUŠwKŽx‰‡uÀFŽÀKƒvƒƒOƒ‰ƒ€‚ÌŽŽ‚Ý‚Æ•]‰¿
“ú–{–òŠw‰ï‘æ130”N‰ïi‰ªŽRjAu‰‰—vŽ|W4Ap.348A2010”N3ŒŽ28“ú
’|’†—»ˆêA“à“cM–çAŽO‰YŠî–õA“à“c‹g˜YA‰Á“¡ˆÀGA•À–Ø“¿”VFŒûo“à•ö‰óù‚Ì‹qŠÏ“I•ö‰óŽžŠÔ‚Æd“x‚É‹y‚Ú‚·‘SŽ©“®ùÜ•ª•ï‹@‚É‚æ‚镪•ï‚̉e‹¿
“ú–{–òÜŠw‰ï‘æ25”N‰ïi“¿“‡jA—vŽ|WAp.232A2010”N5ŒŽ14“ú
“à“c‹g˜YA“à“cM–çAŽO‰YŠî–õA’|’†—»ˆêA‰Á“¡ˆÀGA•À–Ø“¿”VFƒtƒ@ƒ‚ƒ`ƒWƒ“Œûo“à•ö‰óù‚É‚¨‚¯‚éƒtƒŒ[ƒo[‚ÌL‚¢‹y‚ыꖡ‚̃}ƒXƒLƒ“ƒOŒø‰Ê
“ú–{–òÜŠw‰ï‘æ25”N‰ïi“¿“‡jA—vŽ|WAp.229A2010”N5ŒŽ14“ú
”¨’†‡–çAV–¼—R‹GŽqA“à“cM–çA”öã½—ÇAŽR“c×YF•¨«‚È‚ç‚тɌoŒû‹zŽû«‰ü‘P‚ðŽwŒü‚µ‚½ƒZƒ“ƒgƒWƒ‡[ƒ“ƒYƒ[ƒg»Ü‚ÌŠJ”
“ú–{–òÜŠw‰ï‘æ25”N‰ïi“¿“‡jA—vŽ|WAp.207A2010”N5ŒŽ14“ú
ŽO‰YŠî–õA“à“cM–çA“à“c‹g˜YA’|’†—ɈêA‰Á“¡ˆÀGA“nç³—TŽiA•À–Ø“¿”VF“œ”A•aƒ‚ƒfƒ‹ƒ‰ƒbƒg‚É‚¨‚¯‚éƒOƒŠƒƒsƒŠƒh‚Ì‘Ì“à“®‘ԂƃCƒ“ƒXƒŠƒ“•ª”åì—p
‘æ27‰ñ“ú–{TDMŠw‰ïEŠwp‘å‰ïiŽD–yjATDMŒ¤‹†, 27(Suppl), s232, 2010,2010”N6ŒŽ27“ú
Shinya Uchida, Motoyasu Miura, Shingen Misaka, Yasuhiro Katoh, Shizuo Yamada, Kyoichi Ohashi, Hiroshi Watanabe, Noriyuki Namiki: In-vivo phenotyping for CYP3A4 by determination of a single-point plasma concentration and urinary excretion of midazolam and its metabolites.
16th IUPHAR WorldCongress of Basis and Clinical Pharmacology (Copenhagen, Denmark), Basic & Clinical Pharmacology & Toxicology, 107 (Suppl. 1), 625, 2010, 2010”N7ŒŽ22“ú
‰Á“¡ˆÀGA“à“cM–çA•À–Ø“¿”VFɪŒ§—§‘åŠw–òŠw•”‚É‚¨‚¯‚éŽÀ–±ŽÀKŽ–‘OŠwK‚ÉŽg—p‚·‚éˆã–ò•iî•ñ‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²¸
‘æ13‰ñ“ú–{ˆã–ò•iî•ñŠw‰ï‘‰ïEŠwp‘å‰ïi•l¼jA—vŽ|Wp129A2010”N7ŒŽ24“ú
“à“cM–çA•“cl•½A’†¼G•¶A–¥—ÖØ•äA‰Á“¡ˆÀGA“nç³—TŽiA•À–Ø“¿”VAŽR“c×YFƒIƒLƒVƒRƒhƒ“‚ƃtƒFƒ“ƒ^ƒjƒ‹‚̃ʃIƒsƒIƒCƒhŽó—e‘ÌŒ‹‡A’Á’ÉŒø‰Ê‚¨‚æ‚Ñ‘Ì“à“®‘Ô
‘æ4‰ñŠÉ˜aˆã—ÖòŠw‰ïiŽŽ™“‡jA—vŽ|WAp.178A2010”N9ŒŽ25“ú
ŽR“c×YA•“cl•½AˆÉ“¡—R•FA“à“cM–çFƒIƒsƒIƒCƒh’Á’É–ò‚ÌŽó—e‘ÌŒ‹‡‚ðŠî”Õ‚Æ‚µ‚½–ò•¨“®‘Ô/–ò—ÍŠw‚̉ðÍ
‘æ4‰ñŠÉ˜aˆã—ÖòŠw‰ï”N‰ïiŽŽ™“‡jA—vŽ|WAp.163A2010”N9ŒŽ25“ú
•À–Ø“¿”VF–òÜŽt‚ÌE”\‚ƃWƒFƒlƒŠƒbƒNˆã–ò•iAƒVƒ“ƒ|ƒWƒEƒ€uƒWƒFƒlƒŠƒbƒNˆã–ò•i‚Ì‚³‚ç‚È‚é„iv
‘æ43‰ñ“ú–{–òÜŽt‰ïŠwp‘å‰ïi’·–ìjAu‰‰—vŽ|WApp.172A2010”N10ŒŽ11“ú
ŒI–عŠóŒbA“à“cM–çA’rã“Þ•äA“à“c‹g˜YAŽO‰YŠî–õA’|’†—»ˆêA“c’†Ž‡äŽqA‰Á“¡ˆÀGA•À–Ø“¿”VFƒ}ƒgƒŠƒbƒNƒXŒ^“ñŽŸŒ³ƒR[ƒhiQRƒR[ƒhj‚ð—˜—p‚µ‚½Œg‘Ñ“d˜b‚É‚æ‚éˆã–ò•iî•ñ’ñ‹ŸƒVƒXƒeƒ€‚Ì—L—p«‚ÌŒŸ“¢
‘æ20‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïiç—tjA—vŽ|WAp.302A2010”N11ŒŽ13“ú
Hashimoto Hisakuni, Katoh Yasuhiro, Uchida Shinya, Kawai Masayoshi, Takei Noriyoshi, Mori Norio, Kawakami Junichi, Kagawa Yoshiyuki, Yamada Shizuo, Namiki Noriyuki: A major factor affecting plasma concentrations of fluvoxamine, a SSRI, and early predictior of its responsiveness in Japanese patients.
The 23rd Federation of Asian Pharmaceutical Associations Congress (Taipei, Taiwan), Abstract p.288, 2010”N11ŒŽ5“ú
X“cŒ³A¬Žèì‹ÎA’çŠì”üŽqA¡ˆä_ŒõA¡‰i~ŽqAX“c”üçA‘åŽR“NŽiA“à“cM–çA‰eŽR”ü’q‘ãA•À–Ø“¿”VA“nç³—TŽiA‘å‹´‹žˆêFƒgƒŠƒAƒ]ƒ‰ƒ€‚Ì–ò•¨“®‘Ô‹y‚Ñ–ò—ì—p‚É‹y‚Ú‚·ƒNƒŒƒƒWƒ“•¹—pƒ^ƒCƒ~ƒ“ƒO‚̉e‹¿
‘æ31‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi‰¡•lj,—Õ°–ò—, 41(Suppl), S251, 2010A2010”N12ŒŽ1“ú
¬•½’m¢A“à“cM–çA‹›’J‹M—mAŽRo”ü•äŽqA¼–ìáÁŽjA™–{Œõ”ÉA•À–Ø“¿”VA“nç³—TŽiAŒÃ“c—²‹vF13C-ƒiƒvƒƒLƒTƒ“ŒÄ‹CŽŽŒ±‚ÌCYP2C9Šˆ«•]‰¿–@‚Æ‚µ‚Ẳ”\«
‘æ31‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi‰¡•lj,—Õ°–ò—, 41(Suppl), S283, 2010A2010”N12ŒŽ2“ú
‚»‚Ì‘¼‚ÌŠ§s•¨
ŽRŒû•“TA‹´–{—mˆê˜YA•À–Ø“¿”VF”][Ç–«Šú‚É‚¨‚¯‚éRŒŒ¬”—Ö@‚Ì–ðŠ„‚Æ•ž–òŒp‘±‚Ìd—v«
“úŒoƒƒfƒBƒJƒ‹A10A130-133 (2010)
•À–Ø“¿”VFгŽÒ‚ÌQOL‚ð‚‚ß‚é•t‰Á‰¿’lŒ^»ÜiƒOƒ~»Ü‚ÌŠÈ’P‚Èì‚è•ûj
’²Ü‚Æî•ñA16A1425-1429 (2010)
•À–Ø“¿”VA‹´–{—mˆê˜YF”]_Œo޾гƒi[ƒX‚Ì‚½‚߂̂‚·‚è‚Ì’mޝODù‚Ƃ͇@
BRAIN NURSINGA26A1066-1070 (2010)
‰ª“c_”üA—é–ØA–Ø‘º˜a“NA™ŽR³A“y‰®Æ—YA•À–Ø“¿”VA‰êì‹`”VA“¡ˆä‘F–òÜŽtƒŠƒJƒŒƒ“ƒg‘ÌŒ±ŠwK‚ÌŽÀŽ{‚Æ‚»‚Ì•]‰¿
–òŽ–A52A771-774 (2010)
•À–Ø“¿”VF”]‘²’†–«ŠúŠÇ—‚É‚¨‚¯‚éš‹‰ºáŠQ‚ÆODù‚̈Ӌ`i–òÜŽt‚Ì—§ê‚©‚çj
“úŒoDIA4A43-45 (2010)
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
Chise Kodaira, Mitusige Sugimoto, Masashi Nishino, Mihoko Yamade, Naoto Shirai, Shinya Uchida, Mutuhiro Ikuma, Shizuo Yamada, Hiroshi Watanabe, Akira Hishida, Takahisa Furuta: Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects.
Eur J Clin Pharmacol., 65, 593-600 (2009)
Shohei Kurosawa, Shinya Uchida, Yoshihiko Ito, Shizuo Yamada:Effect of ursodeoxycholic acid on the pharmacokinetics of midazolam and CYP3A in the liver and intestine of rats.
Xenobiotica, 39, 162-17, (2009)
o‰_³Ž¡C•½“‡“OC“‡è”ŽŽmC–ì˜C˜a•FC–‘–ΓTC‹àŽq’m—RC–¾ÎŠâ—YCìˆä—´”üC]”¨rÆC“à“cM–çC•À–Ø“¿”VFƒsƒ“ƒ|ƒCƒ“ƒg–ƒŒÜEƒŠƒhƒJƒCƒ“ƒXƒeƒBƒbƒN‚̻܉»‚Æ—Õ°•]‰¿
ˆã—ÖòŠw, 35, 458-467 (2009)
‘à
•À–Ø“¿”VF—Õ°‚ª‹‚ß‚é»Ü‹Zp@—±ŽqÝŒv‚Ìi•à‚ÍŒûo“à•ö‰óù‚Ìi•àD
»Ü‹@ŠB‹ZpŒ¤‹†‰ïŽ, 18, 315-321 (2009)
Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€
‰Á“¡ˆÀGAã“cˆßDA‘O“c—˜’jA“ì’qAâ–{’Bˆê˜YA–Ø‘º—ÎA‰ÍŒ´è‹M”ŒAŽR“c_A‚–س˜aA‰êì‹`”VF‚“xNPŽèpŒã‰h—{—Ö@‚É‚¨‚¯‚鎉–b“û܂̊ə“Š—^‚É‚æ‚é‰h—{ó‘Ô‹y‚іƉu”\‚ւ̉e‹¿
‘æ23‰ñɪŒ§•a‰@–òÜŽt‰ïŠwp‘å‰ïiɪjA2009”N3ŒŽ1“ú
˜a‹v“c_ˆêA“à“cM–çA’r“c‰ë•FA“cŸº³Ž÷AÔ¯•ÛŒõAŽR“c×YF ApoEŒ‡‘¹ƒ}ƒEƒX‚É‚¨‚¯‚é‚”AŽ_ŒŒÇŽ¡—Öò‚ÌR“®–¬d‰»ì—p
“ú–{–òŠw‰ï‘æ129”N‰ïi‹ž“sjAu‰‰—vŽ|W4Ap.170A 2009”N3ŒŽ27“ú
•À–Ø“¿”VF•a‰@–ò܂Ƃ̘AŒg@‰õ“K‚Ȉã—Âð’ñ‹Ÿ‚·‚邽‚߂̑nÜ
“ú–{–òÜŠw‰ï‘æ24”N‰ïiɪjA—vŽ|Wp.39A2009”N5ŒŽ23“ú
“à“cM–çAV–¼—R‹GŽqA”¨’†‡–çA”öã½—ÇA•À–Ø“¿”VAŽR“c×YFƒZƒ“ƒgƒWƒ‡[ƒ“ƒYƒ[ƒg“û‰»Œ^»Ü‚Ì’P‰ñ‹y‚Ñ”½•œŒoŒû“Š—^‚É‚¨‚¯‚é–ò—ì—p‚ÆŠˆ«¬•ªhyperforin‚Ì‘Ì“à“®‘Ô
“ú–{–òÜŠw‰ï‘æ24”N‰ïiɪjA—vŽ|WA p.195A2009”N5ŒŽ21“ú
”¨’†‡–çA‹ßX”äØA“à“cM–çA”öã½—ÇAŽR“c×YFƒ¿|ƒgƒRƒtƒFƒ[ƒ‹‚̃iƒmƒGƒ}ƒ‹ƒWƒ‡ƒ“»Ü‰»‚ª•¨—‰»Šw“I“Á«AŒoŒûƒoƒCƒIƒAƒxƒCƒ‰ƒrƒŠƒeƒB‚¨‚æ‚ÑRŽ_‰»ì—p‚É‹y‚Ú‚·‰e‹¿
“ú–{–òÜŠw‰ï‘æ24”N‰ïiɪjA—vŽ|W4A p.224A2009”N5ŒŽ23“ú
‰Á“¡ˆÀGA‚–س˜aA“ì’qA–Ø‘º—ÎAâ–{’Bˆê˜YA‰ÍŒ´è‹M”ŒA‘O“c—˜’jA‰êì‹`”VF‚“xNPŽèpŒã‰h—{—Ö@‚É‚¨‚¯‚鎉–b“û܂̊ə“Š—^‚É‚æ‚é‰h—{ó‘Ô‚¨‚æ‚іƉu”\‚ւ̉e‹¿
2008USƒtƒH[ƒ‰ƒ€(ɪ)A—vŽ|Wp.15A2009”N8ŒŽ4“ú
•À–Ø“¿”VA“à“cM–çAìˆä—´”üA•½“‡“OA“‡è”ŽŽmF‰ü—ÇŒ^ƒtƒ@ƒ‚ƒ`ƒWƒ“ODùuƒTƒƒCv‚Ì—Õ°»ÜŠw“I•]‰¿
2008USƒtƒH[ƒ‰ƒ€iɪjA—vŽ|Wp.74A2009”N8ŒŽ5“ú
•À–Ø“¿”VF•a‰@–ò܂Ƃ̘AŒg@‰õ“K‚Ȉã—Âð’ñ‹Ÿ‚·‚邽‚߂̑nÜ
“ú–{–òÜŠw‰ï‘æ24”N‰ïiɪjA—vŽ|Wp.39A2009”N5ŒŽ23“ú
Shinya Uchida, Yasuhiro Katoh, Takeshi Ito, Hiroshi Morita, Hirotoshi Nakamura, Noriyuki Namiki, Hiroshi Watanabe, Kyoichi Ohashi: Influence of CYP2C9 genotypes on pharmacokinetics and pharmacodynamics of nateglinide in healthy volunteers and patients with 2 diabetes mellitus.
Asian Federation for Pharmaceutical Sciences (Fukuoka), Abstr. p.129, 2009, 2009”N10ŒŽ16“ú
“‡è”ŽŽmA‹àŽq’q—RA–‘–ΓTAo‰_³Ž¡A–ì˜C˜a•FA•½“‡“OAìˆä—´”üA“à“cM–çA‰Á“¡ˆÀGA•À–Ø“¿”VF ‰ü—ÇŒ^ƒtƒ@ƒ‚ƒ`ƒWƒ“ODùuƒTƒƒCv‚Ì—Õ°»ÜŠw“I•]‰¿
‘æ19‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi’·èjAu‰‰—vŽ|WAp.415A2009”N10ŒŽ25“ú
‹àŽq’q—RA–¾ÎŠâ—YA–‘–ΓTAo‰_³Ž¡A“‡è”ŽŽmA–ì˜C˜a•FA•½“‡“OAìˆä—´”üA“à“cM–çA‰Á“¡ˆÀGA•À–Ø“¿”VF •ÛŒ¯–ò‹Ç‚É‚¨‚¯‚éŒã”ˆã–ò•i‚Ö‚ÌØ‚è‘Ö‚¦‚ÉŠÖ‚·‚éˆÓޝ’²¸
‘æ19‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïi’·èjAu‰‰—vŽ|WAp.415A2009”N10ŒŽ25“ú
“à“cM–çAŽO‰YŠî–õAŽOâáÁŒ³A‰Á“¡ˆÀGAŽR“c×YA‘å‹´‹žˆêA“nç³—TŽiA•À–Ø“¿”VF ƒ~ƒ_ƒ]ƒ‰ƒ€‹y‚Ñ‚»‚Ì‘ãŽÓ•¨‚Ì”A’†”rŸ•—Ê‚ð—p‚¢‚½CYP3A4Šˆ«•]‰¿
‘æ30‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi‰¡•ljAu‰‰—vŽ|WAp.192A2009”N12ŒŽ3“ú
¬•½’m¢A“à“cM–çA¼–ìáÁŽjAŽRo”ü•äŽqA‹›’J‹M—mA™–{Œõ”ÉA•À–Ø“¿”VA“nç³—TŽiAŒÃ“c—²‹vF13C-ƒiƒvƒƒLƒTƒ“ŒÄ‹CŽŽŒ±‚É‚æ‚éNSAIDs’×á‡ƒŠƒXƒN‚ÌŒŸ“¢
‘æ30‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi‰¡•ljAu‰‰—vŽ|WAp.191A2009”N12ŒŽ3“ú
‚‹´“T’jAŠ£’¼‹PAX“c_A’|“à˜a•FA“à“cM–çA’†‘º_iA“nç³—TŽiFbó‘Bƒzƒ‹ƒ‚ƒ“‚ªCYP3AŠˆ«‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚Ä
‘æ30‰ñ“ú–{—Õ°–ò—Šw‰ï”N‰ïi‰¡•ljAu‰‰—vŽ|WAp.193A2009”N12ŒŽ3“ú
‚»‚Ì‘¼‚ÌŠ§s•¨
•À–Ø“¿”VFƒsƒ“ƒ|ƒCƒ“ƒg–ƒŒÜEƒŠƒhƒJƒCƒ“ƒXƒeƒBƒbƒN‚ÌŠJ”
Pharm Tech JapanA25A2347-2354 (2009)
•À–Ø“¿”VFгŽÒ‚É—D‚ꂽ»Ü‚ð’ñ‹Ÿ‚·‚邽‚ß‚É.
Fresh LeafA1i3jA18 (2009)
•À–Ø“¿”VF¡‚±‚»ˆù‚݂₷‚³‚ð’Ç‹‚µ‚½»Ü‚ðl‚¦‚邯‚«D
“s–òŽGŽA31i2jA4-8 (2009)
•À–Ø“¿”VFODù‚ÌŠî‘b‚ɂ‚¢‚ÄŠw‚ÔD
“s–òŽGŽA31i3jA28-33 (2009)
•À–Ø“¿”VFODù‚ÌŠî‘b‚ɂ‚¢‚ÄŠw‚Ô.
“s–òŽGŽA31i3jA28-33 (2009)
•À–Ø“¿”VFODù‚Ì^‰¿‚ɂ‚¢‚Äl‚¦‚éi‘˜_jD
“s–òŽGŽA31i4jA10-17 (2009)
•À–Ø“¿”VFгŽÒƒxƒlƒtƒBƒbƒg‚ð’Ç‹‚µ‚½‰@“à»Ü@ƒŠƒhƒJƒCƒ“ƒXƒeƒBƒbƒND
ŒŽŠ§–òŽ–A51A1275-9 (2009)
•À–Ø“¿”VF»Ü‚ÌŽ‹“_‚©‚犳ŽÒƒxƒlƒtƒBƒbƒg‚ðl‚¦‚éD
ŒŽŠ§–òŽ–A51A1269-73 (2009)
•À–Ø“¿”VF—Õ°Œ»ê‚ÅVAG‚ÌŠˆ—p‚ðI\˜AÚ‚É“–‚½‚Á‚Ä\D
’²Ü‚Æî•ñA15A804-7 (2009)
•À–Ø“¿”VF–òŠw•”6”N§‚Æ4”N§‹³ˆç‚Ƃ̋·ŠÔ‚Ål‚¦‚éD
–òŽ–V•ñA2588A5-6 (2009)
•À–Ø“¿”VFƒmƒ‹ƒoƒXƒN‚ÌNew Benefit vol.1
Medical TribuneA42i25jA36-37 (2009)
•À–Ø“¿”VFгŽÒƒxƒlƒtƒBƒbƒg‚ÌŠÏ“_‚©‚ç»Ü‚É’…–Ú‚µ‚½ƒWƒFƒlƒŠƒbƒN‚ÌŠˆ—p‚ðI
“Œ˜a ƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“ƒvƒ‰ƒUA15A14 (2009)
•À–Ø“¿”VFŒûo“à•ö‰óù‚̃pƒ‰ƒ_ƒCƒ€ƒVƒtƒgD
KyoA161AúH (2009)
•À–Ø“¿”VFV‚µ‚¢}‰ð–òÜŠw@‰ü’ù4”Åi‘•]jD
–ò‹ÇA60A3705 (2009)
ƒy[ƒW‚ÌÅã’i‚É–ß‚é
[Œ´’˜˜_•¶]
Masayoshi Asai, Kazuhiko Takeuchi, Shinya Uchida, Tsuyoshi Urushida, Hideki Katoh, Hiroshi Satoh, Shizuoka Yamada, Hideharu Hayashi and Hiroshi Watanabe: Misinterpretation of the effect of amlodipine on cytosolic calcium concentration with fura-2 fluorospectrometry.
Naunyn-Schmiedebergfs Arch Pharmacol., 377, 423-427 (2008)
Dongmei Yan, Yingbao Yang, Shinya Uchida, Shingen Misaka, Jinghui Luo, Kazuhiko Takeuchi, Naoki Inui, Shizuo Yamada, Kyoichi Ohashi and Hiroshi Watanabe: Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers.
Naunyn-Schmiedebergfs Arch Pharmacol., 377, 629-636 (2008)
Daiki Takahashi, Luvsandorj Oyunzul, Satomi Onoue, Yoshihiko Ito, Shinya Uchida, Rahime Simsek, Miyase Gozde Gunduz, Chiat Safak, and Shizuo Yamada: Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives.
Biol. Pham. Bull., 31, 473-479 (2008)
Shinya Uchida, Keita Hirai, Junya Hatanaka, Junko Hanato and Shizuo Yamada: Antinociceptive Effects of St. Johnfs Wort, Harpagophytum Procumbens Extract and Grape Seed Proanthocyanidins Extract in Mice.
Biol. Pharm. Bull., 31, 240-245 (2008)
Meimi Zhao, Shizuo Yamada, Ikuo Shibuichi, Daisuke Chino, Yusuke Hori, Shinya Uchida, Tomohiro Yamamoto, Yuki Shinoda, Li Zhi and Yasuo Watanabe: Low dosage of streptozotocin and fat-diet reduced rat liver insulin receptor activities.
Pharmacometrics, 74, 19-26 (2008)
Masato Sugimoto, Takahisa Furuta, Akiko Nakamura, Naoto Shirai, Mutsuhiro Ikuma, Singen Misaka, Shinya Uchida, Hiroshi Watanabe, Kyoichi Ohashi, Takashi Ishizaki, Akira Hishida: Maintenance time of sedative effects after an intravenous infusion of diazepam: a guide for endoscopy using diazepam.
World J Gastroenterol., 14: 5197-5203 (2008)
‘à
•À–Ø“¿”VF‚±‚±‚Ü‚Åi‚ñ‚¾I‚—îŽÒ‚ɂ₳‚µ‚¢–ò.
’²Ü‚Æî•ñA14A65-69 (2008)
•À–Ø“¿”VFˆù‚݂₷‚¢»Ü‚Ì“¤’mޝ‚ðˆ•ûÝŒvŽx‰‡‚╞–òŽw“±‚ÉŠˆ‚©‚·.
ŒŽŠ§–òŽ–A50A91-99 (2008)
•À–Ø“¿”VF¡‚±‚»ˆù‚݂₷‚³‚ð’Ç‹y‚µ‚½»Ü‚ðl‚¦‚邯‚«.
ŒŽŠ§–òŽ–A50A19-23 (2008)
’˜‘
•À–Ø“¿”VF–òÜŽt‚É‚æ‚éŽèpŽº‚Ì–òÜŠÇ—ƒ}ƒjƒ…ƒAƒ‹
ª’Õ•FŠÄCA“‡è”ŽŽmA•À–Ø“¿”V•ÒWA‚¶‚Ù‚¤jApp. 270-287 (2008)
“à“cM–çA“nç³—TŽiFˆãŽt‚ɑ΂·‚鈕ûŽx‰‡ƒT[ƒrƒX
‚‚·‚è‚ð‚‚©‚¤ƒGƒrƒfƒ“ƒX‚ð‚‚©‚¤i’Ã’JŠìˆê˜YA“à“c‰p“ñ•ÒA’†ŽR‘“XApp. 23-31 (2007)
ƒvƒƒV[ƒfƒBƒ“ƒO
‹ßX”äØA“à“cM–çA”¨’†‡–çAŽR“c×YFƒ¿|ƒgƒRƒtƒFƒ[ƒ‹‚Ì‘Ì“à“®‘Ô‚¨‚æ‚ÑRŽ_‰»ì—p‚É‹y‚Ú‚·…—n‰»‚̉e‹¿
ɪŽÀŒ±“®•¨Œ¤‹†‰ï‰ï•ñA34A19-20 (2008)
Šw‰ïEƒVƒ“ƒ|ƒWƒEƒ€
˜e¹ŽqAŽR“c_AŽR“cŒOAŠø’J—Y“ñAHŽR—çŽqA‘å–å‹MŽuA“à“cM–çAŽR“c×YA”~Š_ŒhŽOFŒŒ“œƒRƒ“ƒgƒ[ƒ‹‚ƃrƒ^ƒ~ƒ“‚b’lFRŽ_‰»ƒ}[ƒJ[‚Æ‚µ‚Ä‚ÌƒŠƒ“ƒp‹…’†ƒrƒ^ƒ~ƒ“‚b‘ª’è‚̈Ӌ`
‘æ51‰ñ“ú–{“œ”A•aŠw‰ï(“Œ‹ž)A“œ”A•aA51(Suppl.1)AS-292A2008”N5ŒŽ23“ú
‹ßX”äØA“à“cM–çA”¨’†‡–çA”öã½—ÇAŽR“c×YFƒ¿-ƒgƒRƒtƒFƒ[ƒ‹‚̃Gƒ}ƒ‹ƒWƒ‡ƒ“»Ü‚É‚¨‚¯‚é‹zŽû«‚¨‚æ‚ÑRŽ_‰»ì—p
“ú–{–òÜŠw‰ï‘æ23”N‰ïiŽD–yjA—vŽ|Wp.339A2008”N5ŒŽ21“ú
V–¼—R‹GŽqA“à“cM–çA”¨’†‡–çA”öã½—ÇAŽR“c×YFƒZƒ“ƒgƒWƒ‡[ƒ“ƒYƒ[ƒg‚Ì–ò—ì—p‚¨‚æ‚Ñ‚»‚ÌŠˆ«¬•ª‚Ì‘Ì“à“®‘Ô‚É‹y‚Ú‚·‰Â—n‰»‚̉e‹¿
“ú–{–òÜŠw‰ï‘æ23”N‰ïiŽD–yjA—vŽ|Wp.207A2008”N5ŒŽ21“ú
“à“cM–çA•“cl•½A’†¼G•¶A–¥—ÖØ•äA–Ø‘º—ÎA“nç³—TŽiAŽR“c×YFƒIƒLƒVƒRƒhƒ“‚ƃtƒFƒ“ƒ^ƒjƒ‹‚̃ʃIƒsƒIƒCƒhŽó—e‘ÌŒ‹‡A’Á’ÉŒø‰Ê‚¨‚æ‚Ñ‘Ì“à“®‘Ô
‘æ118‰ñ“ú–{–ò—Šw‰ïŠÖ“Œ•”‰ïi“Œ‹žjA—vŽ|Wp.92A2008”N6ŒŽ7“ú
“à“cM–çA”¨’†‡–çAV–¼—R‹GŽqA”öã½—ÇAŽR“c×YF‹@”\«H•i‚Ìì—p‹y‚Ñ‚»‚ÌŠˆ«¬•ª‚Ì‘Ì“à“®‘Ô‚É‹y‚Ú‚·‰Â—n‰»‚̉e‹¿
‘æ24‰ñ“ú–{DDSŠw‰ïi“Œ‹žjA—vŽ|Wp.23A2008”N6ŒŽ29-30“ú
•“cl•½A“à“cM–çA–¥—ÖØ•äA’†¼G•¶A–Ø‘º—ÎA“nç³—TŽiAŽR“c×YFƒIƒLƒVƒRƒhƒ“‚¨‚æ‚уtƒFƒ“ƒ^ƒjƒ‹‚Ì‘Ì“à“®‘ÔAƒIƒsƒIƒCƒhŽó—e‘ÌŒ‹‡‚Æ’Á’ÉŒø‰Ê
‘æ54‰ñ“ú–{–òŠw‰ï“ŒŠCŽx•”‘å‰ïA—vŽ|Wp.60A2008”N7ŒŽ5“ú
Shinya Uchida, Midori Kimura, Kohei Takeda, Nao Etoh, Yoshuyuki Ukishima, Takashi Daimon, Hiroshi Yamada, Hiroshi Watanabe, Kyoichi Ohashi, Shizuo Yamada: Influence of mu-opioid receptor polymorphism on adverse drug effect of oxycodone and fentanyl in Japanese lung cancer patients.
The IXth World Conference on Clinical Pharmacology and Therapeutics (Canada), Abstr. p.80, 2008, July,27-Aug. 1
Makiko Kokudai, Kazuhiko Takeuchi, Naoto Inui, Shinya Uchida, Shizuo Yamada, Junichi Kawakami, Yoshiyuki Kagawa, Hiroshi Watanabe: Effects of simvastatin, atorvastatin and pitavastatin on the pharmacokinetics of oral midazolam in healthy volunteers.
The IXth World Conference on Clinical Pharmacology and Therapeutics (Canada), Abstr. p.51, 2008, July, 27-Aug.1
•À–Ø“¿”VF•a‰@–ò‹Ç»Ü‚Ì’v–½“I2‘å–â‘è“_‚ðl‚¦‚é
“ú–{•a‰@–òÜŽt‰ïŠÖ“ŒƒuƒƒbƒN‘æ38‰ñŠwp‘å‰ïib•{jƒVƒ“ƒ|ƒWƒEƒ€5u•a‰@–ò‹Ç»Ü‚Ì
–â‘è“_‚ð‚Ç‚¤‰ðŒˆ‚·‚é‚©`•K—v«‚Æ¡Œã‚Ì•ûŒü«`vu‰‰—vŽ|WAp.84A2008”N8ŒŽ24“ú
“à“cM–çA–Ø‘º—ÎAŽR“c×YFˆâ“`Žq‘½Œ^î•ñ‚ɊIƒsƒIƒCƒh’Á’É–ò‚Ì“Š—^ŽwjÝ’è‚ð–ÚŽw‚µ‚½–ò•¨“®‘Ô/–ò—ÍŠw“I‰ðÍ
2006USƒtƒH[ƒ‰ƒ€u‰‰—vŽ|WAp.113A2008”N8ŒŽ2“ú
“‡è”ŽŽm A•½“‡“O A–ì˜C˜a•F Ao‰_³Ž¡ A–‘–ΓT Aìˆä—´”ü AŽÅ“c‹M—TA•À–Ø“¿”VFŒûo“à•ö‰óùiODùj‚ªƒRƒ“ƒvƒ‰ƒCƒAƒ“ƒX‚¨‚æ‚ÑŽ¡—ÃŒø‰Ê‚É—^‚¦‚é‰e‹¿
‘æ18‰ñ“ú–{ˆã—ÖòŠw‰ïiŽD–yjAu‰‰—vŽ|WAp.295A2008”N9ŒŽ20“ú
•½“‡“OA“‡è”ŽŽmA–ì˜C˜a•FAo‰_³Ž¡A–‘–ΓTAìˆä—´”üA•À–Ø“¿”VF“ü‰@‘O‚É‚¨‚¯‚éR‹ÃŒÅ–òƒ`ƒFƒbƒN‘̧Šm—§‚ÉŒü‚¯‚Ä|ŽÊ^Œ©–{•t‚«•ž—p’†Ž~Žwަ•[
‘æ18‰ñ“ú–{ˆã—ÖòŠw‰ïiŽD–yjAu‰‰—vŽ|WAp.398A2008”N9ŒŽ21“ú
˜a‹v“c_ˆêA“à“cM–çA’r“c‰ë•FA“cŸº³Ž÷AÔ¯•ÛŒõAŽR“c×YFApoEŒ‡‘¹ƒ}ƒEƒX‚É‚¨‚¯‚é‚”AŽ_ŒŒÇŽ¡—Öò‚ÌR“®–¬d‰»ì—p
‘æ61‰ñ“ú–{–ò—Šw‰ï¼“ì•”‰ïi•ÄŽqjAu‰‰—vŽ|WAp. 38A2008”N11ŒŽ28“ú
‹gìr”ŽAŽR“c_A¼“c·•FA¬›˜amAV”[mA’ñâ—TŽqAŠp“c—²–¤A“à“cM–çAˆÉ“¡—R•FA”öã½—ÇAŽR“c×YA”~Š_ŒhŽOF’ƒƒJƒeƒLƒ“‚Ìێ悪זEŽ¿•ª—ô‘jŠQ¬ŠjŽŽŒ±‚Ö‹y‚Ú‚·‰e‹¿FŒ’N¬l‚ð‘ÎÛ‚Æ‚µ‚½ƒ‰ƒ“ƒ_ƒ€‰»“ñd–ÓŒŸ”äŠrŽŽŒ±.
‘æ29‰ñ“ú–{—Õ°–ò—Šw‰ïi“Œ‹žjAu‰‰—vŽ|WA‚DS232A2008”N12ŒŽ4-6“ú
ƒy[ƒW‚ÌÅã’i‚É–ß‚é